UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 29, 2017

 

GUARDION HEALTH SCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 0-55723 44-4428421

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

 

15150 Avenue of Science, Suite 200

San Diego, CA 92128

(Address of principal executive offices, including zip code)

 

Registrant’s telephone number, including area code: (858) 605-9055

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c)) 

  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨  

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement

 

The disclosure set forth in Item 2.01 below is incorporated herein by reference.

 

Item 2.01 Completion of Acquisition or Disposition of Assets

 

On September 29, 2017, Guardion Health Sciences, Inc. (the “Company”), through a wholly-owned subsidiary, completed the acquisition of substantially all of the assets and liabilities of VectorVision, Inc., an Ohio corporation (“VectorVision”), in exchange for 3,050,000 shares of the Company’s common stock (the “Common Stock”), pursuant to the terms of an Asset Purchase and Reorganization Agreement, dated as of September 29, 2017 (the “Asset Purchase Agreement”), which was entered into on an arm’s-length basis between the parties. VectorVision’s assets acquired by the Company pursuant to the Asset Purchase Agreement included, among others, accounts receivable, fixed assets, inventories, trademarks and copyrights. VectorVision’s liabilities assumed by the Company pursuant to the Asset Purchase Agreement included, among others, certain trade accounts payable to third parties and accrued liabilities, and amounts owed under an outstanding line of credit (not to exceed $35,000).

 

With respect to the 3,050,000 shares of Common Stock issuable pursuant to the Asset Purchase Agreement, 250,000 shares of such Common Stock (the “Holdback Shares”) were held back as security for VectorVision’s indemnification obligations as set forth in the Asset Purchase Agreement and the remaining 2,800,000 shares of Common Stock were issued to VectorVision at the closing of the Asset Purchase Agreement (the “Closing”). The shares of Common Stock issued pursuant to the Asset Purchase Agreement (including the Holdback Shares) represented approximately 11% of the Company’s issued and outstanding Common Stock immediately following consummation of the Asset Purchase Agreement. The shares of Common Stock have certain piggy-back registration rights pursuant to the Asset Purchase Agreement.

 

Pursuant to the terms of the Asset Purchase Agreement, David Evans, the founder of VectorVision, was appointed to the Company’s Board of Directors at Closing. Dr. Evans is recognized as the leading expert in clinical contrast sensitivity and glare testing. He has provided his testing expertise and data analysis capability to a wide range of leading ophthalmic companies. Dr. Evans has published more than 30 scientific articles and 3 book chapters in the areas of refractive surgery, glaucoma, ocular blood flow and visual function, and is the inventor of 5 patents related to vision testing devices. Dr. Evans received his Bachelor of Science degree in Human Factors Engineering from the United States Air Force Academy, a Master of Science degree and Masters in Business Administration from Wright State University in Dayton, Ohio, and a Ph.D. in Ocular Physiology from Indiana University. Dr. Evans will also serve as a consultant to the Company to further the Company’s planned development and commercialization of its portfolio of products.

 

VectorVision develops, manufactures and sells equipment and supplies for standardized vision testing for use by eye doctors in clinical trials, for real-world vision evaluation, and industrial vision testing. VectorVision specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and ETDRS (Early Treatment Diabetic Retinopathy Study) acuity vision testing. The patented standardization system provides the practitioner or researcher with the ability to delineate very small changes in visual capability, either as compared to the population or from visit to visit. VectorVision’s CSV-1000 device is considered the standard of care for clinical trials. The Company believes the acquisition of substantially all of VectorVision’s assets will expand the Company’s technical portfolio and further establish the Company’s position at the forefront of early detection, intervention and monitoring of a range of eye diseases.

 

The Company will account for the transactions contemplated by the Asset Purchase Agreement pursuant to Accounting Standards Codification Topic 805, Business Combinations. Management will identify and evaluate the fair value of the assets acquired, and expects to rely, in part, on the work of an independent third party valuation firm engaged by the Company to provide input as to the fair value of the consideration paid (because there is no established trading market for the Company’s Common Stock) and the assets acquired, including the valuation methodology most relevant to the transactions described herein, and to assist in the related calculations, analysis and allocations. The Company will consolidate VectorVision’s balance sheet with the Company’s balance sheet effective September 30, 2017, and will consolidate VectorVision’s statement of operations with the Company’s statement of operations commencing October 1, 2017.

 

The foregoing description of the Asset Purchase Agreement and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference to the Asset Purchase Agreement, a copy of which is filed as Exhibit 2.1 hereto and is hereby incorporated into this report by reference. The Asset Purchase Agreement has been included to provide investors with information regarding its terms. It is not intended to provide any other factual information about the Company or VectorVision. In particular, the assertions embodied in the representations and warranties contained in the Asset Purchase Agreement are subject to qualifications and limitations agreed to by the respective parties in connection with negotiating the terms of the Asset Purchase Agreement, including information contained in a confidential disclosure schedule provided by VectorVision to the Company in connection with the signing of the Asset Purchase Agreement. The confidential disclosure schedule contains information that modifies, qualifies and creates exceptions to the representations and warranties set forth in the Asset Purchase Agreement. Moreover, certain representations and warranties in the Asset Purchase Agreement were used for the purpose of allocating risk between the Company and VectorVision rather than establishing matters as facts. Accordingly, you should not rely on the representations and warranties in the Asset Purchase Agreement as characterizations of the actual state of facts about the Company, VectorVision, or the assets and liabilities acquired or assumed.

 

  2  

 

 

Pursuant to the Asset Purchase Agreement, the Company also entered into an Intellectual Property Assignment Agreement with VectorVision and Dr. Evans, dated as of September 29, 2017 (the “IP Assignment”), pursuant to which VectorVision and Dr. Evans assigned all right, title and interest in the intellectual property identified therein to the Company. The foregoing description of the IP Assignment does not purport to be complete and is qualified in its entirety by reference to the IP Assignment, a copy of which is filed as Exhibit 10.1 hereto and is hereby incorporated into this report by reference.

 

Pursuant to the Asset Purchase Agreement, the Company also entered into a Consulting Agreement with Dr. Evans, dated as of September 29, 2017 (the “Consulting Agreement”), whereby Dr. Evans has been engaged to serve as a consultant to the Company to further the Company’s planned development and commercialization of the Company’s portfolio of products and technology. The Consulting Agreement has an initial term of 3 years, with automatic one-year renewals unless earlier terminated. Dr. Evans is entitled to compensation of $10,000 per month for the first six months of the term of the Consulting Agreement and $7,500 per month for the remainder of the term of the Consulting Agreement. The foregoing description of the Consulting Agreement does not purport to be complete and is qualified in its entirety by reference to the Consulting Agreement, a copy of which is filed as Exhibit 10.2 hereto and is hereby incorporated into this report by reference.

 

Pursuant to the Asset Purchase Agreement, the Company also entered into an Intellectual Property Purchase Agreement with Dr. Evans, dated as of September 29, 2017 (the “IP Purchase Agreement”), whereby Dr. Evans assigned all right, title and interest in and to certain patent applications identified therein to the Company. Dr. Evans would be entitled to a commercially reasonable royalty under certain circumstances as described in the IP Purchase Agreement. The foregoing description of the IP Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the IP Purchase Agreement, a copy of which is filed as Exhibit 10.3 hereto and is hereby incorporated into this report by reference.

 

Item 3.02 Unregistered Sales of Equity Securities

 

The 3,050,000 shares of Common Stock to be issued pursuant to the Asset Purchase Agreement and disclosed in Item 2.01 above are being issued in reliance upon the exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended.

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

Pursuant to the terms of the Asset Purchase Agreement, David W. Evans was appointed to serve as a member of the Board of Directors of the Company effective on September 29, 2017. The information set forth in Item 2.01 above is incorporated herein by reference.

 

Item 8.01 Other Events

 

On October 2, 2017, the Company issued a press release announcing the closing of the transactions described herein. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

The matters described herein include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company’s ability to raise sufficient financing to implement its business plan and its ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s recent filings with the U. S. Securities and Exchange Commission (the “SEC”), including the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and Post-Effective Amendment No. 1 to the Company’s Registration Statement on Form S-1, as well as the financial statements included therein, and in the Company’s recent Quarterly Reports on Form 10-Q and in other documents the Company files with the SEC from time to time. These filings are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, in each case, except to the extent required by applicable law.

 

  3  

 

 

Item 9.01 Financial Statements and Exhibits

 

(a) Financial statements of businesses acquired .

 

(i) The audited financial statements of VectorVision, Inc. for the years ended December 31, 2016 and 2015, including the report of Weinberg & Company, P.A., VectorVision’s independent registered public accounting firm, are included as Exhibit 99.2 hereto and incorporated by reference herein.

 

(ii) The interim unaudited financial statements of VectorVision, Inc. for the six months ended June 30, 2017 and 2016 are included as Exhibit 99.3 hereto and incorporated by reference herein.  

 

(b) Pro forma financial information.

 

As permitted under Item 9.01(b)(2) of Form 8-K, the unaudited pro forma financial information required to be filed under Item 9.01(b) of Form 8-K in connection with the transactions contemplated by the Asset Purchase Agreement will be filed by an amendment to this report no later than 71 calendar days after the date on which this initial Current Report on Form 8-K must be filed.

 

(c) Shell company transactions .

 

Not applicable.

 

(d) Exhibits .

 

Exhibit No.   Description
     
2.1*   Asset Purchase and Reorganization Agreement dated as of September 29, 2017
     
10.1   Intellectual Property Assignment Agreement with David W. Evans and VectorVision, Inc. dated as of September 29, 2017
     
10.2   Consulting Agreement with David W. Evans dated as of September 29, 2017
     
10.3   Intellectual Property Purchase Agreement with David W. Evans dated as of September 29, 2017
     
23.1   Consent of Weinberg & Company, P.A., independent registered public accounting firm of VectorVision, Inc.
     
99.1   Press Release Announcing Completion of Acquisition
     
99.2   Audited Financial Statements of VectorVision, Inc. for the years ended December 31, 2016 and December 31, 2015
     
99.3   Unaudited Interim Financial Statements of VectorVision, Inc. for the six months ended June 30, 2017 and 2016

 

*Certain schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K promulgated by the SEC. The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.

 

  4  

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  GUARDION HEALTH SCIENCES, INC.
     
  By: /s/ MICHAEL FAVISH
    Name: Michael Favish
    Title: Chief Executive Officer
     
Date: October 5, 2017     

 

  5  

 

Exhibit 2.1

 

EXECUTION VERSION

 

ASSET PURCHASE AND REORGANIZATION AGREEMENT

 

by and among

 

GUARDION HEALTH SCIENCES, INC.,

a Delaware corporation, and

 

VECTORVISION OCULAR HEALTH, INC.,

a Delaware corporation, or its designee on the one hand,

and

 

VECTORVISION, INC.,

an Ohio corporation

 

and its

 

SHAREHOLDERS,

 

on the other hand

 

dated as of

 

September 29, 2017

 

 

 

 

  

TABLE OF CONTENTS

 

ARTICLE I Purchase and Sale 1
     
Section 1.1. Purchase and Sale of Assets 1
Section 1.2. Excluded Assets 2
Section 1.3. Assumed Liabilities 3
Section 1.4. Excluded Liabilities 3
Section 1.5. Purchase Price 3
Section 1.6. Holdback 3
Section 1.7. Withholding Tax 3
Section 1.8. Third Party Consents 4
     
ARTICLE II Closing 4
     
Section 2.1. Closing 4
Section 2.2. Closing Deliverables 4
     
ARTICLE III Representations and Warranties of Seller Parties 5
     
Section 3.1. Organization and Qualification of Seller; Capitalization 5
Section 3.2. Authority of Seller Parties 6
Section 3.3. No Conflicts 6
Section 3.4. Financial Statements 7
Section 3.5. Undisclosed Liabilities; Solvency 7
Section 3.6. Absence of Certain Changes 7
Section 3.7. Material Contracts 7
Section 3.8. No Subsidiaries or Joint Ventures 7
Section 3.9. Title, Condition and Sufficient of Assets 8
Section 3.10. Real Property 8
Section 3.11. Intellectual Property 8
Section 3.12. Inventory 9
Section 3.13. Accounts Receivable 9
Section 3.14. Suppliers and Customers 10
Section 3.15. Insurance 10
Section 3.16. Legal Proceedings; Governmental Orders 10
Section 3.17. Compliance With Laws; Permits 10
Section 3.18. Product Warranties and Liabilities 10
Section 3.19. Environmental 11
Section 3.20. Employment Matters 11
Section 3.21. Taxes 12
Section 3.22. Benefit Plans 14
Section 3.23. Transactions with Affiliates; Capitalization 14
Section 3.24. Documents 14
Section 3.25. Investment Representations by Seller and Shareholders 15
Section 3.26. No Broker 16

 

 - i -

 

  

ARTICLE IV Representations and Warranties of Buyer and Guardion 16
     
Section 4.1. Representations of Buyer 16
Section 4.2. Representations of Guardion 17
     
ARTICLE V Covenants 18
     
Section 5.1. Conduct of Business Prior to the Closing 18
Section 5.2. Access to Information 19
Section 5.3. Notice of Certain Events 19
Section 5.4. Employees 19
Section 5.5. Confidentiality 20
Section 5.6. Non-Competition Agreements 20
Section 5.7. Efforts to Close 21
Section 5.8. Announcements 21
Section 5.9. Bulk Sales Laws 21
Section 5.10. Mail; Receivables 22
Section 5.11. Tax Treatment 22
Section 5.12. Distribution 22
Section 5.13. Transfer Taxes 22
Section 5.14. Name Change 22
Section 5.15. Payment of Excluded Liabilities 22
Section 5.16. Insurance Proceeds 23
Section 5.17. Board Seat 23
Section 5.18. Piggyback Registration Rights 23
     
ARTICLE VI Conditions to Closing 25
     
Section 6.1. Conditions to Obligations of Buyer 25
Section 6.2. Conditions to Obligations of Seller 26
     
ARTICLE VII Indemnification 26
     
Section 7.1. Survival 26
Section 7.2. Indemnification By Seller Parties 27
Section 7.3. Indemnification By Buyer 27
Section 7.4. Certain Limitations 28
Section 7.5. Indemnification Procedures 28
Section 7.6. Tax Treatment of Indemnification Payments 30
Section 7.7. Exclusive Remedies 30
     
ARTICLE VIII Termination 30
     
Section 8.1. Termination 30
Section 8.2. Effect of Termination 31

 

 - ii -

 

  

ARTICLE IX Miscellaneous 31
     
Section 9.1. Expenses 31
Section 9.2. Notices 31
Section 9.3. Interpretation 32
Section 9.4. Severability 32
Section 9.5. Entire Agreement 33
Section 9.6. Successors and Assigns 33
Section 9.7. No Third-Party Beneficiaries 33
Section 9.8. Amendment and Modification; Waiver 33
Section 9.9. Governing Law; Venue 33
Section 9.10. Shareholders’ Obligations 33
Section 9.11. Further Assurances 34
Section 9.12. Independent Review 34
Section 9.13. Counterparts 34

 

 - iii -

 

  

ASSET PURCHASE AND REORGANIZATION AGREEMENT

 

 

This Asset Purchase and Reorganization Agreement (this “ Agreement ”), dated as of September 29 , 2017, is entered into by and among Guardion Health Sciences, Inc., a Delaware corporation (“ Guardion ”), and its direct wholly-owned subsidiary VectorVision Ocular Health, Inc., a Delaware corporation, or such other subsidiary of Guardion as Guardion may designate, (“ Buyer ”), on the one hand, and VectorVision, Inc., an Ohio corporation (“ Seller ”), and David Evans (“ Evans ”) and Tamara Evans, the Shareholders of Seller (the “ Shareholders ” and together with Seller, the “ Seller Parties ”), on the other hand.

 

RECITALS

 

WHEREAS, Seller wishes to transfer and assign to Buyer, and Buyer wishes to acquire from Seller, substantially all the assets of Seller, on the terms and subject to the conditions set forth herein;

 

WHEREAS, the Parties intend that (i) the transactions contemplated by this Agreement will qualify as a reorganization within the meaning of Section 368(a)(1)(C) of the Internal Revenue Code of 1986, as amended (the “ Code ”) and (i) the distribution described in Section 5.12 of this Agreement will meet the requirements of Section 368(a)(2)(G); and

 

WHEREAS, Guardion as the parent corporation of Buyer will benefit from the transactions contemplated hereby; and

 

WHEREAS, the Shareholders, as an indirect beneficiary of the transactions contemplated hereby by virtue of their ownership interests in Seller, wish to make certain representations in connection with such transactions, as specified herein, as inducements to Buyer to execute this Agreement.

 

NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows (initially capitalized terms used but not defined herein have the meanings given them in Appendix A hereto):

 

ARTICLE I
PURCHASE AND SALE

 

Section 1.1. Purchase and Sale of Assets . On the terms and subject to the conditions set forth herein, at the Closing, Seller shall sell, assign, transfer, convey and deliver to Buyer, and Buyer shall purchase from Seller, free and clear of any Liens other than Permitted Liens, all of Seller’s assets, properties and rights of every kind and nature, whether real, personal or mixed, tangible or intangible (including goodwill), wherever located and whether now existing or hereafter acquired (other than the Excluded Assets) (collectively, the “ Purchased Assets ”), including the following assets, properties and rights of Seller:

 

(a)          all cash and cash equivalents;

 

  - 1 -  

 

  

(b)          all accounts and notes receivable and any security, claim, remedy or other right related to any of the foregoing (“ Accounts Receivable ”);

 

(c)          all inventory, finished goods, raw materials, work in progress, packaging, supplies, parts and other inventories (“ Inventory ”);

 

(d)          all Intellectual Property assets;

 

(e)          all furniture, fixtures, equipment, machinery, tools, office equipment, supplies, computers, telephones and other tangible personal property (the “ Tangible Personal Property ”);

 

(f)          the Intellectual Property Agreements identified on Schedule 1.1(f) (the “ Assigned IP Agreements ”);

 

(g)          the Contracts identified on Schedule 1.1(g) (together with the Assigned IP Agreements, the “ Assigned Contracts ”);

 

(h)          all rights to any Actions of any nature available to or being pursued by Seller;

 

(i)          all prepaid expenses, credits, advance payments, claims, security, refunds, rights of recovery, rights of set-off, rights of recoupment, deposits, charges, sums and fees; and

 

(j)          all goodwill and the going concern value of the Seller and the Business.

 

Section 1.2. Excluded Assets . Notwithstanding the foregoing, the Purchased Assets shall not include the following assets, properties and rights of Seller (collectively, the “ Excluded Assets ”):

 

(a)          all corporate seals, organizational documents, minute books, stock books, Tax Returns, books of account or other records having to do with the corporate organization of Seller;

 

(b)          all Contracts that are not Assigned Contracts;

 

(c)          all personnel records and other records that Seller is required by Law to retain in its possession (provided that, to the extent permitted by Law, Seller shall make copies thereof available to Buyer upon its request);

 

(d)          all claims for refund of Taxes, to the extent that such Taxes would be Excluded Liabilities if such Taxes were not refundable;

 

(e)          all Benefit Plans and assets attributable thereto, to the extent that any such plans exist;

 

(f)          the assets, properties and rights specifically set forth on Schedule 1.2(f) ; and

 

(g)          the rights which accrue or will accrue to Seller under the Transaction Documents.

 

  - 2 -  

 

  

Section 1.3. Assumed Liabilities . On the terms and subject to the conditions set forth herein, Buyer shall assume and agree to pay, perform and discharge only the following Liabilities of Seller (collectively, the “ Assumed Liabilities ”):

 

(a)          all trade accounts payable of Seller to third parties in connection with the Business that remain unpaid and are not delinquent as of the Closing Date and that either are reflected on the Most Recent Balance Sheet or arose in the ordinary course of business consistent with past practice since the Most Recent Balance Sheet Date, including up to $15,000 due under MasterCard account ending in -4288 and up to $46,000 due under MasterCard account ending in -8904; but other than Shareholder loans, salaries, severance amounts, accrued vacation and other compensation and benefits payable or accrued through the Closing Date and other than Liabilities of the types identified on Schedule 1.3 ;

 

(b)          Seller’s Liability under the Bank One Loan, which shall not exceed Thirty-Five Thousand Dollars ($35,000); and

 

(c)          all Liabilities in respect of the Assigned Contracts but only to the extent that such Liabilities are required to be performed after the Closing Date, were incurred in the ordinary course of business and do not relate to any failure to perform, improper performance, warranty or other breach, default or violation prior to the Closing Date.

 

Section 1.4. Excluded Liabilities . Notwithstanding the provisions of Section 1.3 or any other provision in this Agreement to the contrary, Buyer shall not assume and shall not be responsible to pay, perform or discharge any Liabilities of Seller of any kind or nature whatsoever other than the Assumed Liabilities (the “ Excluded Liabilities ”).

 

Section 1.5. Purchase Price . The aggregate purchase price for the Purchased Assets shall be Three Million Fifty Thousand (3,050,000) shares of the voting Common Stock of Guardion (the “ Acquired Shares ”) plus the assumption of the Assumed Liabilities (together with the Acquired Shares, the “ Purchase Price ”).

 

Section 1.6. Holdback . At the Closing, Buyer shall holdback Two Hundred Fifty Thousand (250,000) shares from the Acquired Shares (the “ Holdback Shares ”) as security for the satisfaction of the Seller Parties’ indemnification obligations hereunder and, sixty (60) days following the General Survival Period, shall deliver the Holdback Shares, or such portion thereof, if any, after any reduction to the Holdback Shares in accordance with the terms of this Agreement. It is the intention of the parties that the Holdback Shares comply with IRS Rev. Proc. 84-42 and shall be:

 

(a)          Duly authorized, validly issued, outstanding, fully-paid and non-assessable.

 

(b)          All dividends paid on behalf of the Acquired Shares will be distributed to Seller.

 

(c)          Seller shall retain all voting rights.

 

Section 1.7. Withholding Tax . Buyer shall be entitled to deduct and withhold from the Purchase Price all Taxes that Buyer may be required to deduct and withhold under any provision of Tax Law. All such withheld amounts shall be treated as delivered to Seller hereunder.

 

  - 3 -  

 

  

Section 1.8. Third Party Consents . To the extent that Seller’s rights under any Contract or Permit constituting a Purchased Asset, or any other Purchased Asset, may not be assigned to Buyer without the consent of another Person which has not been obtained prior to the Closing, this Agreement shall not constitute an agreement to assign the same if an attempted assignment would constitute a breach thereof or be unlawful, and Seller shall use its reasonable best efforts to obtain any such required consent(s) as promptly as possible. If any such consent shall not be obtained or if any attempted assignment would be ineffective or would impair Buyer’s rights under the Purchased Asset in question so that Buyer would not in effect acquire the benefit of all such rights, Seller, to the maximum extent permitted by Law and the Purchased Asset, shall act after the Closing as Buyer’s agent in order to obtain for Buyer the benefits thereunder and shall cooperate, to the maximum extent permitted by Law and the Purchased Asset, with Buyer in any other reasonable arrangement designed to provide such benefits to Buyer.

 

ARTICLE II
CLOSING

 

Section 2.1. Closing . The consummation of the transactions contemplated by this Agreement (the “ Closing ”) shall take place at the offices of Sheppard, Mullin, Richter & Hampton LLP, 333 S. Hope Street, 43rd Floor, Los Angeles, CA 90071, at 10:00 a.m., local time, on the third Business Day after all of the conditions to Closing set forth in Article VI are either satisfied or waived (other than conditions which, by their nature, are to be satisfied on the Closing Date), or at such other time, date or place as Seller and Buyer may mutually agree upon in writing. The date on which the Closing is to occur is herein referred to as the “ Closing Date ”. The Closing shall be deemed to occur at 11:59 p.m. local time on the Closing Date except as may otherwise be provided herein.

 

Section 2.2.           Closing Deliverables.

 

(a)          At the Closing, Seller shall deliver to Buyer the following:

 

(i)          a bill of sale in the form of Exhibit A duly executed by Seller;

 

(ii)         an assumption agreement in the form of Exhibit B (the “ Assumption Agreement ”), duly executed by Seller;

 

(iii)        assignment of Intellectual Property in the form of Exhibit C, duly executed by Seller and Evans;

 

(iv)         the Consulting Agreement, duly executed by Evans;

 

(v)          an employment and non-solicitation agreement in the form of Exhibit D , duly executed by Brian Wilson;

 

(vi)         the amendment to the Premises Lease for the premises known as 1850 Livingston Road, Suite E, Greenville, Ohio 45331 (the “ Premises ”), duly executed by DWT Evans LLC and Seller in the form of Exhibit E ;

 

  - 4 -  

 

  

(vii)        certificates dated as of a date not earlier than the third (3rd) Business Day prior to the Closing as to the good standing of Seller and payment of all applicable state Taxes by Seller, executed by the appropriate officials of the State of Ohio;

 

(viii)      a certificate pursuant to Treasury Regulations Section 1.1445-2(b) that Seller is not a foreign person within the meaning of Section 1445 of the Code duly executed by Seller and such other clearance certificates or similar documents that may be required by any Governmental Authority in order to relieve Buyer of any obligation to withhold any portion of the Purchase Price;

 

(ix)         a certificate of the Secretary or Assistant Secretary of Seller in the form of Exhibit F , duly executed by such person;

 

(x)          a stock power duly endorsed in blank by Seller for the Holdback Shares;

 

(xi)         the intellectual property purchase agreement dated as of even date herewith, duly executed by Evans; and

 

(xii)        such other documents as Buyer may reasonably request to give effect to this Agreement, duly executed by Seller.

 

(b)          At the Closing, Buyer or Guardion (as applicable) shall:

 

(i)          deliver the Assumption Agreement to Seller, duly executed by Buyer;

 

(ii)         issue certificates representing the Purchase Price and deliver said certificates, less the Holdback Shares, to Seller.

 

(iii)        deliver the Consulting Agreement, duly executed by Guardion; and

 

(iv)         the intellectual property purchase agreement dated as of even date herewith, duly executed by Guardion.

 

ARTICLE III

REPRESENTATIONS AND WARRANTIES OF SELLER PARTIES

 

Except as set forth in the correspondingly numbered Section of the Disclosure Schedule, (i) the Shareholders represent and warrant to Buyer that the statements contained in this Article III that relate to such Shareholders are true and correct as of the date hereof and will be true and correct as of Closing and (ii) Seller represents and warrants to Buyer that the statements contained in this Article III (other than those that relate to the Shareholders) are true and correct as of the date hereof and as of the Closing.

 

Section 3.1.           Organization and Qualification of Seller; Capitalization .

 

(a)          Seller is a corporation duly organized and validly existing under the Laws of the state of Ohio, is in good standing under the Laws of the state of Ohio (which is the only state where it is required to be qualified or licensed to do business) and has full corporate power and authority to own, operate or lease the properties and assets now owned, operated or leased by it and to carry on the Business as currently conducted.

 

  - 5 -  

 

  

(b)          The authorized capital stock of Seller consists of seven hundred fifty (750) shares of the capital stock of Seller, of which one hundred twenty-four (124) shares are issued and outstanding. All of the issued and outstanding shares of the capital stock of Seller have been duly authorized, are validly issued, fully paid, and non-assessable, and are held of record as follows: Tamara Evans ninety six (96) shares and David Evans twenty eight (28) shares. There are no outstanding or authorized options, warrants, purchase rights, subscription rights, conversion rights, exchange rights, or other contracts or commitments that could or would require Seller to issue, sell, or otherwise cause to become outstanding any of its capital stock. There are no outstanding or authorized stock appreciation rights, phantom stock, profit participation or similar rights granted by Seller. There are no voting trusts, proxies, or other agreements or understandings with respect to the voting of the capital stock of Seller to which Seller or the Shareholders are a party.

 

Section 3.2. Authority of Seller Parties . Each Seller Party has full power and authority to enter into this Agreement and the other Transaction Documents to which such Seller Party is a party, to carry out its or his obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. The execution and delivery by such Seller Party of this Agreement and any other Transaction Document to which such Seller Party is a party, the performance by such Seller Party of its obligations hereunder and thereunder and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all requisite action on the part of such Seller Party (including approval of this Agreement and the transactions contemplated hereby by the Shareholders, in his capacity as Shareholders of Seller). This Agreement has been duly executed and delivered by each Seller Party, and (assuming due authorization, execution and delivery by Buyer) this Agreement constitutes a legal, valid and binding obligation of such Seller Party enforceable against such Seller Party in accordance with its terms. When each other Transaction Document to which a Seller Party is or will be a party has been duly executed and delivered by Seller (assuming due authorization, execution and delivery by each other party thereto), such Transaction Document will constitute a legal and binding obligation of such Seller enforceable against it in accordance with its terms.

 

Section 3.3. No Conflicts . The execution, delivery and performance by each Seller Party of this Agreement and the other Transaction Documents to which it is a party, and the consummation of the transactions contemplated hereby and thereby, do not and will not: (a) conflict with or result in a violation or breach of, or default under, any provision of the organizational documents of such Seller Party (if an entity); (b) conflict with or result in a violation or breach of any provision of any Law or Governmental Order applicable to such Seller Party; (c) require the consent, notice or other action by any Person under, conflict with, result in a violation or breach of, constitute a default or an event that, with or without notice or lapse of time or both, would constitute a default under, result in the acceleration of or create in any party the right to accelerate, terminate, modify or cancel or obtain any rights under any material Contract to which such Seller Party is a party; or (d) result in the creation or imposition of any Lien on the Purchased Assets.

 

  - 6 -  

 

  

Section 3.4. Financial Statements . Seller has delivered to Buyer copies of (a) Seller’s balance sheets dated as of December 31, 2016 and December 31, 2015 and the related statements of operations, shareholders’ equity and cash flows for each of the years then ended, including the notes thereto, if any (collectively, the “ Year-End Financial Statements ”) and (b) Seller’s balance sheet (the “ Most Recent Balance Sheet ”) dated as of June 30, 2017 (the “ Most Recent Balance Sheet Date ”) and the related statements of operations, shareholders’ equity and cash flows for the six-month period ended on the Most Recent Balance Sheet Date (together with the Most Recent Balance Sheet Date, the “ Most Recent Financial Statements ”; together with the Year-End Financial Statements, the “ Financial Statements ”). Except as indicated in the Financial Statements (including any notes thereto, if any), the Financial Statements (including the notes thereto, if any) have been consistently prepared and fairly present the results of the consolidated operations and changes in shareholder’s equity and financial position of Seller for the respective fiscal periods or as of the respective dates therein set forth.

 

Section 3.5. Undisclosed Liabilities; Solvency . To Seller’s Knowledge, Seller has no Liabilities with respect to the Business, except (a) those which are adequately reflected or reserved against on the Most Recent Balance Sheet, (b) those which have been incurred in the ordinary course of business consistent with past practice since the Most Recent Balance Sheet Date and (c) executory obligations under Contracts. Section 3.5 of the Disclosure Schedule sets forth each item of Seller Indebtedness as of the date hereof (including the holder of the Indebtedness and the amount thereof). Seller is not now insolvent and will not be rendered insolvent by any of the transactions contemplated hereby. As used herein, “insolvent” means that the sum of the debts and other probable Liabilities of Seller exceeds the present fair saleable value of Seller’s assets.

 

Section 3.6. Absence of Certain Changes . Since the Most Recent Balance Sheet Date, Seller has operated in the ordinary course of business consistent with past practice, there has not been any event, occurrence or development that has had, or could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect and Seller not taken any actions which, had such actions occurred after the date of this Agreement, would have breached any of the covenants set forth in Section 5.1 .

 

Section 3.7. Material Contracts . Section 3.7 of the Disclosure Schedule sets forth a list of each of the written, and a description of the material terms of each of the oral, Contracts to which Seller is a party and which is material to the Business (the “ Material Contracts ”). Each of the Material Contracts is in full force and effect and constitutes a legal, valid and binding obligation of Seller and, to Seller’s Knowledge, of the parties thereto, enforceable in accordance with its terms. There is no default under or breach of any Material Contract by Seller, and, to Seller’s Knowledge, no other party to any such Material Contract is in breach thereof or default thereunder. No party to any such Material Contract has given notice to Seller of, or made a claim against Seller with respect to, any breach or default thereunder, and, to Seller’s Knowledge, no party has threatened to do so.

 

Section 3.8. No Subsidiaries or Joint Ventures . Seller does not control or have any equity participation or similar interest in any corporation, association, or other business entity nor is it a participant in any joint venture, partnership, or similar arrangement. There are no contractual obligations of Seller to provide funds to, or make any investment in, any other Person.

 

  - 7 -  

 

  

Section 3.9. Title, Condition and Sufficient of Assets . Seller is the lawful owner of each of the Purchased Assets and has good and valid title to all of the Purchased Assets, free and clear of Liens except for the Permitted Liens. The Tangible Personal Property is in good operating condition and repair and adequate for the uses to which they are being put, and not in need of maintenance or repairs except for ordinary, routine maintenance and repairs that are not material in nature or cost. The Purchased Assets are sufficient for the continued conduct of the Business after the Closing in substantially the same manner as conducted prior to the Closing and constitute all of the rights, property and assets necessary to conduct the Business as currently conducted. The Excluded Assets are not material, individually or in the aggregate, to the Business.

 

Section 3.10. Real Property . Seller does not own and has never owned any real property. Seller has a valid leasehold interest in the Premises. The Premises Lease is not subject to any prime, ground or master lease, mortgage, deed of trust or other Lien or interest which would entitle the interest holder to interfere with or disturb the tenant’s rights under the Premises Lease in any material respect. Other than Seller, there are no parties in possession or parties having any rights to occupy any portion of the Premises. The Premises are adequate for the conduct of the Business as currently conducted.

 

Section 3.11. Intellectual Property.

 

(a)           Section 3.11(a) of the Disclosure Schedule lists all (i) Intellectual Property Registrations and (ii) Intellectual Property Assets, including software, that are not registered but that are material to the operation of the Business. All required filings and fees related to the Intellectual Property Registrations have been timely filed with and paid to the relevant Governmental Authorities and authorized registrars, and all Intellectual Property Registrations are otherwise in good standing.

 

(b)           Section 3.11(b) of the Disclosure Schedule lists all Intellectual Property Agreements. Each Intellectual Property Agreement is valid and binding on Seller in accordance with its terms and is in full force and effect. Neither Seller, Shareholders nor, to Seller’s Knowledge, any other party thereto is in breach of or default under (or is alleged to be in breach of or default under) in any material respect, or has provided or received any notice of breach or default of or any intention to terminate, any Intellectual Property Agreement. No event or circumstance has occurred that, with notice or lapse of time or both, would constitute an event of default under any Intellectual Property Agreement or result in a termination thereof or would cause or permit the acceleration or other changes of any right or obligation or the loss of any benefit thereunder.

 

(c)          Seller and/or Evans are the sole and exclusive legal and beneficial, and with respect to the Intellectual Property Registrations, record, owners of all right, title and interest in and to the Intellectual Property Assets. Seller and Evans represent and warrant that the Intellectual Property Assets disclosed in Section 3.11(a)(ii) of the Disclosure Schedule are original works of authorship by Seller and/or Evans and are not copied from any other Person.

 

  - 8 -  

 

  

(d)          The consummation of the transactions contemplated hereunder will not result in the loss or impairment of or payment of any additional amounts with respect to, nor require the consent of any other Person in respect of, the Buyer’s right to own, use or hold for use any Intellectual Property as owned, used or held for use in the conduct of the Business as currently conducted.

 

(e)          Seller’s and Evan’s rights in the Intellectual Property Assets are valid, subsisting and enforceable. Seller and Evans have taken all reasonable steps to maintain the Intellectual Property Assets and to protect and preserve the confidentiality of all trade secrets included therein. To Seller’s Knowledge, no Authorized Persons have infringed, misappropriated, diluted or otherwise violated, or is currently infringing, misappropriating, diluting or otherwise violating, any Intellectual Property used to create or produce the Intellectual Property Assets disclosed in Section 3.11(a)(ii) of the Disclosure.

 

(f)          The conduct of the Business as currently and formerly conducted, and the Intellectual Property Assets and Intellectual Property licensed under the Intellectual Property Agreements as currently or formerly owned, licensed or used by Seller or Evans, have not infringed, misappropriated, diluted or otherwise violated, and have not, do not and will not infringe, dilute, misappropriate or otherwise violate, the Intellectual Property or other rights of any Person. To Seller’s Knowledge, no Person has infringed, misappropriated, diluted or otherwise violated, or is currently infringing, misappropriating, diluting or otherwise violating, any Intellectual Property Assets.

 

(g)          There are no Actions (including any oppositions, interferences or re- examinations) settled, pending or, to Seller’s Knowledge, threatened (including in the form of offers to obtain a license): (i) alleging any infringement, misappropriation, dilution or violation of the Intellectual Property of any Person by Seller or Evans in connection with the Business; (ii) challenging the validity, enforceability, registrability or ownership of any Intellectual Property Assets or Seller’s or Evan’s rights with respect to any Intellectual Property Assets; or (iii) by Seller, Evans or any other Person alleging any infringement, misappropriation, dilution or violation by any Person of any Intellectual Property Assets. Seller or Evans is not subject to any outstanding or prospective Governmental Order (including any motion or petition therefor) that does or would restrict or impair the use of any Intellectual Property Assets.

 

Section 3.12. Inventory . Inventory consists of a quality and quantity usable and salable in the ordinary course of business consistent with past practice, except for obsolete, damaged, defective or slow-moving items that have been written off or written down to fair market value or for which adequate reserves have been established. Inventory is owned by Seller free and clear of all Liens, and no Inventory is held on a consignment basis. The quantities of each item of Inventory (whether raw materials, work-in-process or finished goods) are not excessive, but are reasonable in the present circumstances of Seller.

 

Section 3.13. Accounts Receivable . The Accounts Receivable reflected on the Most Recent Balance Sheet and the Accounts Receivable arising after the date thereof (a) have arisen from bona fide transactions entered into by Seller involving the sale of goods or the rendering of services in the ordinary course of business consistent with past practice; (b) constitute only valid, undisputed claims of Seller; and (c) to Seller’s knowledge are not subject to claims of set-off or other defenses or counterclaims other than normal cash discounts accrued in the ordinary course of business consistent with past practice.

 

  - 9 -  

 

  

Section 3.14. Suppliers and Customers .

 

(a)          In the past two years, no supplier of Seller has canceled or, to Seller’s Knowledge, threatened to cancel, any Contract with Seller or to not provide, products, supplies, or services to Seller. Seller’s relationship with its suppliers is satisfactory. To Seller’s Knowledge, none of its suppliers is unable to supply the products or services supplied by them to Seller in order to meet the specifications provided with respect thereto. To Seller’s Knowledge, none of Seller’s suppliers intends to cease or materially diminish or raise prices for its supply of goods or services to Seller at any time in the foreseeable future.

 

(b)          In the past two years, no customer of Seller has canceled any Contract with Seller and to Seller’s Knowledge, there has been no threat by any customer to cancel any order for (or to not exercise any option for) products, supplies or services from Seller at any time in the past two years. Seller’s relationship with its customers is good. To Seller’s Knowledge, none of Seller’s customers intends to cease or materially diminish its purchase of goods or services from Seller at any time in the foreseeable future.

 

Section 3.15. Insurance . Section 3.15 of the Disclosure Schedule sets forth (a) a true and complete list of all current policies of insurance maintained by Seller (the “ Insurance Policies ”) and (b) a list of all pending claims and the claims history for Seller. There are no claims related to the Business, the Purchased Assets or the Assumed Liabilities pending under any such insurance policies as to which coverage has been questioned, denied or disputed or in respect of which there is an outstanding reservation of rights. Seller has not received any notice of cancellation of, premium increase with respect to, or alteration of coverage under, any of such insurance policies. All premiums due on such Insurance Policies have either been paid or, if not yet due, accrued.

 

Section 3.16. Legal Proceedings; Governmental Orders . There are no Actions pending or, to Seller’s or Shareholders’ Knowledge, threatened by or against Seller or the Shareholders with respect to any of the Purchased Assets. No event has occurred or circumstances exist that, to Seller’s or Shareholders’ Knowledge, may give rise to, or serve as a basis for, any such Action. There are no outstanding Governmental Orders and no unsatisfied judgments, penalties or awards against, relating to or affecting Seller or the Shareholders.

 

Section 3.17. Compliance With Laws; Permits . Seller has complied, and is now complying, in all material respects with all Laws applicable to the conduct of the Business as currently conducted or the ownership and use of the Purchased Assets. All Permits required for Seller to conduct the Business as currently conducted or for the ownership and use of the Purchased Assets have been obtained by Seller and are valid and in full force and effect.

 

Section 3.18. Product Warranties and Liabilities . Section 3.18 of the Disclosure Schedule lists all forms of warranties, savings guaranties and other guaranties or assurances of products and services that are in effect or proposed to be used by Seller. Section 3.18 of the Disclosure Schedule sets forth a description of each pending or, to the Knowledge of Seller, threatened Action under any warranty or guaranty against Seller. Seller has not incurred, nor, to the Knowledge of Seller, is there any basis for alleging, any Losses as a result of any material defect or other material deficiency with respect to any product sold or services rendered by or on behalf of Seller that has had or, insofar as can be reasonably foreseen, could have an adverse effect on the Business.

 

  - 10 -  

 

  

Section 3.19. Environmental . Seller has at all times been in compliance with all Environmental Laws. Seller has not received notice of actual or threatened liability under any Environmental Laws from any Governmental Authority or any third party and, to Seller’s Knowledge, there are no facts or circumstances which could form the basis for the assertion of any claim against Seller under any Environmental Laws.

 

Section 3.20. Employment Matters .

 

(a)           Section 3.20(a) of the Disclosure Schedule contains a list of all persons who are employees, independent contractors or consultants of Seller as of the date hereof, and sets forth for each such individual the following: (i) name; (ii) title or position (including whether full or part time); (iii) hire date; (iv) current annual base compensation rate; (v) commission, bonus or other incentive-based compensation; and (vi) a description of the fringe benefits provided to each such individual as of the date hereof. There are no outstanding agreements, understandings or commitments of Seller with respect to any compensation, commissions or bonuses.

 

(b)          Seller is not, and has never been, a party to, bound by, or negotiating any collective bargaining agreement or other Contract with a union, works council or labor organization (collectively, “ Union ”), and there is not, and has not been, any Union representing or purporting to represent any employee of Seller, and, to Seller’s Knowledge, no Union or group of employees is seeking or has sought to organize employees for the purpose of collective bargaining.

 

(c)          Seller is and has been in compliance in all material respects with all Laws relating to labor relations, equal employment opportunities, fair employment practices, employment discrimination, harassment, retaliation, reasonable accommodation, disability rights or benefits, immigration, wages, hours, overtime compensation, child labor, hiring, promotion and termination of employees, working conditions, meal and break periods, privacy, health and safety, workers’ compensation, leaves of absence and unemployment insurance. All individuals characterized and treated by Seller as consultants or independent contractors of the Business are properly treated as independent contractors under all applicable Laws. All employees classified as exempt under the Fair Labor Standards Act and state and local wage and hour laws are properly classified. There are no Actions against Seller pending, or to Seller’s Knowledge, threatened to be brought or filed, by or with any Governmental Authority or arbitrator in connection with the employment of any current or former applicant, employee, consultant or independent contractor of the Business, including, without limitation, any claim relating to unfair labor practices, employment discrimination, harassment, retaliation, equal pay, wages and hours or any other employment related matter arising under applicable Laws.

 

  - 11 -  

 

  

Section 3.21. Taxes .

 

(a)          (A) All Tax Returns that are required to be filed on or before the Closing Date (taking into account any extensions of time within which to file that have not expired) by or with respect to the Seller have been or will be timely filed on or before the Closing Date, (B) all such Tax Returns are or will be true, correct and complete in all material respects, (C) all Taxes due and payable by or with respect to the Seller (whether or not shown as due on any Tax Return) have been timely paid in full, (D) the unpaid Taxes of the Seller did not, as of the date of the Most Recent Financial Statements exceed the reserve for Tax liability set forth on the face of such financial statements and will not exceed that reserve as adjusted for the passage of time through the Closing Date in accordance with the past custom and practice of the Seller Group in filing its Tax Returns, (E) all deficiencies asserted or assessments made as a result of examinations conducted by any taxing authority have been paid in full, (F) no issues that have been raised by the relevant taxing authority in connection with the examination of any of the Tax Returns referred to in clause (A) are currently pending and (G) no statutes of limitation with respect to any Taxes of the Seller have been waived or extended by or on behalf of the Seller.

 

(b)          The Seller has made available to Guardion (A) true and correct copies of the U.S. federal, state, local and foreign income Tax Returns filed by or on behalf of the Seller for each of the two most recent fiscal years for which such returns have been filed and (B) any audit report issued within the last three years relating to Taxes due from or with respect to the Seller or its income, assets or operations. Section 3.21(b) of the Disclosure Schedule sets forth any income or franchise Tax Returns filed by or on behalf of the Seller that have been examined by any taxing authority since January 1, 2013.

 

(c)          To Seller’s knowledge, there are no audits or investigations by any taxing authority or proceedings in progress with respect to the Seller. The Seller has not received any notice from any taxing authority that it intends to conduct such an audit or investigation.

 

(d)          No claim has been made in writing during the past five (5) years by a taxing authority in a jurisdiction where the Seller does not already file Tax Returns that the Seller is or may be subject to taxation by that jurisdiction.

 

(e)          The Seller has withheld and paid over all Taxes required to have been withheld and paid over, and complied with all information reporting and backup withholding requirements, including maintenance of required records thereto, in connection with amounts paid or owing to any employee, creditor, independent contractor, or other third party and has complied in all material respects with all applicable laws, rules and regulations relating to the withholding and payment of Taxes.

 

(f)          The Seller does not have a permanent establishment in any country other than the United States under any applicable Tax treaty between the United States and such other country and is not subject to income Tax in any country other than the United States.

 

(g)          There are no Liens or other encumbrances on any of the assets of the Seller that arose in connection with any failure (or alleged failure) to pay any Tax.

 

  - 12 -  

 

  

(h)          No closing agreements, extensions of time within which to file any Tax Return, private letter rulings (or comparable rulings), technical advice memoranda or similar agreements or rulings have been entered into, requested of or issued by any taxing authority with respect to the Seller.

 

(i)          The Seller has been at all times since January 1, 1988 an "S corporation" within the meaning of Sections 1361 and 1362 of the Code. Buyer will not be liable for any Tax under Section 1374 of the Code (or any corresponding provision of state, local or foreign Law) in connection with the transactions contemplated under this Agreement.

 

(j)          No member of the Seller has been, in the past five (5) years, a party to a transaction reported or intended to qualify as a reorganization under Section 368 of the Code. No member of the Seller has been a "distributing corporation" or a "controlled corporation" (within the meaning of Section 355(a)(1)(A) of the Code) in a distribution of shares that was reported or otherwise constituted a distribution of shares under Section 355 of the Code in the two (2) years prior to the date of this Agreement or that could otherwise constitute part of a "plan" or "series of related transactions" (within the meaning of Section 355(e) of the Code) that includes the Transaction contemplated by this Agreement.

 

(k)          The transactions contemplated by this Agreement are not subject to withholding under Section 1445 of the Code, and no stock transfer Taxes, sales Taxes, use Taxes or real estate transfer or gains Taxes will be imposed on the transaction contemplated by this Agreement.

 

(l)          The Seller will not be required to include any material item of income in, or exclude any material item of deduction from its taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of any of the following that occurred or exists on or prior to the Closing Date: (A) a "closing agreement" as described in Section 7121 of the Code (or any corresponding or similar provision of the Code or of the Tax laws of any state or locality), (B) an installment sale or open transaction, (C) a prepaid amount, or (D) change in the accounting method of Seller pursuant to Section 481 of the Code (or any corresponding or similar provision of the Code or of the Tax laws of any state or locality).

 

(m)          The Seller is not a party to any Tax sharing, Tax allocation or similar agreement or arrangement (whether or not written) with any Person.

 

(n)          The Seller has not (A) consummated or participated in, and is not currently participating in, any transaction which was or is a "tax shelter" transaction as defined in Section 6662, 6011, 6111 or 6112 of the Code, applicable regulations thereunder or other related published guidance from the IRS or (B) engaged in any transaction that could give rise to (1) a registration obligation with respect to any Person under Section 6111 of the Code or the regulations thereunder, (2) a list maintenance obligation with respect to any person under Section 6112 of the Code or the regulations thereunder, or (3) a disclosure obligation as a "reportable transaction" under Section 6011 of the Code or the regulations thereunder.

 

(o)          No power of attorney granted by the Seller relating to Taxes is currently in force.

 

  - 13 -  

 

  

(p)          The Seller has not been a member of a consolidated, combined, unitary or affiliated group or has any liability for Taxes of any Person under Section 1.1502-6 of the regulations of the U.S. Treasury ("Treasury Regulations") or any similar provision of state, local, or foreign law, or as a transferee or successor, by contract, or otherwise.

 

(q)          No property owned by the Seller (A) is property required to be treated as being owned by another Person pursuant to the provisions of Section 168(f)(8) of the Internal Revenue Code of 1954, as amended and in effect immediately prior to the enactment of the Tax Reform Act of 1986, (B) constitutes "tax-exempt use property" within the meaning of Section 168(h)(1) of the Code or (C) is "tax-exempt bond financed property" within the meaning of Section 168(g)(5) of the Code.

 

(r)          The Seller Group is not required to include in income any amount for an adjustment pursuant to (A) election by the Seller under Section 108(i) of the Code or the Treasury Regulations thereunder or (B) any other election, action, or agreement by the Seller Group that would have the effect of deferring any liability for Taxes of the Seller Group.

 

Section 3.22. Benefit Plans . Section 3.22 of the Disclosure Schedule contains a true and complete list of each Benefit Plan. Each Benefit Plan has been established, administered and maintained in accordance with its terms and in compliance with all applicable Laws (including ERISA and the Code). Each Benefit Plan that is intended to be qualified under Section 401(a) of the Code (a “ Qualified Benefit Plan ”) is so qualified and has received a favorable and current determination letter from the Internal Revenue Service, or with respect to a prototype plan, can rely on an opinion letter from the Internal Revenue Service to the prototype plan sponsor, to the effect that such Qualified Benefit Plan is so qualified and that the plan and the trust related thereto are exempt from federal income taxes under Sections 401(a) and 501(a), respectively, of the Code. Neither Seller nor any of its ERISA Affiliates has (a) incurred or reasonably expects to incur, either directly or indirectly, any material Liability under Title I or Title IV of ERISA or related provisions of the Code or foreign Law relating to employee benefit plans; (b) failed to timely pay premiums to the Pension Benefit Guaranty Corporation; (c) withdrawn from any Benefit Plan that is a “multiemployer plan” within the meaning of Section 3(37) of ERISA; or (d) engaged in any transaction which would give rise to liability under Section 4069 or Section 4212(c) of ERISA.

 

Section 3.23. Transactions with Affiliates; Capitalization . Section 3.23 of the Disclosure Schedule sets forth a list of all business relationships and transactions between Seller and any of the Affiliates, officers, directors, or shareholders thereof or any of such officer’s, director’s, or Shareholders’ Affiliates, in each case currently in existence or that existed within the prior two years. No such Person is engaged in competition with Seller nor does Seller or any such person have an interest in any customer, supplier or other business relation of Seller. Section 3.23 of the Disclosure Schedule also sets forth the capitalization of Seller, including the percentage of the outstanding common stock of the Seller on a fully-diluted basis owned by each Shareholders.

 

Section 3.24. Documents . Seller has provided Buyer with true, correct and complete copies of all documents listed or described in this Article III or in the Disclosure Schedule.

 

  - 14 -  

 

  

Section 3.25. Investment Representations by Seller and Shareholders.

 

(a)          The Seller and the Shareholders are acquiring the Acquired Shares for their own account and not with a view to distribution within the meaning of Section 2(11) of the Securities Act of 1933, as amended (the “ Securities Act ”);

 

(b)          The Seller and the Shareholders are each an “accredited investor” within the meaning set forth in Regulation D promulgated under the Securities Act;

 

(c)          The Seller and the Shareholders either (x) have a pre-existing relationship with Guardion or one or more of its officers, managers or controlling persons; or (y) are capable of evaluating the risks and merits of an investment in the interests in Guardion and of protecting their own interests in connection with this investment;

 

(d)          The Seller and the Shareholders have not seen, received, been presented with, or been solicited by any leaflet, public promotional meeting, newspaper or magazine article or advertisement, radio or television advertisement, or any other form of advertising or general solicitation with respect to the issuance of the Acquired Shares of Guardion;

 

(e)          The Seller and the Shareholders acknowledge that (v) the Acquired Shares have not been registered under the Securities Act or any applicable state securities laws; (w) neither Guardion nor the board of directors of Guardion is under any obligation to register or qualify the interests in Guardion under the Securities Act or under any state securities law, or to assist the Seller or Shareholders in complying with any exemption from registration and qualification; (x) any investment in the interests in Guardion is a speculative investment which involves a substantial degree of risk of loss of such their entire investment in Guardion; (y) they each understand and take full cognizance of the risk factors related to the interests in Guardion; and (z)          that it may not be possible to liquidate an investment in Guardion; and

 

(f)          Without limiting the representations set forth above, the Seller and the Shareholders will not make any disposition of all or any part of their interests in Guardion in a manner that will result in the violation by either the Seller or the Shareholders or Guardion of the Securities Act or any other applicable securities laws.

 

(g)          The Seller and Shareholders acknowledge that the Acquired Shares will bear one or all of the following legends:

 

“THESE SECURITIES HAVE NOT BEEN REGISTERED OR QUALIFIED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR THE SECURITIES OR BLUE SKY LAWS OF ANY STATE. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT OR QUALIFICATION IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT AND STATE BLUE SKY LAWS OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO GUARDION HEALTH SCIENCES, INC. THAT SUCH REGISTRATION AND QUALIFICATION IS NOT REQUIRED OR UNLESS SOLD PURSUANT TO RULE 144 OF SUCH ACT.”

 

  - 15 -  

 

  

“SALE, TRANSFER, PLEDGE, ENCUMBRANCE, HYPOTHECATION, OR DISPOSITION OF THE SHARES REPRESENTED BY THIS CERTIFICATE IS RESTRICTED BY THE PROVISIONS OF AN ASSET PURCHASE AND REORGANIZATION AGREEMENT AMONG THE SHAREHOLDERS AND THE COMPANY DATED AS OF SEPTEMBER , 2017. ALL PROVISIONS OF THE AGREEMENT ARE INCORPORATED BY REFERENCE IN THIS CERTIFICATE. A COPY OF THE AGREEMENT MAY BE INSPECTED AT THE PRINCIPAL OFFICE OF THE COMPANY.”

 

Section 3.26. No Broker . No broker, finder or similar agent has been employed by or on behalf of the Seller or the Shareholders in connection with this Agreement or the transactions contemplated hereby, and the Seller and the Shareholders have not entered into any agreement, arrangement or understanding of any kind with any Person for the payment of any brokerage commission, finder’s fee or any similar compensation in connection with this Agreement or the transactions contemplated hereby.

 

ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF BUYER AND GUARDION

 

Section 4.1. Representations of Buyer . Buyer represents and warrants to Seller that the statements contained in this Article IV are true and correct as of the date hereof and will be true and correct as of the Closing.

 

(a)           Organization and Authority of Buyer . Buyer is a corporation duly organized, validly existing and in good standing under the Laws of the state of Delaware. Buyer has full corporate power and authority to enter into this Agreement and the other Transaction Documents to which Buyer is a party, to carry out its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. The execution and delivery by Buyer of this Agreement and any other Transaction Document to which Buyer is a party, the performance by Buyer of its obligations hereunder and thereunder and the consummation by Buyer of the transactions contemplated hereby and thereby have been duly authorized by all requisite corporate action on the part of Buyer. This Agreement has been duly executed and delivered by Buyer, and (assuming due authorization, execution and delivery by the other parties) this Agreement constitutes a legal, valid and binding obligation of Buyer enforceable against Buyer in accordance with its terms. When each other Transaction Document to which Buyer is or will be a party has been duly executed and delivered by Buyer (assuming due authorization, execution and delivery by each other party thereto), such Transaction Document will constitute a legal and binding obligation of Buyer enforceable against it in accordance with its terms.

 

(b)           No Conflicts . The execution, delivery and performance by Buyer of this Agreement and the other Transaction Documents to which it is a party, and the consummation of the transactions contemplated hereby and thereby, do not and will not: (a) conflict with or result in a violation or breach of, or default under, any provision of the organizational documents of Buyer; (b) conflict with or result in a violation or breach of any provision of any Law or Governmental Order applicable to Buyer; or (c) require the consent, notice or other action by any Person under any Contract to which Buyer is a party.

 

  - 16 -  

 

  

(c)           Legal Proceedings; Governmental Orders . There are no Actions pending or, to Buyer's Knowledge, threatened by or against Buyer with respect to any of its assets that are likely to have a Material Adverse Effect on Buyer.

 

(d)           Compliance with Laws . Buyer has complied, will comply, in all material respects with all Laws applicable to the conduct of the Business as currently conducted except where the failure to so comply will not have a Material Adverse Effect on Buyer.

 

Section 4.2. Representations of Guardion Guardion represents and warrants to Seller that the statements contained in this Article IV are true and correct as of the date hereof and will be true and correct as of the Closing.

 

(a)           Organization and Authority of Guardion . Guardion is a corporation duly organized, validly existing and in good standing under the Laws of the state of Delaware. Guardion has full corporate power and authority to enter into this Agreement and the other Transaction Documents to which Guardion is a party, to carry out its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. The execution and delivery by Guardion of this Agreement and any other Transaction Document to which Guardion is a party, the performance by Guardion of its obligations hereunder and thereunder and the consummation by Guardion of the transactions contemplated hereby and thereby have been duly authorized by all requisite corporate action on the part of Guardion. This Agreement has been duly executed and delivered by Guardion, and (assuming due authorization, execution and delivery by the other parties) this Agreement constitutes a legal, valid and binding obligation of Guardion enforceable against Guardion in accordance with its terms. When each other Transaction Document to which Guardion is or will be a party has been duly executed and delivered by Guardion (assuming due authorization, execution and delivery by each other party thereto), such Transaction Document will constitute a legal and binding obligation of Guardion enforceable against it in accordance with its terms.

 

(b)           No Conflicts . The execution, delivery and performance by Guardion of this Agreement and the other Transaction Documents to which it is a party, and the consummation of the transactions contemplated hereby and thereby, do not and will not: (a) conflict with or result in a violation or breach of, or default under, any provision of the organizational documents of Guardion; (b) conflict with or result in a violation or breach of any provision of any Law or Governmental Order applicable to Guardion; or (c) require the consent, notice or other action by any Person under any Contract to which Guardion is a party.

 

(c)           Interests Duly Authorized . All of the Acquired Shares to be issued to Seller pursuant to this Agreement, when issued and delivered in accordance with the terms of this Agreement, will be duly authorized, validly issued, fully paid and non-assessable and shall be free and clear of all Liens.

 

(d)           No General Solicitation . Guardion has not conducted any general solicitation or general advertisement in connection with the contribution or an investment in Guardion by any Person.

 

  - 17 -  

 

  

(e)           Legal Proceedings; Governmental Orders . There are no Actions pending or, to Guardion’s Knowledge, threatened by or against Guardion with respect to any of its assets that are likely to have a Material Adverse Effect on Guardion.

 

(f)           Compliance with Laws . Guardion has complied, will comply, in all material respects with all Laws applicable to the conduct of the Business as currently conducted except where the failure to so comply will not have a Material Adverse Effect on Guardion.

 

ARTICLE V
COVENANTS

 

Section 5.1. Conduct of Business Prior to the Closing . From the date hereof until the Closing, except as otherwise provided in this Agreement or consented to in writing by Buyer (which consent shall not be unreasonably withheld or delayed), Seller shall (x) conduct the Business in the ordinary course of business consistent with past practice; and (y) use reasonable best efforts to maintain and preserve intact its current Business organization, operations and franchise and to preserve the rights, franchises, goodwill and relationships of its employees, customers, licensors, licensees and others having relationships with the Business. Without limiting the foregoing, from the date hereof until the Closing Date, Seller shall not

 

(a)          sell, transfer, pledge otherwise create any Lien or otherwise dispose of any assets other than the sale of Inventory in the ordinary course of business;

 

(b)          acquire assets (other than purchases of supplies in the ordinary course of business);

 

(c)          incur, create, assume or otherwise become liable for any Liability other than in the ordinary course of business;

 

(d)          amend or terminate, or waive, release or assign any material rights or claims with respect to, any Contract or permit, other than in the ordinary course of business;

 

(e)          enter into any Contract that would constitute a Material Contract;

 

(f)          accelerate collection of Accounts Receivable, delay payment of accounts payable, or change cash balances from the collection, payment, and cash management policies of Seller;

 

(g)          forgive or cancel any other debt or claim, or voluntarily waive any material right;

 

(h)          introduce any material change with respect to the Business;

 

(i)          take any action that would result in any of the representations and warranties set forth in Article III becoming untrue in any material respect;

 

  - 18 -  

 

  

(j)          make or change any Tax election or method of Tax accounting, settle or otherwise finally resolve any dispute or proceeding with respect to Taxes; file any amended Tax return with respect to a material amount of Taxes;

 

(k)          take any action that would result in a Material Adverse Effect; or

 

(l)          agree to or otherwise take any of the foregoing actions.

 

Section 5.2. Access to Information . From the date hereof until the Closing, Seller shall afford Buyer and its Representatives reasonable access to and the right to inspect all of the properties, assets, premises, and other documents and data related to the Business.

 

Section 5.3. Notice of Certain Events . From the date hereof until the Closing, Seller shall promptly notify Buyer in writing of any fact, circumstance, event or action the existence, occurrence or taking of which (a) has resulted in, or could reasonably be expected to result in, any representation or warranty made by a Seller Party hereunder not being true and correct or (b) has resulted in, or could reasonably be expected to result in, the failure of any of the conditions set forth in Section 6.1 to be satisfied. Buyer’s receipt of information pursuant to this Section 5.3 shall not operate as a waiver or otherwise affect any representation, warranty or agreement given or made by Seller in this Agreement and shall not be deemed to amend or supplement the Disclosure Schedule.

 

Section 5.4. Employees . Buyer may at its option offer employment to such number of Seller’s employees as Buyer determines and, without limiting the foregoing, may condition each such offer on the employee successfully passing customary background checks requested by Buyer and having in place all certifications, clearances, and authorizations, including any necessary foreign worker or immigration documentation, required to perform the duties of the specified position. Buyer shall set the initial terms and conditions of such employment. Seller shall allow Buyer to communicate with the employees at any time after the date hereof to determine whether such employment offers will be made and, subject to applicable Laws, Buyer will upon request have reasonable access to the personnel records (including performance appraisals, disciplinary actions, grievances and medical records) of Seller for the purpose of preparing for and conducting employment interviews with the employees. Prior to the Closing Date, Buyer shall negotiate and communicate directly with Seller’s employees and shall deliver to Seller a list of those employees who have accepted Buyer’s offer of employment (“ Transferred Employees ”). On the Closing Date, Seller shall terminate the Transferred Employees and pay them all salaries, severance amounts, accrued vacation and other compensation and benefits payable or accrued through the Closing Date.

 

  - 19 -  

 

  

Section 5.5. Confidentiality . From and after the Closing, each Seller Party shall, and shall cause its Affiliates to, hold, and shall use its reasonable best efforts to cause its or their respective Representatives to hold, in confidence any and all information, whether written or oral, concerning the Business, except to the extent that such Seller Party can show that such information (a) is generally available to and known by the public through no fault of such Seller Party, any of its Affiliates or their respective Representatives; or (b) is lawfully acquired by such Seller Party, any of its Affiliates or their respective Representatives from and after the Closing from sources which are not prohibited from disclosing such information by a legal, contractual or fiduciary obligation. If a Seller Party or any of its Affiliates or their respective Representatives are compelled to disclose any information by judicial or administrative process or by other requirements of Law, such Seller Party shall promptly notify Buyer in writing and shall disclose only that portion of such information which such Seller Party is advised by its counsel in writing is legally required to be disclosed, provided that such Seller Party shall use reasonable best efforts to obtain an appropriate protective order or other reasonable assurance that confidential treatment will be accorded such information.

 

Section 5.6.           Non-Competition Agreements .

 

(a)           Seller Noncompete . Seller agrees that for a period of five (5) years following the Closing Date, it shall not:

 

(i)          directly or indirectly, as owner, employer, creditor or otherwise, engage in any aspect of the Business in the United State of America (the “ Territory ”);

 

(ii)         directly or indirectly, solicit, divert, take away, or attempt to solicit, divert or take away, any of the customers of Buyer or Guardion, or the business or patronage of any such customers, either for itself or on behalf of any other Person within Buyer's market or Guardion's market; and

 

(iii)        directly or indirectly facilitate, encourage, or participate in any way in the solicitation or recruitment of any employee of Buyer or Guardion either for itself or on behalf of any other Person.

 

(b)           Shareholders’ Noncompete . Except as otherwise set forth in Section 3.23 of the Disclosure Schedules, Shareholders will not during the term of the Consulting Agreement and for a period of at least two (2) years following expiration of the term of the Consulting Agreement, but in any case not less than five (5) years from the Closing Date:

 

(i)          directly or indirectly, as owner, employer, creditor or otherwise, engage in any aspect of the Business in the Territory;

 

(ii)         directly or indirectly, solicit, divert, take away, or attempt to solicit, divert or take away, any of the customers of Buyer or Guardion, or the business or patronage of any such customers, either for himself or on behalf of any other Person within Buyer's market or Guardion's market; and

 

(iii)        directly or indirectly facilitate, encourage, or participate in any way in the solicitation or recruitment of any employee of Buyer or Guardion either for himself or on behalf of any other Person.

 

The noncompetition agreement of Shareholders set forth in this Section 5.6 is in addition to the Consulting Agreement to be delivered by David Evans at the Closing.

 

(c)           Reasonableness of Restrictions . Shareholders and Seller acknowledge that compliance with the provisions of this Section 5.6 is reasonable and necessary to protect the value of the Purchased Assets and Buyer's and its Affiliates' legitimate business interests.

 

  - 20 -  

 

  

(d)           Irreparable Harm and Injunctive Relief . Shareholders and Seller acknowledge that a breach of their obligations under this Section 5.6 will result in great, irreparable and continuing harm and damage to Buyer and Guardion for which there is no adequate remedy at law. Shareholders and Seller agree that in the event Shareholders or Seller breaches this Agreement, Buyer and Guardion shall be entitled to seek, from any court of competent jurisdiction, preliminary and permanent injunctive relief to enforce the terms of this Agreement, in addition to any and all monetary damages allowed by law, against Shareholders and Seller.

 

(e)           Extension of Covenants . In the event Shareholders or Seller violates any one or more of the covenants contained in this Section 5.6 , the term of each such covenant so violated shall be automatically extended for a period equal to the period during which Shareholders or Seller is in violation of such covenants.

 

(f)           Judicial Modification . The non-competition provisions of this Agreement shall be deemed to consist of a series of separate covenants, one for each line of business carried on by Buyer (and its Affiliates, as applicable) and each county included within the Territory. The parties expressly agree that the character, duration and geographical scope of such provisions are reasonable in light of the circumstances as they exist on the date upon which this Agreement has been executed. The parties have attempted to limit Seller's and Shareholders' right to compete only to the extent necessary to protect the value of the Purchased Assets and Buyer's and its Affiliates goodwill and business interests related thereto. The parties recognize, however, that reasonable people may differ in making such a determination. Consequently, the parties hereby agree that a court having jurisdiction over the enforcement of this Agreement shall exercise its power and authority to reform the covenants under this Section 5.6 to the extent necessary to cause the limitations contained therein as to time, geographic area and scope of activity to be restrained to be reasonable and to impose a restraint that is not greater than necessary to protect the value of the Purchased Assets and Buyer's and its Affiliates goodwill and business interests related thereto.

 

Section 5.7. Efforts to Close . From the date hereof until the Closing, each party shall use reasonable commercial efforts to take such actions as are necessary to expeditiously consummate the transactions contemplated hereby.

 

Section 5.8. Announcements . Unless otherwise required by applicable Law prior to the Closing no party and following the Closing no Seller Party shall, nor shall it permit any Affiliate thereof to, make any public announcements in respect of this Agreement or the transactions contemplated hereby or otherwise communicate with any news media or to any Person (other than its Affiliates and advisors) without the prior written consent of the other party (which consent shall not be unreasonably withheld or delayed); provides, however , that the foregoing shall not preclude communications or disclosures necessary to implement the provisions of this Agreement, for the Buyer to operate the Business or for either Party or its Affiliates to comply with Securities and Exchange Commission disclosure and/or filing obligations or the rules and regulations of any stock exchange or national market system.

 

Section 5.9. Bulk Sales Laws . The parties hereby waive compliance with the provisions of any bulk sales, bulk transfer or similar Laws of any jurisdiction that may otherwise be applicable with respect to the sale of any or all of the Purchased Assets to Buyer; it being understood that any Liabilities arising out of the failure of Seller to comply with the requirements and provisions of any bulk sales, bulk transfer or similar Laws of any jurisdiction which would not otherwise constitute Assumed Liabilities shall be treated as Excluded Liabilities.

 

  - 21 -  

 

  

Section 5.10. Mail; Receivables . Seller hereby irrevocably authorizes Buyer from and after the Closing to receive and open all mail and other communications received by Buyer and relating to the Business or the Purchased Assets and addressed or directed to Seller and to act with respect to such communications in such manner as Buyer may elect, and to endorse and cash any checks or instruments payable or endorsed to Seller or its order which are received by Buyer and which are not Excluded Assets. From and after the Closing, if Seller or any of its Affiliates receives or collects any funds relating to any Accounts Receivable or any other Purchased Asset, Seller shall remit such funds to Buyer within five Business Days after its receipt thereof.

 

Section 5.11. Tax Treatment . The Transactions contemplated by this Agreement are intended to qualify as a reorganization within the meaning of Section 368(a)(1)(C) of the Code and this Agreement is hereby adopted as a “plan of reorganization” within the meaning of the Treasury Regulations promulgated under Section 368 of the Code. Until the Closing, each party to this Agreement shall use its commercially reasonable efforts to cause the transactions contemplated by this Agreement to so qualify, and will not knowingly take any action, cause any action to be taken, fail to take any action or cause any action not to be taken, which action or failure to act could prevent the transactions contemplated by this Agreement from qualifying as a reorganization within the meaning of Section 368(a).

 

Section 5.12. Distribution . As a part of the plan of reorganization described in Section 5.11 , on the Closing Date (or promptly after receipt thereof), the Company shall distribute to its Shareholders in liquidation all of the Common Stock received pursuant to this Agreement and all its other assets and liabilities.

 

Section 5.13. Transfer Taxes . All transfer, documentary, sales, use, stamp, registration, value added and other such Taxes and fees (including any penalties and interest) incurred in connection with this Agreement and the other Transaction Documents (including any real property transfer Tax and any other similar Tax) shall be borne and paid equally by Seller and Buyer when due. The party responsible under applicable law shall file any applicable transfer tax, with the cooperation and reasonable assistance of the other party.

 

Section 5.14. Name Change . Within ten (10) days following the Closing, Seller shall change its corporate name to one which does not include or bear any likeness to “VectorVision”, and shall deliver to Buyer evidence of the same.

 

Section 5.15. Payment of Excluded Liabilities . Seller shall pay all Excluded Liabilities when they become due. If any Excluded Liabilities are not so paid, or if Buyer reasonably determines that failure to make any payments would impair Buyer’s use or enjoyment of the Purchased Assets or conduct of the Business, then Buyer may, at any time after the Closing Date, elect to make such payments directly (but shall have no obligation to do so) and obtain indemnification hereunder.

 

  - 22 -  

 

  

Section 5.16. Insurance Proceeds . Seller shall, to the extent assignable, assign to Buyer any proceeds of Seller’s third party insurance policies to the extent related to any Purchased Assets or Assumed Liabilities. Seller agrees to use reasonable efforts to obtain any necessary consents or approvals of any insurance company or other third party relating to any such assignment. If such proceeds are not assignable, Seller agrees to pay any such proceeds received by either it or any of its members or other Affiliates to Buyer promptly upon the receipt thereof.

 

Section 5.17. Board Seat . Guardion shall appoint David Evans to the Board to serve until the next annual meeting of the shareholders of Guardion.

 

Section 5.18. Piggyback Registration Rights .

 

(a)           Company Registration . If Guardion shall determine to register any of its securities either for its own account or the account of a security holder or holders, other than Guardion’s first Qualified Public Offering, a registration relating solely to employee benefit plans, a registration relating to the offer and sale of debt securities, a registration relating to a corporate reorganization or other Rule 145 transaction, or a registration on any registration form that does not permit secondary sales, Guardion will:

 

(i)          give written notice of the proposed registration to Seller and the Shareholders; and

 

(ii)         use its commercially reasonable efforts to include in such registration (and any related qualification under blue sky laws or other compliance), except as set forth in Section 5.18(b) below, and in any underwriting involved therein, all of such Registrable Securities as are specified in a written request or requests made by Seller or the Shareholders received by Guardion within ten (10) days after such written notice from Guardion is mailed or delivered. Such written request may specify all or a part of the Registrable Securities.

 

(b)           Underwriting . If the registration of which Guardion gives notice is for a registered public offering involving an underwriting, Guardion shall so advise Seller and the Shareholders as a part of the written notice given pursuant to Section 5.18(a)(i). In such event, the right of Seller and the Shareholders to registration pursuant to this Section 5.18(b) shall be conditioned upon Seller and the Shareholders’ participation in such underwriting and the inclusion of Seller and the Shareholders’ Registrable Securities in the underwriting to the extent provided herein. Seller and the Shareholders’ proposing to distribute their securities through such underwriting shall (together with Guardion, and any Other Selling Stockholders with registration rights to participate therein distributing their securities through such underwriting) enter into an underwriting agreement in customary form with the representative of the underwriter or underwriters selected by Guardion.

 

Notwithstanding any other provision of this Section 5.18(b) , if the underwriters advise Guardion in writing that marketing factors require a limitation on the number of shares to be underwritten, the underwriters may (subject to the limitations set forth below) limit the number of Registrable Securities to be included in, the registration and underwriting. Guardion shall so advise all holders of securities requesting registration, and the number of shares of securities that are entitled to be included in the registration and underwriting shall be allocated, as follows: (i) first, to Guardion for securities being sold for its own account, (ii) second, to the Seller and Shareholders requesting to include Registrable Securities in such registration statement based on the pro rata percentage of Registrable Securities held by Seller, the Shareholders, and any Other Selling Stockholders.

 

  - 23 -  

 

  

If Seller or the Shareholders have requested inclusion in such registration as provided above does not agree to the terms of any such underwriting, Seller and the Shareholders shall be excluded therefrom by written notice from Guardion or the underwriter. The Registrable Securities or other securities so excluded shall also be withdrawn from such registration.

 

(c)           Right to Terminate Registration . Guardion shall have the right to terminate or withdraw any registration initiated by it under this Section 5.18(c) prior to the effectiveness of such registration whether or not Seller and the Shareholders have elected to include securities in such registration, provided that Guardion shall promptly notify Seller and the Shareholders of such termination or withdrawal. The expenses of such withdrawn registration shall be borne by Guardion in accordance with Section 5.18(c) hereof.

 

(d)           Expenses of Registration . All Registration Expenses incurred in connection with registrations pursuant to Section 5.18 shall be borne by Guardion. All Selling Expenses relating to securities registered on behalf of Seller shall be borne by the holders of securities included in such registration pro rata among each other on the basis of the number of Registrable Securities so registered.

 

(e)           Indemnification . To the extent permitted by law, Seller and the Shareholders will, if Registrable Securities held by Seller and the Shareholders are included in the securities as to which such registration, qualification or compliance is being effected, indemnify and hold harmless Guardion, each of its directors, officers, partners, legal counsel and accountants and each underwriter, if any, of Guardion’s securities covered by such a registration statement, each person who controls Guardion or such underwriter within the meaning of Section 15 of the Securities Act, and each of their officers, directors and partners, against all claims, losses, damages and liabilities (or actions in respect thereof) arising out of or based on: (i) any untrue statement (or alleged untrue statement) of a material fact contained or incorporated by reference in any prospectus, offering circular or other document (including any related registration statement, notification, or the like) incident to any such registration, qualification or compliance, or (ii) any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse Guardion and its directors, officers, partners, legal counsel and accountants, persons, underwriters, or control persons for any legal or any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability or action, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in such registration statement, prospectus, offering circular or other document in reliance upon and in conformity with written information furnished to Guardion by Seller and the Shareholders and stated to be specifically for use therein; provided , however , that the obligations of Seller and the Shareholders hereunder shall not apply to amounts paid in settlement of any such claims, losses, damages or liabilities (or actions in respect thereof) if such settlement is effected without the consent of Seller and the Shareholders (which consent shall not be unreasonably withheld); and provided that in no event shall any indemnity under this Section 5.18(e) exceed the net proceeds from the offering received by Seller and the Shareholders, except in the case of fraud or willful misconduct by Seller and the Shareholders.

 

  - 24 -  

 

  

(f)           Information by Seller and Shareholders . Seller and the Shareholders shall furnish to Guardion such information regarding Seller and the Shareholders and the distribution proposed by Seller and the Shareholders as Guardion may reasonably request in writing and as shall be reasonably required in connection with any registration, qualification, or compliance referred to in this Section 5.18(f) .

 

(g)           Delay of Registration . Seller and the Shareholders shall not have any right to take any action to restrain, enjoin, or otherwise delay any registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 5.18(g) .

 

(h)           Transfer or Assignment of Registration Rights . The rights to cause Guardion to register securities granted to Seller and the Shareholders by Guardion under this Section 5.18(h) may not be transferred or assigned by Seller or the Shareholders.

 

ARTICLE VI
CONDITIONS TO CLOSING

 

Section 6.1. Conditions to Obligations of Buyer . The obligation of Buyer to consummate the transactions contemplated by this Agreement shall be subject to the fulfillment or Buyer’s waiver, at or prior to the Closing, of each of the following conditions:

 

(a)          The representations and warranties of the Seller Parties contained in this Agreement, the other Transaction Documents and any certificate or other writing delivered pursuant hereto shall be true and correct in all respects (in the case of any representation or warranty qualified by materiality or Material Adverse Effect) or in all material respects (in the case of any representation or warranty not qualified by materiality or Material Adverse Effect) on and as of the date hereof and on and as of the Closing Date with the same effect as though made at and as of such date.

 

(b)          Each Seller Party shall have duly performed and complied in all material respects with all agreements, covenants and conditions required by this Agreement and each of the other Transaction Documents to be performed or complied with by it prior to or on the Closing Date.

 

(c)          All approvals, consents, waivers and Permits that are listed on Schedule 6.1(c) shall have been received.

 

(d)          From the date of this Agreement, there shall not have occurred any Material Adverse Effect, nor shall any event or events have occurred that, individually or in the aggregate, with or without the lapse of time, could reasonably be expected to result in a Material Adverse Effect.

 

(e)          Seller shall have delivered to Buyer duly executed counterparts to the Transaction Documents (other than this Agreement) and such other documents and deliveries set forth in Section 2.2(a).

 

  - 25 -  

 

  

(f)          Buyer shall have received a certificate, dated the Closing Date and signed by a duly authorized officer of Seller, that each of the conditions set forth in Section 6.1(a) and Section 6.1(b) have been satisfied.

 

Section 6.2. Conditions to Obligations of Seller . The obligation of Seller to consummate the transactions contemplated by this Agreement shall be subject to the fulfillment or Seller’s waiver, at or prior to the Closing, of each of the following conditions:

 

(a)          The representations and warranties of Buyer contained in this Agreement, the other Transaction Documents and any certificate or other writing delivered pursuant hereto shall be true and correct in all respects (in the case of any representation or warranty qualified by materiality or Material Adverse Effect) or in all material respects (in the case of any representation or warranty not qualified by materiality or Material Adverse Effect) on and as of the date hereof and on and as of the Closing Date with the same effect as though made at and as of such date.

 

(b)          Buyer and Guardion shall have duly performed and complied in all material respects with all agreements, covenants and conditions required by this Agreement and each of the other Transaction Documents to be performed or complied with by it prior to or on the Closing Date.

 

(c)          Seller shall have received a certificate, dated as of the Closing Date and signed by a duly authorized officer of Buyer and Guardion, that each of the conditions set forth in Section 6.2(a) and Section 6.2(b) have been satisfied.

 

(d)          Buyer and Guardion shall have delivered to Seller duly executed counterparts to the Transaction Documents (other than this Agreement) and such other documents and deliveries set forth in Section 2.2(b) applicable to each.

 

ARTICLE VII
INDEMNIFICATION

 

Section 7.1. Survival . The representations and warranties contained herein shall survive the Closing and shall remain in full force and effect until the date that is twenty four (24) months from the Closing Date (the “ General Survival Period ”); provided , that the representations and warranties in Section 3.1 (Organization and Qualification of Seller), Section 3.2 (Authority of Seller Parties), and Section 3.9 (Title, Condition and Sufficiency of Assets) shall survive for indefinitely following the Closing Date, the representations and warranties in Section 3.19 (Environmental), Section 3.21 (Taxes), and Section 3.22 (Benefit Plans) shall survive for the full period of all applicable statutes of limitations (giving effect to any waiver, mitigation or extension thereof) plus 60 days and there shall be no limitation on any representation and warranty the breach of which constitutes fraud. All covenants and agreements of the parties contained herein shall survive the Closing indefinitely or for the period explicitly specified therein. Notwithstanding the foregoing, any claims asserted in good faith with reasonable specificity (to the extent known at such time) and in writing by notice from the non- breaching party to the breaching party prior to the expiration date of the applicable survival period shall not thereafter be barred by the expiration of the relevant representation or warranty and such claims shall survive until finally resolved.

 

  - 26 -  

 

  

Section 7.2. Indemnification By Seller Parties . Subject to the other terms and conditions of this Article VII , from and after the Closing, each Seller Party shall indemnify and defend each of Buyer and its Affiliates and their respective Representatives (collectively, the “ Buyer Indemnitees ”) against, and shall hold each of them harmless from and against, and shall pay and reimburse each of them for, any and all Losses incurred or sustained by, or imposed upon, the Buyer Indemnitees based upon, arising out of, with respect to or by reason of:

 

(a)          any inaccuracy in or breach of any of the representations or warranties of Seller or of such Seller Party contained in this Agreement, the other Transaction Documents or in any certificate or instrument delivered by or on behalf of a Seller Party pursuant to this Agreement, as of the date such representation or warranty was made or as if such representation or warranty was made on and as of the Closing Date;

 

(b)          any breach or non-fulfillment of any covenant, agreement or obligation to be performed by Seller or such Seller Party pursuant to this Agreement, the other Transaction Documents or any certificate or instrument delivered by or on behalf of a Seller Party pursuant to this Agreement;

 

(c)          any Excluded Asset or any Excluded Liability (including any Seller Indebtedness and Seller Transaction Expenses); or

 

(d)          any Indemnified Taxes; or

 

(e)          any Third Party Claim based upon, resulting from or arising out of the business, operations, properties, assets or obligations of Seller or any of its Affiliates (other than the Purchased Assets or Assumed Liabilities) conducted, existing or arising on or prior to the Closing Date.

 

Section 7.3. Indemnification By Buyer . Subject to the other terms and conditions of this Article VII , from and after the Closing Buyer shall indemnify and defend each of Seller and its Affiliates and their respective Representatives (collectively, the “ Seller Indemnitees ”) against, and shall hold each of them harmless from and against, and shall pay and reimburse each of them for, any and all Losses incurred or sustained by, or imposed upon, the Seller Indemnitees based upon, arising out of, with respect to or by reason of:

 

(a)          any inaccuracy in or breach of any of the representations or warranties of Buyer contained in this Agreement or in any certificate or instrument delivered by or on behalf of Buyer pursuant to this Agreement, as of the date such representation or warranty was made or as if such representation or warranty was made on and as of the Closing Date;

 

(b)          any breach or non-fulfillment of any covenant, agreement or obligation to be performed by Buyer pursuant to this Agreement; or

 

(c)          any Assumed Liability.

 

  - 27 -  

 

  

Section 7.4.           Certain Limitations .

 

(a)          The Seller Parties shall not be liable to the Buyer Indemnitees for indemnification under Section 7.2(a) until the aggregate amount of all Losses in respect of indemnification under Section 7.2(a) exceeds Thirty Thousand Dollars ($30,000) (the “ Basket ”), in which event the Seller Parties shall be liable for all such Losses in excess of the Basket. The aggregate amount of all Losses for which the Seller Parties shall be liable pursuant to Section 7.2(a) shall not exceed the Value of the Acquired Shares (the “ Cap ”); provided, however , that the aggregate amount of all Losses for which the Seller Parties shall be liable pursuant to Section 7.2(a) (except in the case of fraud) shall not exceed the Purchase Price.

 

(b)          The Buyer Indemnitees will seek to recover on indemnification claims first from the Holdback Shares valued at the Per Share Value and, only if and to the extent such funds are insufficient, from the Seller Parties; provided, however , that the foregoing shall not preclude a Buyer Indemnitee from filing an Action against one or more Seller Parties to preserve its legal rights and remedies.

 

(c)          No Shareholder shall be liable to the Buyer Indemnitees for indemnification under Section 7.2(a) by reason of an inaccuracy in or breach of a representation and warranty of Seller for more than such Shareholders pro rata share of the Loss.

 

(d)          The amount of Losses on account of which the Seller Parties would otherwise be required to indemnify the Buyer Indemnitees shall be reduced by any insurance proceeds (net of any deductibles or co-payments and reasonable attorney’s fees and other expenses actually incurred by the Buyer Indemnitees in connection with such recovery) received by the Buyer Indemnitees from any insurance provided by any insurance company not Affiliated therewith and, for the avoidance of doubt, excluding any self-insurance, risk management program or other funds set aside by such Person in connection therewith.

 

Section 7.5. Indemnification Procedures . The party making a claim under this Article VII is referred to as the “ Indemnified Party ”, and the party against whom such claims are asserted under this Article VII is referred to as the “ Indemnifying Party ”.

 

  - 28 -  

 

  

(a)           Third Party Claims . If any Indemnified Party receives written notice of the assertion or commencement of any Action made or brought by any Person who is not a party to this Agreement or an Affiliate of a party to this Agreement or a Representative of the foregoing (a “ Third Party Claim ”) against such Indemnified Party with respect to which the Indemnifying Party is obligated to provide indemnification under this Agreement, the Indemnified Party shall give the Indemnifying Party reasonably prompt written notice thereof. The failure to give such reasonably prompt written notice shall not, however, relieve the Indemnifying Party of its indemnification obligations, except and only to the extent that the Indemnifying Party forfeits rights or defenses by reason of such failure. Such notice by the Indemnified Party shall describe the Third Party Claim in reasonable detail, shall include copies of all material written evidence thereof and shall indicate the estimated amount, if reasonably practicable, of the Loss that has been or may be sustained by the Indemnified Party. The Indemnifying Party shall have the right to participate in, or by giving written notice to the Indemnified Party, to assume the defense of any Third Party Claim at the Indemnifying Party’s expense and by the Indemnifying Party’s own counsel, and the Indemnified Party shall cooperate in good faith in such defense; provided , that if the Indemnifying Party is a Seller Party, such Indemnifying Party shall not have the right to defend or direct the defense of any such Third Party Claim that (x) is asserted directly by or on behalf of a Person that is a supplier, customer, licensor or licensee of the Business or by a Governmental Authority, (y) seeks an injunction or other equitable relief or criminal sanctions against the Indemnified Party, (z) involves claims for infringement of Intellectual Property or (aa) would likely, in the good faith determination of the Indemnified Party, have a material adverse effect on the Indemnified Party if the Third Party Claim is successful. The Indemnified Party shall have the right to participate in the defense of any Third Party Claim with counsel selected by it (subject to the Indemnifying Party’s right to control the defense thereof) and the fees and disbursements of such counsel shall be at the expense of the Indemnified Party, provided , that if in the reasonable opinion of counsel to the Indemnified Party, (A) there are legal defenses available to an Indemnified Party that are different from or additional to those available to the Indemnifying Party; or (B) there exists a conflict of interest between the Indemnifying Party and the Indemnified Party that cannot be waived, the Indemnifying Party shall be liable for the reasonable fees and expenses of counsel to the Indemnified Party in each jurisdiction for which the Indemnified Party determines counsel is required. If the Indemnifying Party elects not to or is not entitled to compromise or defend such Third Party Claim, fails to promptly notify the Indemnified Party in writing of its election to defend as provided in this Agreement, or fails to diligently prosecute the defense of such Third Party Claim, the Indemnified Party may pay, compromise, defend such Third Party Claim and seek indemnification for any and all Losses based upon, arising from or relating to such Third Party Claim.

 

(b)           Settlement of Third Party Claims . Notwithstanding any other provision of this Agreement, the Indemnifying Party shall not enter into settlement of any Third Party Claim without the prior written consent of the Indemnified Party, except as provided in this Section 7.5(b) . If a firm offer is made to settle a Third Party Claim without leading to liability or the creation of a financial or other obligation on the part of the Indemnified Party and provides, in customary form, for the unconditional release of each Indemnified Party from all liabilities and obligations in connection with such Third Party Claim and the Indemnifying Party desires to accept and agree to such offer, the Indemnifying Party shall give written notice to that effect to the Indemnified Party. If the Indemnified Party fails to consent to such firm offer within twenty

(20) days after its receipt of such notice, the Indemnified Party may continue to contest or defend such Third Party Claim and in such event, the maximum liability of the Indemnifying Party as to such Third Party Claim shall not exceed the amount of such settlement offer.

 

(c)           Direct Claims . Any Action by an Indemnified Party on account of a Loss which does not result from a Third Party Claim (a “ Direct Claim ”) shall be asserted by the Indemnified Party giving the Indemnifying Party reasonably prompt written notice thereof The failure to give such reasonable prompt written notice shall not, however, relieve the Indemnifying Party of its indemnification obligations, except and only to the extent that the Indemnifying Party forfeits rights or defenses by reason of such failure. Such notice by the Indemnified Party shall describe the Direct Claim in reasonable detail, shall include copies of all material written evidence thereof and shall indicate the estimated amount, if reasonably practicable, of the Loss that has been or may be sustained by the Indemnified Party.

 

  - 29 -  

 

  

Section 7.6. Tax Treatment of Indemnification Payments . All indemnification payments made under this Agreement shall be treated by the parties as an adjustment to the Purchase Price for Tax purposes, unless otherwise required by Law.

 

Section 7.7. Exclusive Remedies . The parties acknowledge and agree that their sole and exclusive remedy with respect to any and all claims (other than claims arising from fraud or willful misconduct on the part of a party in connection with the transactions contemplated by this Agreement) for any breach of any representation, warranty, covenant, agreement or obligation set forth herein or otherwise relating to the subject matter of this Agreement, shall be pursuant to the indemnification provisions set forth in this Article VII . Nothing in this Section 7.8 shall limit any Person’s right to seek and obtain any equitable relief to which any Person shall be entitled or to seek any remedy on account of any party’s fraudulent, criminal or intentional misconduct.

 

ARTICLE VIII

TERMINATION

 

Section 8.1. Termination . This Agreement may be terminated at any time prior to the Closing:

 

(a)          by the mutual written consent of Seller and Buyer;

 

(b)          by Buyer by written notice to Seller if (i) Buyer is not then in material breach of any provision of this Agreement and there has been a breach, inaccuracy in or failure to perform any representation, warranty, covenant or agreement made by a Seller Party pursuant to this Agreement that would give rise to the failure of any of the conditions specified in Section 6.1 and such breach, inaccuracy or failure has not been cured within ten (10) days of Seller’s receipt of written notice of such breach from Buyer; or (ii) any of the conditions set forth in Section 6.1 shall not have been fulfilled by the ninetieth (90th) day hereafter, unless due to the failure of Buyer to perform or comply with any of the covenants, agreements or conditions hereof to be performed or complied with by it prior to the Closing;

 

(c)          by Seller by written notice to Buyer if (i) no Seller Party is then in material breach of any provision of this Agreement and there has been a breach, inaccuracy in or failure to perform any representation, warranty, covenant or agreement made by Buyer pursuant to this Agreement that would give rise to the failure of any of the conditions specified in Section 6.2 and such breach, inaccuracy or failure has not been cured within ten days of Buyer’s receipt of written notice of such breach from Seller; or (ii) any of the conditions set forth in Section 6.2 shall not have been, or if it becomes apparent that any of such conditions will not be, fulfilled by the ninetieth (90th) day hereafter, unless due to the failure of Seller to perform or comply with any of the covenants, agreements or conditions hereof to be performed or complied with by it prior to the Closing; or

 

(d)          by Buyer or Seller in the event that (i) there shall be any Law that makes consummation of the transactions contemplated by this Agreement illegal or otherwise prohibited, (ii) any Governmental Authority shall have issued a Governmental Order restraining or enjoining the transactions contemplated by this Agreement, and such Governmental Order s hall have become final and non-appealable or (iii) an Action shall have been commenced against any party which could prevent the Closing.

 

  - 30 -  

 

  

Section 8.2. Effect of Termination . In the event of the termination of this Agreement in accordance with this Article VIII , this Agreement shall forthwith become void (other than the provisions of Section 5.9 , Article IX and this Article VIII ) provided that nothing herein shall relieve any party from liability for any willful breach of any provision hereof.

 

ARTICLE IX

MISCELLANEOUS

 

Section 9.1. Expenses . Except as otherwise expressly provided herein, all costs and expenses, including fees and disbursements of legal counsel, financial advisors and accountants, incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the party incurring such costs and expenses, whether or not the Closing shall have occurred.

 

Section 9.2. Notices . All notices, requests, consents, claims, demands, waivers and other communications hereunder shall be in writing and shall be deemed to have been given (a) when delivered by hand (with written confirmation of receipt); (b) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested); (c) on the date sent by facsimile or e-mail of a PDF document (with confirmation of transmission) if sent during normal business hours of the recipient, and on the next Business Day if sent after normal business hours of the recipient or (d) on the third day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Such communications must be sent to the respective parties at the addresses therefor set forth below, or such other address as may be designated in writing hereafter, in the same manner, by such party:

 

To Buyer:

 

Guardion Health Sciences, Inc.

15150 Avenue of Science, Suite 200

San Diego, CA 92128

Attention: Michael Favish

Telephone: 858-605-9055 Ext 201

Facsimile: 858-630-5543

Email: mfavish@guardionhealth.com

 

with a copy to (which shall not constitute notice):

 

Sheppard, Mullin, Richter & Hampton LLP

333 South Hope Street, 43rd Floor

Los Angeles, CA 90071

Attention: David I. Sunkin, Esq.

Telephone: (213) 617-4252

Facsimile: (213) 443-2750

Email: dsunkin@sheppardmullin.com

 

  - 31 -  

 

  

To Seller:

 

David W. Evans

4141 Jutland Drive, Suite 215

San Diego, CA 92117

Telephone: 937-548-7970

Facsimile: 937-548-2773

Email: devans@vectorvision.com

 

with a copy to (which shall not constitute notice):

 

Robert W. Hicks

600 W Broadway, Suite 700

San Diego, CA 92101

Telephone: (619) 794-4313

Facsimile: (619) 236-3413

Email: rhicks@rwhlaw.com

 

Section 9.3. Interpretation . For purposes of this Agreement, (a) the words “include,” “includes” and “including” shall be deemed to be followed by the words “without limitation”; (b)          the word “or” is not exclusive; and (c) the words “herein,” “hereof,” “hereby,” “hereto” and “hereunder” refer to this Agreement as a whole. Unless the context otherwise requires, references herein: (x) to Articles, Sections, Disclosure Schedule, Schedules, Annexes and Exhibits mean the Articles and Sections of, and Disclosure Schedule, Schedules, Annexes and Exhibits attached to, this Agreement; (y) to an agreement, instrument or other document means such agreement, instrument or other document as amended, supplemented and modified from time to time to the extent permitted by the provisions thereof (z) to a statute means such statute as amended from time to time and includes any successor legislation thereto and any regulations promulgated thereunder and (aa) a party means a party to this Agreement. This Agreement shall be construed without regard to any presumption or rule requiring construction or interpretation against the party drafting an instrument or causing any instrument to be drafted. The Disclosure Schedule, Schedules, Annexes and Exhibits referred to herein shall be construed with, and as an integral part of, this Agreement to the same extent as if they were set forth verbatim herein. The headings in this Agreement are for reference only and shall not affect the interpretation of this Agreement.

 

Section 9.4. Severability . If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction. Upon such determination that any term or other provision is invalid, illegal or unenforceable, the parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the greatest extent possible.

 

  - 32 -  

 

  

Section 9.5. Entire Agreement . This Agreement and the other Transaction Documents, constitute the sole and entire agreement of the parties with respect to the subject matter contained herein and therein, and supersede all prior and contemporaneous understandings and agreements, both written and oral, with respect to such subject matter.

 

Section 9.6. Successors and Assigns . This Agreement shall be binding upon and shall inure to the benefit of the parties and their respective successors and permitted assigns. No party may assign or delegate its rights or obligations hereunder without the prior written consent of the other parties; provided , however , that Buyer shall be entitled to assign or delegate all or any part of its rights or obligations hereunder (a) to any one or more Affiliates of Buyer, (b) in connection with the sale of all or any substantial portion of the assets of Buyer or one or more Affiliates of Buyer or (c) for collateral security purposes to any lender providing financing to Buyer. No assignment shall relieve the assigning party of any of its obligations hereunder.

 

Section 9.7. No Third-Party Beneficiaries . Except with respect to the Shareholders and Guardion, as provided in Article VII or as otherwise expressly provided herein, this Agreement is for the sole benefit of the parties and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other Person y any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.

 

Section 9.8. Amendment and Modification; Waiver . This Agreement may only be amended, modified or supplemented by an agreement in writing signed by each party. No waiver by any party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the party so waiving. No waiver by any party shall operate or be construed as a waiver in respect of any failure, breach or default not expressly identified by such written waiver, whether of a similar or different character, and whether occurring before or after that waiver. No failure to exercise, or delay in exercising, any right, remedy, power or privilege arising from this Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.

 

Section 9.9. Governing Law; Venue . This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction). Each party irrevocably consents and submits to the personal jurisdiction and venue of the federal and state courts located in San Diego County, California and irrevocably waives any and all claims and defenses which such party might otherwise have in any action or proceeding in any of such courts based upon any alleged lack of personal jurisdiction, improper venue, forum non conveniens or any similar claim or defense. The prevailing party in any action brought pursuant to the terms hereof shall be entitled to its attorneys’ fees and costs.

 

Section 9.10. Shareholders’ Obligations . The Shareholders’ obligations hereunder are unconditional irrespective of any circumstances which might otherwise constitute, by operation of Law, a discharge of a guarantor and it shall not be necessary for Buyer to institute, pursue or exhaust any remedies or causes of action against Seller or any other Person as a condition to the obligations of the Shareholders hereunder.

 

  - 33 -  

 

  

Section 9.11. Further Assurances . Each of the parties shall, and shall cause their respective Affiliates to, execute and deliver such additional documents, instruments, conveyances and assurances and take such further actions as may be reasonably required to carry out the provisions hereof and give effect to the transactions contemplated by this Agreement and the other Transaction Documents.

 

Section 9.12. Independent Review . Each Party represents and warrants that such Party (i) has been represented by independent legal counsel, and it's tax, accounting and other professional advisors with respect to the negotiation and preparation of this Agreement and the other Transaction Documents, (ii) has had an adequate opportunity to make whatever investigation or inquiry that such Party may deem reasonably necessary or desirable in connection with the subject matter of this Agreement and the other Transaction Documents prior to the execution hereof and thereof, and (iii) understands the contents, implications, and consequences of this Agreement and the other Transaction Documents and has executed this Agreement and the other Transaction Documents voluntarily. If any ambiguity or question of intent or interpretation arises, then this Agreement and the other Transaction Documents shall be construed as if drafted jointly by the Parties, and no presumption or burden of proof will arise favoring or disfavoring either party by virtue of the authorship of any of the provisions of this Agreement and the other Transaction Documents.

 

           
(Seller)   (Shareholder)   (Shareholder)  

 

Section 9.13. Counterparts . This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

 

[SIGNATURE PAGE FOLLOWS]

 

  - 34 -  

 

  

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the date first written above.

 

  GUARDION HEAL TH SCIENCES , INC.
   
  /Michael Favish/
  Michael Favish President
   
  VECTORVISION OCULAR HEALTH , INC .
   
  /Michael Favish/
  Michael Favish President
   
  VEC TO RVIS IO N, INC.
   
  /David Evans/
  David Evans
  Chief Executive Officer
   
  Shareho ld ers
   
  /David Evans/
  David Evans
   
  /Tamara Evans/
  Tamara Evans

 

Signature Page to Asset Purchase and Reorganization Agreement

 

 

 

  

Appendix A

 

DEFINITIONS

 

The following terms have the meanings specified or referred to in this Appendix A.

 

Accounts Receivable ” has the meaning set forth in Section 1.1(b) .

 

Acquired Shares ” has the meaning set forth in Section 1.5 .

 

Action ” means any claim, action, cause of action, demand, lawsuit, arbitration, inquiry, audit, notice of violation, proceeding, litigation, citation, summons, subpoena or investigation of any nature, civil, criminal, administrative, regulatory or otherwise, whether at law or in equity.

 

Affiliate ” of a Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such Person. The term “control” (including the terms “controlled by” and “under common control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.

 

Agreement ” has the meaning set forth in the Preamble.

 

Assigned Contracts ” has the meaning set forth in Section 1.1(g).

 

Assumed Liabilities ” has the meaning set forth in Section 1.3 .

 

Assumption Agreement ” has the meaning set forth in Section 2.2(a)(ii) .

 

Bank One Loan ” means that certain Business Credit Application and Agreement dated effective as of October 30, 1998 by and between Seller, and Shareholders, on the one hand, and Bank One, N.A., on the other hand.

 

Basket ” has the meaning set forth in Section 7.4(a) .

 

Benefit Plan ” means any pension, benefit, retirement, compensation, profit-sharing, deferred compensation, incentive, performance award, phantom equity, stock or stock-based, change in control, retention, severance, vacation, paid time off, fringe-benefit and other similar agreement, plan, policy, program or arrangement (and any amendments thereto), in each case whether or not reduced to writing and whether funded or unfunded, including each “employee benefit plan” within the meaning of Section 3(3) of ERISA, whether or not tax-qualified and whether or not subject to ERISA, which is or has been maintained, sponsored, contributed to, or required to be contributed to by Seller for the benefit of any current or former employee, officer, director, retiree, independent contractor or consultant of the Business or any spouse or dependent of such individual, or under which Seller has or may have any Liability.

 

Board ” means the Board of Directors of Guardion.

 

Appendix A
- 1

 

  

Business ” means the business conducted by Seller, including the development, manufacture, sales and distribution of equipment and supplies for standardized vision testing for glare, contrast sensitivity and ETDRS acuity by eye doctors and in clinical trials for practical vision evaluation and industrial vision testing.

 

Business Day ” means any day except Saturday, Sunday or any other day on which commercial banks located in Los Angeles, California are authorized or required by Law to be closed for business.

 

Buyer ” has the meaning set forth in the Preamble.

 

Buyer Indemnitees ” has the meaning set forth in Section 7.2 .

 

Cap ” has the meaning set forth in Section 7.4(a) .

 

Closing ” has the meaning set forth in Section 2.1 .

 

Closing Date ” has the meaning set forth in Section 2.1 .

 

Code ” has the meaning set forth in the Recitals .

 

Common Stock ” means the common stock of Guardion, par value $0.001 per share.

 

“Consulting Agreement” means that certain consulting agreement between Guardion and David Evans.

 

Contracts ” means all contracts, leases, deeds, mortgages, licenses, instruments, notes, commitments, undertakings, indentures, joint ventures and all other agreements, commitments and legally binding arrangements, whether written or oral.

 

Direct Claim ” has the meaning set forth in Section 7.5(c) .

 

Disclosure Schedule ” means the Disclosure Schedule delivered by Seller to Buyer concurrently with the execution and delivery of this Agreement.

 

Dollars ” or “ $ ” means the lawful currency of the United States.

 

Environmental Law ” means any applicable Law, and any Governmental Order or binding agreement with any Governmental Authority: (a) relating to pollution (or the cleanup thereof) or the protection of natural resources, endangered or threatened species, human health or safety, or the environment (including ambient air, soil, surface water or groundwater, or subsurface strata); or (b) concerning the presence of, exposure to, or the management, manufacture, use, containment, storage, recycling, reclamation, reuse, treatment, generation, discharge, transportation, processing, production, disposal or remediation of any Hazardous Materials.

 

ERISA ” means the Employee Retirement Income Security Act of 1974, as amended, and the regulations promulgated thereunder.

 

Appendix A
- 2

 

  

ERISA Affiliate ” means, with respect to any Person, any other Person that, together with such first Person, would be treated as a single employer within the meaning of Section 414(b), (c), (m) or (o) of the Code.

 

Evans ” has the meaning set forth in the Preamble. “ Excluded Assets ” has the meaning set forth in Section 1.2 .

 

Excluded Liabilities ” has the meaning set forth in Section 1.4 .

 

Financial Statements ” has the meaning set forth in Section 3.4 .

 

GAAP ” means United States generally accepted accounting principles in effect from time to time.

 

General Survival Period ” has the meaning set forth in Section 7.1 .

 

Governmental Authority ” means any federal, state, local or foreign government or political subdivision thereof, or any agency or instrumentality of such government or political subdivision, or any self-regulated organization or other non-governmental regulatory authority or quasi-governmental authority (to the extent that the rules, regulations or orders of such organization or authority have the force of Law), or any arbitrator, court or tribunal of competent jurisdiction.

 

Governmental Order ” means any order, writ, judgment, injunction, decree, stipulation, determination or award entered by or with any Governmental Authority.

 

Guardion ” has the meaning set forth in the Preamble.

 

Hazardous Materials ” means: (a) any material, substance, chemical, waste, product, derivative, compound, mixture, solid, liquid, mineral or gas, in each case, whether naturally occurring or manmade, that is hazardous, acutely hazardous, toxic, or words of similar import or regulatory effect under Environmental Laws; and (b) any petroleum or petroleum-derived products, radon, radioactive materials or wastes, asbestos in any form, lead or lead-containing materials, urea formaldehyde foam insulation and polychlorinated biphenyls.

 

Holdback Shares ” has the meaning set forth in Section 1.6 .

 

Indemnified Party ” has the meaning set forth in Section 7.5 .

 

Indemnifying Party ” has the meaning set forth in Section 7.5 .

 

Appendix A
- 3

 

  

Indemnified Tax ” means mean (i) any Taxes of any Seller or any direct or indirect owner thereof; (ii) any Tax imposed on Seller with respect to any taxable period or portion thereof ending on or prior to the Closing Date; (iii) any Tax of a Person other than the Seller imposed on a controlled, combined, unitary or other group basis under Treasury Regulation 1.1502-6 or any similar provision of local, state, provincial, federal, foreign law; (iv) any Tax attributable to a breach of representation with respect to Taxes; or (v) any transfer tax for which Seller is responsible pursuant to this Agreement. For purposes of this Agreement, in order to apportion appropriately any Taxes relating to a taxable period beginning before but ending after the Closing Date, the parties hereto shall, to the extent permitted or required under applicable law, treat the Closing Date as the last day of the taxable period of the Seller for all Tax purposes. In any case where applicable law does not permit the Seller to treat the Closing Date as the last day of the Taxable period, the amount of Taxes that are allocable to the portion such period ending on and including the Closing Date shall be: in the case of Taxes imposed on a periodic basis with respect to the business or assets of the Entities (such as ad valorem and property Taxes) the amount of such Taxes for the entire period multiplied by a fraction, the numerator of which is the number of calendar days ending on and including the Closing Date, and the denominator of which is the number of calendar days in the entire period; and (ii in the case of Taxes that are based upon or related to income, gross or net sales, payments or receipts (including any income Taxes), deemed equal to the amount that would be payable if the taxable period ended on the Closing Date.

 

Insurance Policies ” has the meaning set forth in Section 3.15 .

 

Intellectual Property ” means all intellectual property and industrial property rights and assets, and all rights, interests and protections that are associated with, similar to, or required for the exercise of, any of the foregoing, however arising, pursuant to the Laws of any jurisdiction throughout the world, whether registered or unregistered, including any and all: (a) trademarks, service marks, trade names, brand names, logos, trade dress, design rights and other similar designations of source, sponsorship, association or origin, together with the goodwill connected with the use of and symbolized by, and all registrations, applications and renewals for, any of the foregoing; (b) internet domain names, whether or not trademarks, registered in any top-level domain by any authorized private registrar or Governmental Authority, web addresses, web pages, websites and related content, accounts with Twitter, Facebook and other social media companies and the content found thereon and related thereto, and URLs; (c) works of authorship, expressions, designs and design registrations, whether or not copyrightable, including copyrights, author, performer, moral and neighboring rights, and all registrations, applications for registration and renewals of such copyrights; (d) inventions, discoveries, trade secrets, business and technical information and know-how, databases, data collections and other confidential and proprietary information and all rights therein; (e) patents (including all reissues, divisionals, provisionals, continuations and continuations-in-part, re-examinations, renewals, substitutions and extensions thereof), patent applications, and other patent rights and any other Governmental Authority-issued indicia of invention ownership (including inventor’s certificates, petty patents and patent utility models); (f) software and firmware, including data files, source code, object code, application programming interfaces, architecture, files, records, schematics, computerized databases and other related specifications and documentation; (g) semiconductor chips and mask works; (h) royalties, fees, income, payments and other proceeds now or hereafter due or payable with respect to any and all of the foregoing; and (i) all rights to any Actions of any nature available to or being pursued by Seller or Evans to the extent related to the foregoing, whether accruing before, on or after the date hereof, including all rights to and claims for damages, restitution and injunctive relief for infringement, dilution, misappropriation, violation, misuse, breach or default, with the right but no obligation to sue for such legal and equitable relief, and to collect, or otherwise recover, any such damages.

 

Appendix A
- 4

 

 

Intellectual Property Agreements ” means all licenses, sublicenses, consent to use agreements, settlements, coexistence agreements, covenants not to sue, permissions and other Contracts (including any right to receive or obligation to pay royalties or any other consideration), whether written or oral, relating to any Intellectual Property to which Seller or Evans is a party, beneficiary or otherwise bound.

 

Intellectual Property Assets ” means all Intellectual Property that is owned or licensed by Seller or Evans.

 

Intellectual Property Registrations ” means all Intellectual Property Assets that are subject to any issuance, registration, application or other filing by, to or with any Governmental Authority or authorized private registrar in any jurisdiction, including registered trademarks, domain names and copyrights, issued and reissued patents and pending applications for any of the foregoing.

 

Inventory ” has the meaning set forth in Section 1.1(c) .

 

Knowledge of Seller ” or any other similar knowledge qualification means the actual knowledge of any of the following persons, after due inquiry: David W. Evans, Tamara Evans, and Brian Wilson.

 

Law ” means any statute, law, ordinance, regulation, rule, code, order, constitution, treaty, common law, judgment, decree, other requirement or rule of law of any Governmental Authority.

 

Liabilities ” means liabilities, obligations or commitments of any nature whatsoever, asserted or unasserted, known or unknown, absolute or contingent, accrued or unaccrued, matured or unmatured or otherwise.

 

Lien ” means any charge, claim, community property interest, pledge, condition, equitable interest, lien (statutory or other), option, security interest, mortgage, easement, encroachment, right of way, right of first refusal, or restriction of any kind, including any restriction on use, voting, transfer, receipt of income or exercise of any other attribute of ownership.

 

Losses ” means losses, damages, liabilities, deficiencies, Actions, judgments, interest, awards, penalties, fines, costs or expenses of whatever kind, including reasonable attorneys’ fees and the cost of enforcing any right to indemnification hereunder and the cost of pursuing any insurance providers; provided, however , that “Losses” shall not include punitive damages, except in the case of fraud or to the extent actually awarded to a Governmental Authority or other third party.

 

Appendix A
- 5

 

  

Material Adverse Effect ” means any event, occurrence, fact, condition or change that is, or could reasonably be expected to become, individually or in the aggregate, materially adverse to (a) the business, results of operations, condition (financial or otherwise) or assets of the Business, (b) the value of the Purchased Assets, or (c) the ability of Seller to consummate the transactions contemplated hereby on a timely basis; provided , however , that “Material Adverse Effect” shall not include any event, occurrence, fact, condition or change, directly or indirectly, arising out of or attributable to: (i) general economic or political conditions; (ii) conditions generally affecting the industries in which the Business operates; (iii) any changes in financial or securities markets in general; (iv) acts of war (whether or not declared), armed hostilities or terrorism, or the escalation or worsening thereof; or (v) any changes in applicable Laws or accounting rules, including GAAP; provided further, however , that any event, occurrence, fact, condition or change referred to in clauses (i) through (iv) immediately above shall be taken into account in determining whether a Material Adverse Effect has occurred or could reasonably be expected to occur to the extent that such event, occurrence, fact, condition or change has a disproportionate effect on the Business compared to other participants in the industries in which the Business operates.

 

Material Contracts ” has the meaning set forth in Section 3.7 .

 

Most Recent Balance Sheet ” has the meaning set forth in Section 3.4 .

 

Most Recent Balance Sheet Date ” has the meaning set forth in Section 3.4 .

 

Most Recent Financial Statements ” has the meaning set forth in Section 3.4 .

 

Other Selling Stockholders ” means persons other than Seller or the Shareholders who, by virtue of agreements with Guardion, are entitled to include their Other Shares in certain registrations hereunder.

 

Other Shares ” means shares of Common Stock, other than Registrable Securities, with respect to which registration rights have been granted.

 

“Per Share Value” means the fair market value per share for the Common Stock, as determined, in a written report, by SPH or such other qualified valuation firm chosen by Guardion, to be provided to Seller.

 

Permits ” means all permits, licenses, franchises, approvals, authorizations, registrations, certificates, variances and similar rights obtained, or required to be obtained, from Governmental Authorities.

 

Permitted Liens ” means (a) Liens for Taxes and other governmental charges and assessments, not yet due or which can be paid currently with no penalty; (b) mechanics’ or materialmen’s’ liens statutorily imposed or other like Liens for which adequate reserves have been established in accordance with GAAP that are included on the Most Recent Financial Statements; (c) Liens relating to deposits made in the ordinary course of business in connection with workers’ compensation, unemployment insurance and other types of social security or to secure the performance of leases, trade contracts or other similar agreements; and (d) Liens under the terms and conditions of the Bank One Loan.

 

Person ” means an individual, corporation, partnership, joint venture, limited liability company, Governmental Authority, unincorporated organization, trust, association or other entity.

 

Premises ” has the meaning set forth in Section 2.2(a)(vi) .

 

Appendix A
- 6

 

  

Premises Lease ” means that certain Lease Agreement between Seller and DWT Evans LLC dated February 27, 2017 for the Premises.

 

Purchase Price ” has the meaning set forth in Section 1.5 .

 

Purchased Assets ” has the meaning set forth in Section 1.1 .

 

Qualified Public Offering ” means the closing of Guardion’s first firm commitment underwritten public offering of Guardion’s Common Stock registered under the Securities Act.

 

Registrable Securities ” means any Common Stock issued as a dividend or other distribution with respect to or in exchange for or in replacement of the shares referenced in (i) above; provided, however , that Registrable Securities shall not include any shares of Common Stock described in clause (i) or (ii) above which have previously been registered or which have been sold to the public either pursuant to a registration statement or Rule 144, or which have been sold in a private transaction in which the transferor’s rights under this Agreement are not validly assigned in accordance with this Agreement.

 

Registration Expenses ” means all expenses incurred in effecting any registration pursuant to this Agreement, including, without limitation, all registration, qualification, and filing fees, printing expenses, escrow fees, fees and disbursements of counsel for Guardion and one special counsel for Seller and the Shareholders (not to exceed $35,000), blue sky fees and expenses, and expenses of any regular or special audits incident to or required by any such registration, but shall not include Selling Expenses, and the compensation of regular employees of Guardion, which shall be paid in any event by Guardion.

 

Representative ” means, with respect to any Person, any and all directors, officers, employees, consultants, financial advisors, counsel, accountants and other agents of such Person.

 

Rule 145 ” means Rule 145 as promulgated by the Securities and Exchange Commission under the Securities Act, as such Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Securities and Exchange Commission.

 

Seller ” has the meaning set forth in the Preamble.

 

“Seller Indebtedness ” means the amount, without duplication, of the following: (i) all indebtedness or other obligations of Seller for borrowed money, whether current, short-term or long-term, secured or unsecured, including all overdrafts and negative cash balances, (ii) all indebtedness of Seller for the deferred purchase price for purchases of property or services (except any trade payable incurred in the ordinary course of business that is treated (in its entirety) as a current account payable under United States GAAP), (iii) all lease obligations of Seller under leases that have been or should be capitalized in accordance with United States GAAP, (iv) the aggregate face amount of all outstanding letters of credit issued on behalf of Seller; (v) all obligations of Seller arising under acceptance facilities; (vi) all guaranties, endorsements and other contingent obligations of Seller to purchase, to provide funds for payment, to supply funds to invest in any other entity, or otherwise to assure a creditor against loss; (vii) all obligations of Seller under any interest rate protection, foreign currency exchange, or other interest or exchange rate swap or hedging agreement or arrangement, or other derivative product; (viii) all obligations secured by an Lien upon any assets or properties of Seller; (ix) all indebtedness referred to in clauses (i) through (xv) above of any Person other than Seller that is guaranteed by Seller; and (x) accrued and unpaid interest on, and prepayment premiums, penalties or similar contractual charges arising as a result of the discharge of, any such foregoing obligation.

 

Appendix A
- 7

 

  

Seller Indemnitees ” has the meaning set forth in Section 7.3 .

 

Seller Parties ” has the meaning set forth in Preamble.

 

Seller Transaction Expenses ” means any and all (a) legal, accounting, tax, financial advisory, environmental consultants and other professional or transaction related costs, fees and expenses incurred by Seller in connection with this Agreement or in investigating, pursuing or completing the transactions contemplated hereby (including any amounts owed to any consultants, auditors, accountants, attorneys, brokers or investment bankers), (b) payments, bonuses or severance which become due or are otherwise required to be made by Seller as a result of or in connection with the Closing, and (c) payroll, employment or other Taxes, if any, required to be paid Seller with respect to the amounts payable pursuant to this Agreement, the amounts described in clause (a) and (b).

 

Selling Expenses ” shall mean all underwriting discounts, selling commissions and stock transfer taxes applicable to the sale of Registrable Securities and fees and disbursements of counsel for Seller and the Shareholders (other than the fees and disbursements of one special counsel to Seller and the Shareholders included in Registration Expenses).

 

“Shareholders ” has the meaning set forth in Preamble.

 

“SPH” means Sanli Pastore & Hill, Inc.

 

Tangible Personal Property ” has the meaning set forth in Section 1.1(e) .

 

Tax Return ” means any return, declaration, report, claim for refund, information return or statement or other document relating to Taxes, including any schedule or attachment thereto, and including any amendment thereof.

 

Taxes ” means all federal, state, local, foreign and other income, gross receipts, sales, use, production, ad valorem, transfer, documentary, franchise, registration, profits, license, lease, service, service use, withholding, payroll, employment, unemployment, estimated, excise, severance, environmental, stamp, occupation, premium, property (real or personal), real property gains, windfall profits, customs, duties or other taxes, fees, assessments or charges of any kind whatsoever, together with any interest, additions or penalties with respect thereto and any interest in respect of such additions or penalties.

 

Territory ” has the meaning set forth in Section 5.6(a) .

 

Third Party Claim ” has the meaning set forth in Section 7.5(a) .

 

Appendix A
- 8

 

  

Transaction Documents ” means this Agreement and the other agreements, instruments and documents required to be delivered at the Closing pursuant to this Agreement.

 

Union ” has the meaning set forth in Section 3.20(b) .

 

“Value of the Acquired Shares” means the Per Share Value multiplied by the Acquired Shares.

 

Appendix A
- 9

 

 

Exhibit 10.1

 

EXECUTION VERSION

 

INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT

 

This INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT (this “IP Assignment”), dated as of September 29, 2017, is made by and between VectorVision, Inc., an Ohio corporation, having a principal place of business at 1850 Livingston Road, Suite E, Greenville, Ohio 45331 and David W. Evans, a U.S. citizen, having a principal place of business at 4141 Jutland Drive, Suite 214, San Diego, CA 92117 on the one hand (“Assignors”) and Guardion Health Sciences, Inc., a Delaware corporation, having a principal place of business at 15150 Avenue of Science, Suite 200, San Diego California 92128 on the other hand (“Assignee”)

 

WHEREAS, Assignee, Assignors, and certain other parties signatory thereto are parties to that certain Asset Purchase and Reorganization Agreement, dated as September 29, 2017 (as amended, restated, supplemented, or otherwise modified from time to time, the “ Reorganization Agreement ”). Capitalized terms not otherwise defined herein shall have the meanings given to such terms in the Reorganization Agreement.

 

WHEREAS, under the terms of the Reorganization Agreement, Assignors have agreed to convey, transfer, and assign to Assignee, among other assets, certain intellectual property of Assignors, and have agreed to execute and deliver this IP Assignment for recording with Governmental Authorities, including, but not limited to, the US Patent and Trademark Office.

 

WHEREAS, in connection with the consummation of the transactions contemplated by the Reorganization Agreement, Assignors hereby desire to convey, transfer, and assign to Assignee all of Assignors’ right, title, and interest in, to, and under all of the Assigned IP (as hereinafter defined), and Assignee hereby desires accept from Assignors all of Assignors’ right, title, and interest in, to, and under all of the Assigned IP.

 

NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

 

1.           Assignment . In consideration for the execution of the Reorganization Agreement, the payment of the consideration stipulated in the Reorganization Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignors hereby irrevocably convey, transfer, and assign to Assignee, all of which Assignors represent and warrant are exclusively owned by Assignors free and clear of any encumbrances, and Assignee hereby accepts, all of Assignors’ right, title, and interest in, to, and under the following (collectively, the “ Assigned IP ”):

 

(a)          all inventions, including without limitation, the patents and patent applications set forth on Schedule 1 hereto, and all issuances, divisions, continuations, continuations-in-part, reissues, extensions, reexaminations, and renewals thereof, including all priority rights, and the right to claim priority rights and the privileges and benefits thereof, including those under the International Convention, and all other conventions, and the worldwide right to file applications for said inventions in Assignee’s own name;

 

  - 1 -  

 

  

(b)          all trade secrets, non-public know-how, discoveries, improvements, concepts, ideas, methods, processes, procedures, designs, plans, schematics, invention disclosure statements, drawings, formulae, technical data, specifications, research and development information, technology and product roadmaps and data bases and other proprietary or confidential information, including customer, supplier and mailing lists;

 

(c)          all marks, names, trade dress, whether registered or unregistered, including without limitation, the trademark registrations and applications set forth on Schedule 2 hereto, together with the goodwill connected with the use thereof and symbolized thereby, and all issuances, extensions, and renewals thereof, provided, that with respect to the United States intent-to-use trademark applications, if any, set forth on Schedule 2 hereto, the transfer of such applications accompanies, pursuant to the Reorganization Agreement, the transfer of Assignors’ business, or portion of the business to which the trademark pertains, and that business is ongoing and existing; all social media names and accounts;

 

(d)          all copyrights, including, without limitation, the copyrights set forth on Schedule 3 hereto, including, without limitation, any unregistered copyrights, applications, any renewals and extensions thereof, and in and to all works based upon, derived from, or incorporating the copyrights, and in and to all rights corresponding to the foregoing throughout the world, and all the rights embraced therein, including but not limited to, the right to duplicate, reproduce, copy, distribute, display, license, adapt, and prepare derivative works from the copyrights, together with all physical or tangible embodiments of the copyrights, in Assignors’ possession or under Assignors’ control;

 

(e)         the domain names set forth in Schedule 4 hereto;

 

(f)           the intellectual property rights, information or assets arising from or related to the agreements set forth in Schedule 5 hereto;

 

(g)         in the case of each of the foregoing:

 

i.            all rights of any kind whatsoever of Assignors accruing under any of the foregoing provided by applicable law of any jurisdiction, by international treaties and conventions, and otherwise throughout the world;

 

ii.            any and all royalties, fees, income, payments, and other proceeds now or hereafter due or payable with respect to any and all of the foregoing; and

 

iii.          any and all claims and causes of action with respect to any of the foregoing, whether accruing before, on, and/or after the date hereof, including all rights to and claims for damages, restitution, and injunctive and other legal and equitable relief for past, present, and future infringement, dilution, misappropriation, violation, misuse, breach, or default, with the right but not the obligation to sue for such legal and equitable relief and to collect, or otherwise recover, any such damages.

 

  - 2 -  

 

  

2.           Assignors’ Use and Enjoyment . The rights, title and interest assigned under Section 1 above shall be for Assignee’s own use and enjoyment, and for the use and enjoyment of Assignee’s successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignors if this IP Assignment had not been made.

 

3.           Remainder of Intellectual Property . Assignors hereby declare that, as to any of the assets, rights or interests intended to be included in the Assigned IP hereby conveyed, the title to which may not have passed to the Assignee by virtue of this Assignment or any transfer or assignment which may from time to time be executed and delivered pursuant to the provisions hereof, Assignors hold such assets, rights or interests in trust for the benefit of the Assignee to transfer and assign the same as the Assignee may from time to time direct. Assignors shall hold such asset or other right for the exclusive benefit of the Assignee and shall take any and all action with respect thereto as the Assignee may reasonably direct for the Assignee’s account and benefit.

 

4.           Recordation . Assignors authorize the Commissioner for Patents, the Commissioner for Trademarks, and any other governmental officials to record and register this IP Assignment upon request by Assignee.

 

5.           Cooperation . Assignors agree to perform all commercially reasonable acts deemed necessary or desirable by the Assignee to permit and assist the Assignee, at the Assignee’s expense, in obtaining and enforcing the full benefits, enjoyment, rights and title throughout the world in the Assigned IP, to be assigned, or licensed to the Assignee under this Agreement. Such acts may include, but are not limited to, execution of documents and assistance or cooperation (i) in the filing, prosecution, registration, and memorialization of assignment of any applicable patents, copyrights, trademark, mask work, or other applications, (ii) in the enforcement of any applicable patents, copyrights, trademark, mask work, moral rights, trade secrets, or other proprietary rights, and (iii) in other legal proceedings related to the Assigned IP. In the event that the Assignee is unable for any reason to secure Assignors’ signature(s) to any document required to file, prosecute, register, or memorialize the assignment of any patent, copyright, trademark, mask work or other applications or to enforce any patent, copyright, mask work, moral right, trade secret or other proprietary right under any Assigned IP (including derivative works, improvements, renewals, extensions, continuations, divisionals, continuations in part, continuing patent applications, reissues, and reexaminations of such Assigned IP), Assignors hereby irrevocably designate and appoint the Assignee and the Assignee’s duly authorized officers and agents as Assignors’ agents and attorneys-in-fact to act for and on Assignors’ behalf and instead of Assignors, (i) to execute, file, prosecute, register and memorialize the assignment of any such application, (ii) to execute and file any documentation required for such enforcement, and (iii) to do all other lawfully permitted acts to further the filing, prosecution, registration, memorialization of assignment, issuance, and enforcement of patents, copyrights, mask works, moral rights, trade secrets or other rights under the Assigned IP, all with the same legal force and effect as if executed by Assignors.

 

6.           Terms of the Reorganization Agreement . The terms of the Reorganization Agreement, including, but not limited to, the representations, warranties, covenants, agreements, and indemnities relating to the Assigned IP are incorporated herein by this reference. The parties hereto acknowledge and agree that the representations, warranties, covenants, agreements, and indemnities contained in the Reorganization Agreement shall not be superseded hereby but shall remain in full force and effect to the full extent provided therein. In the event of any conflict or inconsistency between the terms of the Reorganization Agreement and the terms hereof, the terms of the Reorganization Agreement shall govern.

 

  - 3 -  

 

  

7.           Successors and Assigns . This IP Assignment shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns.

 

8.           Governing Law . This IP Assignment shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than those of the State of Delaware.

 

9.           Counterparts . This IP Assignment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this IP Assignment delivered by facsimile, e-mail, or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this IP Assignment.

 

[SIGNATURE PAGE FOLLOWS]

 

  - 4 -  

 

  

The parties hereto are signing this IP Assignment as of the date first set fort h above.

 

ASSIGNORS   ASSIGNEE
     
VECTORVISION, INC.   GUARDION HEALTH SCIENCES, INC.
     
By: /David W. Evans/   By: /Michael Favish/
         
Name: David W. Evans   Name: Michael Favish
         
Title: CEO   Title: CEO
       
DAVID W. EVANS    
       
By: /David W. Evans/    

 

Signatur e Page to IP As s ignment

 

  - 5 -  

 

  

SCHEDULE 1

 

PATENTS

 

None.

 

  - 6 -  

 

 

SCHEDULE 2

 

COPYRIGHTS

 

Registered or Pending:

 

N/A

 

Common Law:

 

1.          Vision Testing Chart #1

 

2.          Vision Testing Chart #2

 

3.          Vision Testing Chart #3

 

  - 7 -  

 

  

SCHEDULE 3

 

TRADEMARKS

 

Registered or Pending:

   

Jurisdiction   Status   Application No. /
Filing Date
  Registration No. /
Registration Date
  Mark
USA   Registered  

85/683,064

July 20, 2012

 

4,341,403

May 28, 2013

  VECTORVISION
USA   Registered  

85/683,115

July 20, 2012

 

4,500,241

March 25, 2014

  CSV-1000

 

Common Law:

 

None.

 

  - 8 -  

 

  

SCHEDULE 4

 

DOMAIN NAMES

 

1.          vectorvision.com

 

  - 9 -  

 

  

SCHEDULE 5

 

AGREEMENTS

 

1.    Product Manufacturing & Distribution Agreement dated November ____, 2006 between VectorVision, Inc. and Good-Lite Company.

 

2.    Service Agreement dated March 22, 2017 between VectorVision, Inc. and Pinakin Davey, OD, PhD.

 

3.    Sponsored Research Agreement dated__________ between VectorVision, Inc. and Western University of Health Sciences.

 

  - 10 -  

 

 

Exhibit 10.2

 

EXECUTION VERSION

 

CONSULTING AGREEMENT

 

This Consulting Agreement (this “ Agreement ”), dated September 29, 2017 is by and between Guardion Health Sciences, Inc., a Delaware corporation (the “ Company ”), and David W. Evans (“ Consultant ”).

 

WHEREAS, concurrently herewith, the Company and VectorVision Ocular Health, Inc., on the one hand, and VectorVision, Inc. (“ VectorVision ”) and Consultant, on the other hand, are entering into that certain Asset Purchase and Reorganization Agreement, dated as of September 29, 2017 (the “ Reorganization Agreement ”), pursuant to which the Company will purchase certain assets of VectorVision, as more particularly described in the Reorganization Agreement;

 

WHEREAS, execution and delivery of this Agreement is a condition precedent to the consummation of the transactions contemplated by the Reorganization Agreement;

 

WHEREAS, VectorVision is engaged in the business of standardized vision testing for glare, contrast sensitivity and ETDRS acuity (the “ Business ”);

 

WHEREAS, upon the closing of the Reorganization Agreement (the “ Closing ”), Consultant will become a member of the Board of Directors of the Company;

 

WHEREAS, Consultant is an internationally recognized expert, author and speaker and has considerable experience and expertise in the measurement of visual function related to refractive surgery, glaucoma, eye diseases, visual performance and ocular blood flow.

 

WHEREAS, the Company desires to retain Consultant to provide consulting services to the Company and its Affiliates (as defined below); and

 

WHEREAS, Consultant is willing to provide such services in accordance with the terms and conditions of this Agreement.

 

NOW, THEREFORE, in consideration of such engagement and the mutual covenants and promises herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and Consultant agree as follows:

 

1.            Services . During the Consulting Period, Consultant shall provide services to the Company and its Affiliates as described in Schedule A attached hereto (the “ Services ”). Consultant shall use Consultant’s best efforts to perform the Services such that the results are satisfactory to the Company. “ Affiliate ” of Company means any individual, corporation, partnership, joint venture, limited liability company, unincorporated organization, trust, association or other entity that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, Company. The term “control” (including the terms “controlled by” and “under common control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of an Affiliate, whether through the ownership of voting securities, by contract or otherwise.

 

  - 1 -  

 

 

2.            Compensation . As consideration for the Services, the Company agrees to pay Consultant the fixed rate of Ten Thousand Dollars ($10,000) per month for the first six (6) months of Services, and Seven Thousand Five Hundred Dollars ($7,500.00) per month for the remainder of the Consulting Period (the “Fees”).

 

3.            Term . The initial term of this Agreement shall be for three (3) years from the date of the Closing (the “ Effective Date ”) (the “ Initial Term ”) and thereafter this Agreement shall automatically renew for additional twelve-month periods (each such extension, a “ Renewal Term ”) unless the Company or Consultant provides written notice of non-renewal to the other party at least thirty (30) days in advance of the expiration of the Initial Term or any Renewal Term, as applicable (the Initial Term, together with any Renewal Term, the “ Consulting Period ”).

 

4.            Termination . Consultant’s services hereunder may be terminated prior to the end of the Consulting Period as follows:

 

4.1          Automatically in the event of the death of Consultant;

 

4.2          At the option of the Company, on thirty (30) days prior written notice to Consultant or Consultant’s personal representative in the event of the Disability of Consultant. As used herein, the term Disability shall mean Consultant’s becoming incapacitated for a period of at least one hundred eighty (180) days by accident, sickness or other circumstance that renders Consultant mentally or physically incapable of performing the material duties and services required of Consultant hereunder during such period;

 

4.3          At the option of the Company for Cause (as defined in Section 5.4 ), immediately upon written notice to Consultant;

 

4.4          At the option of the Company without Cause, on prior written notice to Consultant (provided that the assignment of this Agreement to and assumption of this Agreement by the purchaser of all or substantially all of the assets of the Company shall not be treated as a termination without Cause under this Section 4.4 );

 

4.5          At the option of Consultant in the event that Company (i) dissolves or (ii) files, or has filed against it, a petition for voluntary or involuntary bankruptcy or pursuant to any other insolvency law, makes or seeks to make a general assignment for the benefit of its creditors or applies for, or consents to, the appointment of a trustee, receiver or custodian for a substantial part of its property;

 

4.6          At any time after the completion of the Initial Term at the option of the Consultant, by providing one hundred twenty (120) days prior written notice to the Company; or

 

4.7          By mutual agreement of the parties.

 

  - 2 -  

 

  

5.            Payment for Early Termination .

 

5.1           Termination by the Company Without Cause . If Consultant’s services hereunder are terminated prior to the end of the Consulting Period by the Company without Cause (and not due to death or Disability), subject to Section 5.5 hereof, Consultant shall be entitled to:

 

(a)           within thirty (30) days following such termination, payment of Consultant’s accrued and unpaid Fees and reimbursement of expenses under Section 7 hereof in each case accrued through the date of termination; and

 

(b)           continuation of Consultant’s Fees for the longer of: (i) the remainder of the then-current Initial Term or Renewal Term, as applicable, or (ii) one (1) year (such longer period, the “ Fee Continuation Period ”), payable at the same time Fees would have been paid if Consultant had continued to provide services to the Company or its Affiliates for the remainder of such Fee Continuation Period; provided , however , if the Consultant’s review period for the release of claims required pursuant to Section 5.5 hereof spans two of Consultant’s taxable years, the first payment shall be made on the first regularly scheduled payroll date of the later taxable year following the effective date of such release of claims and shall include any amounts due prior thereto.

 

5.2           Termination due to Death or Disability . Upon the termination of Consultant’s services hereunder prior to the end of the Consulting Period due to Consultant’s death or Disability pursuant to Section 4.1 or Section 4.2 respectively, Consultant or Consultant’s legal representatives shall be entitled to receive the payments and benefits described under Section 6.1(a) hereof.

 

5.3           Termination by the Company for Cause or Termination by Consultant . Except for the payments and benefits described in Section 5.1(a) , Consultant shall not be entitled to receive payments or benefits after the last date the Consultant provides services to the Company or its Affiliates upon the termination of Consultant’s services hereunder prior to the end of the Consulting Period by the Company for Cause pursuant to Section 4.3 or by Consultant pursuant to Section 4.5 .

 

5.4           Cause . For purposes of this Agreement, “ Cause ” shall mean:

 

(i)           Consultant’s willful failure or refusal to perform the Services after being given written notice and thirty (30) days to remedy such failure or refusal;

 

(ii)         Consultant’s willful misconduct, gross negligence or breach of fiduciary duty in connection with Consultant’s performance of the Services;

 

(iii)        Consultant’s act of dishonesty or breach of trust in connection with Consultant’s performance of the Services that is reasonably likely to be materially injurious to the Company or its Affiliates or misappropriation of any assets or business opportunities of the Company or its Affiliates;

 

(iv)        Consultant’s conviction of, a plea of guilty or no contest to, or indictment for, any indictable criminal offence or any other criminal offence involving fraud, dishonesty or misappropriation;

 

  - 3 -  

 

  

(v)         Consultant’s conduct which is reasonably likely to injure the reputation or business of the Company, including, without limitation, any willful violation by Consultant of any policies of the Company or its Affiliates;

 

(vi)        Consultant’s breach of any confidentiality, non-solicitation or non- competition obligations to the Company, including, without limitation, Section 8.1 of this Agreement;

 

(vii)       material breach by Consultant of any of the provisions of this Agreement or any other agreement in effect between Consultant and the Company which (if curable) is not cured within thirty (30) days of written notice; or

 

(viii)      as provided in Section 12.1 hereof.

 

5.5           Conditions to Payment . All payments due to Consultant under this Section 5 which are not otherwise required by law shall only be payable if Consultant (or Consultant’s beneficiary or estate) delivers to the Company and does not revoke (under the terms of applicable law) a general release of all claims in a form provided by the Company. Such general release shall be executed and delivered (and no longer subject to revocation) within sixty (60) days following termination. Failure to timely execute and return such release or revocation thereof shall be a waiver by Consultant of Consultant’s right to payment for the early termination of the Consulting Period. In addition, payment for the early termination of the Consulting Period shall be conditioned on Consultant’s compliance with Section 8 hereof.

 

6.            Reimbursement of Expenses . The Company shall reimburse Consultant for Consultant’s reasonable and necessary expenses actually incurred by Consultant directly in connection with Consultant’s performance of the Services hereunder, including, without limitation, reasonable travel expenses, program attendance fees and membership fees, subject to appropriate substantiation and itemization of such expenses in accordance with the guidelines and limitations established by the Company from time to time.

 

7.            Independent Contractor Status . It is expressly understood by the Company and Consultant, and Consultant specifically requested, that Consultant will be performing the Services under this Agreement as an independent contractor for the Company and that neither Consultant nor any employee, representative, agent or subcontractor of Consultant is an employee or agent of the Company or its Affiliates. Consultant shall not hold out himself as an employee, agent, partner or joint venture of the Company or its Affiliates. Consultant will provide his own equipment and materials as may be required to perform the Services, will perform the Services at a location of his choice, will set his own schedule for performing the Services (subject to interim and final deadlines for the delivery of work product as may from time to time be stated by the Company), and will not be subject to the direction or control of the Company or its Affiliates in conjunction with his performance of the Services (subject to specifications to be stated by the Company from time to time relating to the work product) but will be subject to all decisions and actions of the Company’s Board of Directors. Consultant will be solely responsible for all withholding and payment of taxes and similar charges related to the compensation paid hereunder, as well as any applicable insurance, including but not limited to any worker’s compensation. The Company will report all payments to Consultant hereunder via a Form 1099.

 

  - 4 -  

 

  

8.            Restrictions on Activities of Consultant .

 

8.1           Non-Competition . During the Consulting Term and either (i) the Fee Continuation Period, if Consultant’s Services are terminated by the Company without Cause, or (ii) the one (1) year period commencing on the date Consultant ceases to provide the Services to the Company or its Affiliates pursuant to this Agreement, if Consultant’s Services are terminated by the Company for any other reason or by Consultant pursuant to Section 4.5 (the “ Restriction Period ”), Consultant covenants and agrees that Consultant shall not directly or indirectly (whether for compensation or otherwise) own or hold any interest in, manage, operate, control, consult with, render services for, or in any manner participate in, any Competitive Business, either as a general or limited partner, proprietor, shareholder, officer, director, agent, employee, consultant, trustee, affiliate or otherwise. Nothing herein shall prohibit Consultant from being a passive owner of not more than two percent (2%) of the outstanding securities of any publicly traded company engaged in a Competitive Business. For purposes of this Agreement, “ Competitive Business ” shall mean any business in the United States that the Company or, to Evan's knowledge, any of its Affiliates is conducting or is considering conducting at the time Consultant’s services hereunder are terminated. For purposes of this Agreement, "Competitive Business" shall not include any of the activities of listed on Section 3.23 of the Disclosure Schedule provided in connection with the Reorganization Agreement.

 

8.2           Non-Solicitation . Consultant covenants and agrees that during the Restriction Period, Consultant shall not directly or indirectly (i) influence or attempt to influence or solicit any employees or independent contractors of the Company or any of its Affiliates to restrict, reduce, sever or otherwise alter their relationship with the Company or such Affiliates, (ii) hire any employees or independent contractors of the Company or any of its Affiliates, (iii) solicit or induce, or attempt to solicit or induce, any person or entity that is a client, customer or business relation of the Company or any of its Affiliates to cease being a client, customer or business relation of the Company or any of its Affiliates or to divert all or any part of such person or entity’s business from the Company or any of its Affiliates, or (iv) assist any other person or entity in any way to do, or attempt to do, anything prohibited by Sections 8.2(i) , (ii) , or (iii) .

 

8.3           Confidentiality .

 

(a)           Consultant shall not, during the Consulting Period or at any time thereafter directly or indirectly, disclose, reveal, divulge or communicate to any person other than authorized officers, directors and employees of the Company or use or otherwise exploit for Consultant’s own benefit or for the benefit of anyone other than the Company, any Confidential Information (as defined below). Consultant shall not have any obligation to keep confidential any Confidential Information if and to the extent disclosure thereof is specifically required by applicable law, court order or other legal or regulatory process; provided, however, that in the event disclosure is required by applicable law, Consultant shall provide the Company with prompt notice, to the extent reasonably possible, of such requirement prior to making any disclosure so that the Company may seek an appropriate protective order.

 

  - 5 -  

 

  

(b)           “ Confidential Information ” means any information with respect to the Company or its Affiliates, including methods of operation, customer lists, products, prices, fees, costs, technology, formulas, inventions, trade secrets, know-how, software, marketing methods, plans, personnel, suppliers, competitors, markets or other specialized information or proprietary matters; provided, that, there shall be no obligation hereunder with respect to, information that (i) is generally available to the public on the Effective Date, (ii) becomes generally available to the public other than as a result of a disclosure not otherwise permissible hereunder, or (iii) is required to be disclosed by law, court order or other legal or regulatory process and Consultant gives the Company prompt written notice and the opportunity to seek a protective order.

 

8.4          Intellectual Property and Ownership .

 

(a)            Intellectual Property Rights Defined. Intellectual Property Rights (“IPR”) means all intellectual property or other similar rights arising out of: (i) any patent or any application therefor and any and all reissues, divisions, continuations, renewals, reexaminations, extensions, and continuations-in-part thereof; (ii) inventions (whether patentable or not in any country), invention disclosures, industrial designs, improvements, trade secrets, proprietary information, know-how, technology, and technical data; (iii) other proprietary rights in technology, including databases, software, all source and object code, algorithms, architecture, structure, display screens, layouts, inventions, development tools, and all documentation and media constituting, describing, or relating to the above, including, without limitation, manuals, memoranda, records, or business information, anywhere in the world; (iv) any trademark or any application therefor; (v) any work of authorship; and (vi) any applications, registrations, provisional applications, or other filings for, or to obtain, protect, perfect, or secure, any of the foregoing, anywhere in the world.

 

(b)            Sole and Exclusive Benefit of Company. The Parties agree that all IPR that Consultant prepares, creates or otherwise develops (i) under this Agreement, (ii) or in performing the Services, or (iii) for or related to the Business (" Consultant-Created IPR "), is prepared for the sole and exclusive benefit of the Company and is the intellectual property of the Company. The Parties agree that IPR solely prepared, created or developed in connection with Consultant’s other professional activities identified in Section 3.23 of the Disclosure Schedule provided in connection with the Reorganization Agreement (“Excluded IPR”) shall not constitute Consultant-Created IPR, provided, however, that in the event that any Excluded IPR has joint applicability or relevance to the Business, such IPR shall constitute Consultant-Created IPR. Consultant shall sign such documents and take such steps as the Company may reasonably require, at the cost and expense of the Company, to enable the Company to acquire, perfect, and enforce its IPR and other legal protections for the Consultant-Created IPR, or to otherwise assist the Company in securing the full benefit of the rights conferred in this Agreement. Unless otherwise agreed to in writing, the Company shall have the sole and exclusive right to register all such Consultant-Created IPR in its name as the owner and author of such Consultant- Created IPR.

 

(c)            Ownership of Intellectual Property Rights. Company and Consultant further acknowledge and agree that all Consultant-Created IPR, any existing IPR of the Company, and all IPR in the Business (“ Company IPR ”) are and shall become, upon creation, the sole and exclusive property of Company. Company shall have and retain the right, but not the obligation, to seek, apply for and obtain any or all copyrights, patents, registrations and similar protections which may be available or applicable to Company IPR, including reissues, extensions, divisions, continuations, and continuations-in-part thereof. Consultant shall promptly disclose in writing to Company each new development of Consultant-Created IPR and Excluded IPR as may be necessary to ensure Company’s ownership of Company IPR. Consultant shall be bound to the terms of Section 8.3 in respect to Confidential Information related to Company IPR.

 

  - 6 -  

 

  

(d)            Assignment . Notwithstanding Sections 8.4(b) and 8.4(c) above, Consultant and Consultant’s heirs, assigns and representatives hereby irrevocably assigns, transfers, and conveys to Company the sole and exclusive right, title, and interest in and to the Company IPR, including, without limitation: (a) all patents, patent applications, copyrights, mask works, trade secrets, trademarks, and other Intellectual Property Rights related to any of the Company IPR anywhere in the world, and (b) any and all Moral Rights (as defined below) that Consultant may have in or with respect to any Company IPR. Consultant hereby forever waives and agrees never to assert any and all Moral Rights that Consultant may have in or with respect to the Company IPR. For purposes of this Agreement, “Moral Rights” shall mean any rights to claim authorship of the Company IPR, to object to or prevent the modification of any Company IPR, or to withdraw from circulation or control the publication or distribution of any Company IPR, and any similar right, existing under judicial or statutory law of any country in the world, or under any treaty, regardless of whether or not such right is denominated or generally referred to as a “moral right.”

 

(e)           Whether during or after the Consulting Period, Consultant further agrees to execute and acknowledge all papers and to do, at the Company’s expense, any and all other things necessary for or incident to the applying for, obtaining and maintaining of such letters patent, copyrights, trademarks or other intellectual property rights, as the case may be, and to execute, on request, all papers necessary to assign and transfer such Company IPR to the Company and its successors and assigns. In the event that the Company is unable, after reasonable efforts and, in any event, after ten (10) business days, to secure Consultant’s signature on a written assignment to the Company, of any application for letters patent, trademark registration or to any common law or statutory copyright or other property right therein, whether because of Consultant’s physical or mental incapacity, or for any other reason whatsoever, Consultant irrevocably designates and appoints the Secretary of the Company as Consultant’s attorney-in-fact to act on Consultant’s behalf to execute and file any such applications and to do all lawfully permitted acts to further the prosecution or issuance of such assignments, letters patent, copyright or trademark.

 

8.5           Return of Company Property . Within ten (10) days following the date of any termination of Consultant’s services, Consultant or Consultant’s personal representative shall return all property of the Company or its Affiliates in Consultant’s possession, including but not limited to all Company-owned computer equipment (hardware and software), smart phones, facsimile machines, Blackberry, tablet computers and other communication devices, credit cards, office keys, security access cards, badges, identification cards and all copies (including drafts) of any documentation or information (however stored) relating to the business of the Company, its Affiliates, or customers and clients or prospective customers and clients of Company or its Affiliates. For any property of the Company or its Affiliates not returned within such period, the Company may withhold the reasonable costs of such property from Consultant’s Fees, at the Company’s sole discretion, until such property is returned. Anything to the contrary notwithstanding, Consultant shall be entitled to retain (i) personal papers and other materials of a personal nature, provided that such papers or materials do not include Confidential Information, (ii) information showing Consultant’s compensation or relating to reimbursement of expenses, and (iii) copies of agreements relating to Consultant’s engagement, or termination thereof, with the Company.

 

  - 7 -  

 

  

8.6           Maintenance of Records . Consultant agrees to keep and maintain adequate, current, accurate, and authentic written records of all Consultant-Created IPR made by Consultant (solely or jointly with others) during the term of this Agreement, and for a period of three (3) years thereafter. The records will be in the form of notes, sketches, drawings, electronic files, reports, or any other format that is customary in the industry and/or otherwise specified by the Company. Such records are and remain the sole property of the Company at all times and upon Company’s request, Consultant shall deliver (or cause to be delivered) the same.

 

8.7           Non-Disparagement . During the Consulting Period and at any time thereafter, the parties agree not to disparage or encourage or induce others to disparage each other, any of their Affiliates or any of their respective past or present officers, directors, employees, products or services. For purposes of this Section 8.7 , the term “disparage” includes, without limitation, comments or statements to the press, to the parties’ or their Affiliates’ employees or to any individual or entity with whom the the parties or their Affiliates have a business relationship (including, without limitation, any vendor, supplier, customer or distributor), or any public statement, that in each case is intended to, or can be reasonably expected to, materially damage any of the parties. Notwithstanding the foregoing, nothing in this Section 8.7 shall prevent the parties from making any truthful statement to the extent, but only to the extent (A) necessary with respect to any litigation, arbitration or mediation involving this Agreement, including, but not limited to, the enforcement of this Agreement, in the forum in which such litigation, arbitration or mediation properly takes place or (B) required by law, legal process or by any court, arbitrator, mediator or administrative or legislative body (including any committee thereof) with apparent jurisdiction over any of the parties.

 

8.8           Cooperation . During and following the Consulting Period, Consultant shall give Consultant’s assistance and cooperation willingly, upon reasonable advance notice, in any matter relating to Consultant’s services to the Company or its Affiliates, or Consultant’s knowledge as a result thereof as the Company may reasonably request, including Consultant’s attendance and truthful testimony where deemed appropriate by the Company, with respect to any investigation or the Company’s defense or prosecution of any existing or future claims or litigations or other proceeding relating to matters in which he was involved or had knowledge by virtue of Consultant’s services to the Company. The Company will reimburse Consultant for reasonable out-of-pocket travel costs and expenses incurred by him (in accordance with Company policy) as a result of providing such requested assistance, upon the submission of the appropriate documentation to the Company.

 

8.9           No Conflicting Obligations . Consultant represents and warrants that Consultant has no agreements, relationships, or commitments to any other person or entity that conflict with the provisions of this Agreement, Consultant’s obligations to the Company under this Agreement, and/or Consultant’s ability to perform the Services. Consultant will not enter into any such conflicting agreement during the term of this Agreement. The parties acknowledge that Consultant's activities set forth in Section 3.23 of the Disclosure Schedule provided in connection with the Reorganization Agreement shall not constitute such conflicting obligations.

 

8.10          Tolling . In the event of any violation of the provisions of this Section 8 , Consultant acknowledges and agrees that the post-termination restrictions contained in this Section 8 shall be extended by a period of time equal to the period of such violation, it being the intention of the parties hereto that the running of the applicable post-termination restriction period shall be tolled during any period of such violation.

 

  - 8 -  

 

  

8.11          Survival . This Section 8 shall survive any termination or expiration of this Agreement.

 

8.12          Obligations Cumulative . The parties acknowledge and agree that the obligations and covenants contained in this Section 8 is in addition to the obligations and covenants contained in the Reorganization Agreement.

 

9.            Enforcement of Agreement . The parties acknowledge and agree that they would be irreparably damaged and continually injured if any of the provisions of Section 8 are not performed in accordance with their specific terms and that any breach of Section 8 could not be adequately compensated by monetary damages alone. Accordingly, in addition to any other right or remedy to which it may be entitled at law or in equity, the parties shall be entitled to enforce any provision of Section 8 by a decree of specific performance and to temporary, preliminary and permanent injunctive or other appropriate equitable relief to prevent breaches or threatened breaches of Section 8 , without posting any bond or other security (to the extent permitted by law) or showing or proving any actual damages, the inadequacy of money damages, likelihood of success on the merits or irreparable harm or other undertaking. Further, the parties hereby waive any claim or defense that there is an adequate remedy at law for such breaches or threatened breaches.

 

10.          Severability . If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction. Upon such determination that any term or other provision is invalid, illegal or unenforceable, the parties shall negotiate in good faith to modify this Agreement so as to affect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the greatest extent possible.

 

11.          Notices . All notices, consents and other communications required or permitted by this Agreement must be in writing and shall be (a) delivered to the appropriate address by hand, by nationally recognized overnight service or by courier service (costs prepaid); (b) sent by facsimile or e-mail; or (c) sent by registered or certified mail, return receipt requested, in each case to the following addresses, facsimile numbers or e-mail addresses and marked to the attention of the Person (by name or title) designated below (or to such other address, facsimile number, e-mail address or Person as a party may designate by notice to the other parties):

 

Consultant :

 

David W. Evans

4141 Jutland Drive, Suite 215

San Diego, CA 92117

Telephone: 937-548-7970

Facsimile: 937-548-2773

Email: devans@vectorvision.com

 

  - 9 -  

 

  

with a copy (which shall not constitute notice) to:

 

Robert W. Hicks

Robert W. Hicks & Associates

600 W. Broadway, Suite 700

San Diego, CA 92101

Telephone: 619-236-3403

Email: rhicks@rwhlaw.com

 

Company :

 

Guardion Health Sciences, Inc.

15150 Avenue of Science, Suite 200

San Diego, CA 92128

Attention: Michael Favish

Telephone: 858-605-9055 Ext 201

Facsimile: 858-630-5543

Email: mfavish@guardionhealth.com

 

with a copy (which shall not constitute notice) to:

 

SHEPPARD MULLIN RICHTER & HAMPTON LLP

 

333 South Hope Street, 43rd Floor

Los Angeles, CA 90071

Attention: David I. Sunkin, Esq.

Telephone: (213) 617-4252

Facsimile: (213) 443-2750

Email: dsunkin@sheppardmullin.com

 

All notices, consents, waivers and other communications shall be deemed have been duly given (as applicable): if delivered by hand, when delivered by hand; if delivered by overnight service, when delivered by nationally recognized overnight service; if delivered by courier, when delivered by courier; if sent via registered or certified mail, three (3) business days after being deposited in the mail, postage prepaid; or if delivered by email or facsimile, when transmitted if transmitted without indication of delivery failure prior to 5:00 p.m. local time for the recipient (and if transmitted without indication of delivery failure after 5:00 p.m. local time for the recipient, then delivery will be deemed duly given at 9:00 a.m. local time for the recipient on the subsequent business day, or upon earlier acknowledgment, if acknowledged by the recipient).

 

12.           Miscellaneous .

 

12.1          Consultant Representation . Consultant hereby represents to the Company that the execution and delivery of this Agreement by Consultant and the Company and the performance by Consultant of Consultant’s duties hereunder shall not constitute a breach of, or otherwise contravene, or be prevented, interfered with or hindered by, the terms of any other agreement or policy to which Consultant is a party or otherwise bound, and further that Consultant is not subject to any limitation on his activities on behalf of the Company or its Affiliates as a result of agreements into which Consultant has entered except for obligations of confidentiality with former employers. To the extent this representation and warranty is not true and accurate, it shall be treated as a Cause event and the Company may terminate Consultant’s services under this Agreement for Cause or not permit Consultant to commence providing services under this Agreement.

 

  - 10 -  

 

  

12.2          No Mitigation or Offset . In the event of any termination of Consultant’s services hereunder, Consultant shall be under no obligation to seek other engagement or otherwise mitigate the obligations of the Company under this Agreement, and there shall be no offset against amounts due Consultant under this Agreement on account of future earnings by Consultant.

 

12.3          Entire Agreement . This Agreement supersedes all prior agreements, whether written or oral, between the parties hereto with respect to its subject matter and constitutes, along with the Reorganization Agreement, a complete and exclusive statement of the terms of the agreement between the parties with respect to the subject matter hereof.

 

12.4          Assignment and Transfer . The provisions of this Agreement shall be binding on and shall inure to the benefit of the Company and any successor in interest to the Company who acquires all or substantially all of the Company’s assets. The Company may assign this Agreement to an Affiliate; provided, however, that, without Consultant’s consent, no such assignment shall relieve the Company of its obligations hereunder. Neither this Agreement nor any of the rights, duties or obligations of Consultant shall be assignable by Consultant, nor shall any of the payments required or permitted to be made to Consultant by this Agreement be encumbered, transferred or in any way anticipated, except as required by applicable laws. All rights of Consultant under this Agreement shall inure to the benefit of and be enforceable by Consultant’s personal or legal representatives, estates, executors, administrators, heirs and beneficiaries. This Agreement is for the sole benefit of the parties and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other person or entity any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.

 

12.5          Modifications; Waiver; Remedies Cumulative . No provision of this Agreement may be amended, supplemented, waived or otherwise modified except by a written agreement executed by all the parties. The rights and remedies of the parties hereunder are cumulative and not alternative. Neither any failure nor any delay by any party in exercising any right, power or privilege under this Agreement or any of the documents referred to in this Agreement will operate as a waiver of such right, power or privilege, and no single or partial exercise of any such right, power or privilege will preclude any other or further exercise of such right, power or privilege or the exercise of any other right, power or privilege. To the maximum extent permitted by applicable law, (a) no waiver that may be given by a party will be applicable except in the specific instance for which it is given, and (b) no notice to or demand on one party will be deemed to be a waiver of any obligation of that party or of the right of the party giving such notice or demand to take further action without notice or demand as provided in this Agreement.

 

  - 11 -  

 

  

12.6        Construction . Unless the express context otherwise requires: (a) the words “hereof”, “herein”, and “hereunder” and words of similar import, when used in this Agreement, shall refer to this Agreement as a whole and not to any particular provision of this Agreement; (b) the terms defined in the singular have a comparable meaning when used in the plural, and vice versa; (c) references herein to a specific Section shall refer to the Sections of this Agreement; (d) wherever the word “include,” “includes,” or “including” is used in this Agreement, it shall be deemed to be followed by the words “without limitation”; (e) any reference to the masculine, feminine or neuter gender shall include each other gender; and (f) any reference to a party means a party to this Agreement. The parties agree that they have been represented by counsel during the negotiation and execution of this Agreement and, therefore, waive the application of any applicable law or rule of construction providing that ambiguities in an agreement or other document will be construed against the party or parties drafting such agreement or document. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement. Wherever a conflict exists between this Agreement and any other agreement, this Agreement shall control but solely to the extent of such conflict.

 

12.7        Code Section 409A .

 

(a)           The parties agree that this Agreement shall be interpreted to comply with or be exempt from Section 409A of the Code and the regulations and guidance promulgated thereunder to the extent applicable (collectively “ Code Section 409A ”), and all provisions of this Agreement shall be construed in a manner consistent with the requirements for avoiding taxes or penalties under Code Section 409A. In no event whatsoever will the Company be liable for any additional tax, interest or penalties that may be imposed on Executive under Code Section 409A or any damages for failing to comply with Code Section 409A.

 

(b)           For purposes of Code Section 409A, Consultant’s right to receive any installment payments pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments. Whenever a payment under this Agreement specifies a payment period with reference to a number of days ( e.g ., “payment shall be made within thirty (30) days following the date of termination”), the actual date of payment within the specified period shall be within the sole discretion of the Company.

 

12.8        Dispute Resolution; Arbitration . If any contest or dispute arises between the parties with respect to this Agreement or Consultant’s engagement or termination thereof, other than injunctive and equitable relief with regard to Section 9 hereof, such contest or dispute shall be submitted to binding arbitration in San Diego, California in accordance with the rules and procedures of the Commercial Arbitration Rules and the expedited arbitration procedures of the American Arbitration Association (“ AAA ”) then in effect. The decision of the arbitrator shall be final and binding on the parties and may be entered in any court of applicable jurisdiction. The parties shall split the fees of AAA and the arbitrator, which fees shall be recoverable as costs by the prevailing party pursuant to Section 12.11.

 

  - 12 -  

 

  

12.9          Governing Law . In all respects, including matters of construction, validity and performance, this Agreement shall be governed by, and construed and enforced in accordance with, the internal laws of the State of California applicable to contracts made and performed in that state (without regard to the choice of law or conflicts of law provisions thereof that would require the application of the law of any other jurisdiction).

 

12.10         Attorneys’ Fees . If any action, including any arbitration pursuant to Section 12.9 or equitable action pursuant to Section 9 of this Agreement, is brought for the enforcement of this Agreement, or because of an alleged dispute, breach, default or misrepresentation in connection with any of the provisions of this Agreement, the successful or prevailing party shall be entitled to recover reasonable attorneys’ fees (including in-house attorneys costs billed at reasonable rates) and other costs incurred in that action from the non-prevailing party, in addition to any other relief to which it may be entitled.

 

12.11          Execution of Agreement . This Agreement may be executed in counterpart signature pages executed and delivered via facsimile transmission or via email with scan or email attachment. Any such counterpart executed and delivered via facsimile transmission or via email with scan or email attachment will be deemed an original for all intents and purposes, and all such counterparts shall together constitute one and the same instrument.

 

[SIGNATURE PAGE FOLLOWS]

 

  - 13 -  

 

  

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.

 

  COMPANY
   
  GUARDION HEALTH SCIENCES, INC.
   
  /Michael Favish/
  Michael Favish
  Pre sident
   
  CONSULTANT
   
  /David W. Evans/
  David W. Evans

 

Signature Page to Evans Consulting Agreement

 

 

 

  

SCHEDULE A

 

SERVICES

 

1.    Services:

 

Consultant will dedicate an adequate amount of his business time to providing the services listed below, as well as on-going services as shall be identified by Company from time to time.

 

· Identifying and attending medical conferences, trade shows, leadership forums and other events or programs to advance Company’s or an Affiliate’s business interests;
· Securing speaking engagements, leadership positions, industry expert appointments or other engagements within the medical field;
· Identifying, researching, facilitating and interfacing with investors and potential investors in Company’s or Affiliate’s business;
· Creating introductions (potential partners, providers, etc.) for Company or Affiliates;
· Attending regular meetings of Company’s or Affiliates’ management team, as requested from time to time by Company;
· Conducting medical and scientific research in the field of and relating to the measurement of visual function related to refractive surgery, glaucoma, eye diseases, visual performance and ocular blood flow;
· Writing and submitting scientific articles in the field of and relating to measurement of visual function related to refractive surgery, glaucoma, eye diseases, visual performance and ocular blood flow;
· Performing other duties related to the Business as reasonably requested from time to time by Company.

 

  - 14 -  

 

 

Exhibit 10.3

 

EXECUTION VERSION

 

INTELLECTUAL PROPERTY PURCHASE AGREEMENT

 

This intellectual property purchase agreement (the "Agreement") is entered into as of September 29, 2017 (the "Effective Date"), by and between David W. Evans, a US citizen (“Seller”) and Guardion Health Sciences, Inc., a Delaware corporation, or its assigns (“Buyer”).

 

WHEREAS, Seller solely owns all right, title, and interest in and to the patent applications listed in Schedule A attached hereto, any patents issuing therefrom, and any patents or patent applications throughout the world claiming priority from any of the foregoing, including, without limitation, all continuation patents, divisional patents, continuation-in-part patents, patent applications (including, without limitation, provisional applications), reissues, reexaminations, extensions, substitutes and foreign counterparts concerning or relating to said patents and patent applications, as well as any inventions disclosed in any of the foregoing (collectively, the “Patented Technology”);

 

WHEREAS, Seller has not transferred, licensed or otherwise encumbered Seller’s right, title and interest in the Patented Technology;

 

WHEREAS, Buyer desires to purchase from Seller all right, title, and interest in and to the Patented Technology; and

 

WHEREAS Seller desires to sell his right, title, and interest in and to the Patented Technology.

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the covenants and promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:

 

1.      Definitions .

 

(a)           Covered Goods or Services means goods or services sold or otherwise provided by Buyer to third parties that constitute a method and apparatus for vision acuity testing that fall within the claims of the patents and patent applications included in the Patented Technology.

 

(b)           Net Revenues means the cash revenue of Buyer determined in accordance with United States generally accepted accounting principles consistently applied with past practice (GAAP) for each Covered Good or Service that is sold anywhere in the world , after deduction of the following: rebates, commissions, discounts, insurance, freight, duties, taxes and bad debts from amounts earlier booked as revenue on sales of the Covered Goods or Services.

 

  - 1 -  

 

  

2.      Asset Transfer . Seller hereby conveys, transfers, assigns, delivers, and contributes to Buyer all of Seller’s right, title, and interest in and to the Patented Technology, including without limitation, damages, and payments for past or future infringements, all rights to sue for past, present, and future infringements, and all other intellectual property rights owned or claimed by Seller embodied in the Patented Technology, including renewal rights therein, the exclusive right to enforce and file related patent applications therefor in the United States and throughout the world.

 

3.      Consideration . As consideration for this Agreement, Buyer shall pay to Seller a commercially reasonable royalty (“Royalty”) of Net Revenues during the Royalty Term (defined hereinafter). The Parties agree to negotiate the amount and the terms and conditions of the Royalty in good faith, provided that the Parties agree and acknowledge that the Royalty for Covered Goods and Services not covered by an issued patent shall be less than the Royalty for Covered Goods and Services covered by an issued patent. There shall be no minimum requirements.

 

4.      Royalty Term . Buyer’s payment of the Royalty to Seller shall begin thirty (30) days after the first sale or provision of the Covered Goods or Services, if any, and remain in effect until the sooner of (a) the expiration of the last-to-expire of the Patented Technology or

(b) the cessation of sales or provision of Covered Goods or Services (“Royalty Term”).

 

5.      No Obligation . Seller agrees and acknowledges that:

 

(a)          Subject to Section 6, Buyer, in its sole and exclusive discretion, shall (i) have the right, but not the obligation, to file or continue to prosecute any patent application, secure any patent, or maintain any patent included in the Patented Technology; and (ii) have the right, but not the obligation, to bring or prosecute actions or suits against any third parties for infringement of the Patented Technology;

 

(b)          Buyer (i) may engage in the conception, development, manufacture, use, practice, or sale of other products or methods which may compete with the Covered Goods or Services, (ii) must contribute significant resources of its own to successfully develop, manufacture, use, and sell the Covered Goods or Services; and (iii) may be obligated to submit certain notices and obtain certain approvals, licenses and rights required by applicable law before it can develop, manufacture, use or sell the Covered Goods or Services, thus Buyer shall only be required to use its reasonable efforts to develop, manufacture and sell the Covered Goods or Services; and

 

(c)          In no event does Buyer guarantee that the Covered Goods or Services can or will be commercialized and Buyer may cease to commercialize, develop or move forward with the Patented Technology at any time at its sole and exclusive discretion.

 

  - 2 -  

 

  

6.     In the event that Buyer decides not to continue to prosecute the patent applications listed in Schedule A hereto (“Pending Patent Applications”), or to otherwise commercially exploit the Patented Technology, Buyer shall give reasonable notice to Seller of its decision. Buyer agrees to either notify Seller of its intent to not pursue the Pending Patent Applications at least 30 days prior to the expiration of any deadline in the US or foreign patent process or to otherwise timely comply with said deadlines. In the event that Buyer decides not to pursue the Pending Patent Applications or continue to economically exploit the Patented Technology, Seller shall have the right to require that the Pending Patent Applications and/or the Patented Technology, whichever is applicable based on what Buyer decides not to pursue, be assigned back to Seller at no cost to Seller. In such event, Buyer shall have an irrevocable, unrestricted, royalty free license (notwithstanding any royalty negotiated pursuant to this Agreement) to practice any invention in such Pending Patent Applications should a patent be issued on such invention as needed by Buyer to exploit the Covered Goods and Services to the extent their compositions or methods fall within the claims included in the Patented Technology.

 

7.      Representations and warranties .

 

Seller hereby represents and warrants that:

 

(a)          he has not assigned, transferred, sold, conveyed any interest in, or otherwise disposed of his rights, title and interest in the Patented Technology to anyone;

 

(b)          he has sole, exclusive, valid, and unencumbered title to his rights, title and interest in the Patented Technology and has not granted any liens, mortgages, encumbrances, licenses or other agreements thereon or thereto;

 

(c)          he has full right, power and authority to grant all of the rights, title and interests granted in this Agreement, and no consents of any other parties are necessary or appropriate under any agreements concerning the Patented Technology in order for the transfer and assignment of any of his rights, title and interest in the Patented Technology under this Agreement to be legally effective;

 

(d)          no dispute exists which challenges the use, legality, validity, or enforceability of the Patented Technology, and no circumstances or grounds exist that would give rise to such disputes; and

 

(e)          to Seller’s knowledge, use of the Patented Technology will not interfere with, infringe upon, misappropriate, or otherwise breach the rights of any third party.

 

8.      Indemnity . Seller shall indemnify, make good, save and hold harmless Buyer, its parent, successors, Buyers and assigns and their respective officers, agents and employees, from all liabilities, damages, costs, charges, reasonable attorneys' fees, recoveries, actions, judgments, penalties, expenses and other losses whatsoever which may be obtained against, imposed upon or suffered by Buyer, its parent, successors, Buyers and assigns arising from a third party claim resulting from breach of any of Seller’s representations, warranties or agreements hereunder.

 

  - 3 -  

 

  

9.      Successors and Assigns . This Agreement shall be binding upon and shall inure to the benefit of the parties and their respective successors and permitted assigns. No party may assign or delegate its rights or obligations hereunder without the prior written consent of the other parties; provided, however, that Buyer shall be entitled to assign or delegate all or any part of its rights or obligations hereunder (a) to any one or more affiliates of Buyer, (b) in connection with the sale of all or any substantial portion of the assets of Buyer or one or more affiliates of Buyer or (c) for collateral security purposes to any lender providing financing to Buyer. No assignment shall relieve the assigning party of any of its obligations hereunder. “Affiliate” of Buyer means any individual, corporation, partnership, joint venture, limited liability company, unincorporated organization, trust, association or other entity that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, Buyer. The term “control” (including the terms “controlled by” and “under common control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of an Affiliate, whether through the ownership of voting securities, by contract or otherwise.

 

10.    Further Documents . The Parties shall execute all such further documents as shall be reasonable, convenient, necessary, or desirable to carry out the provisions of the Agreement.

 

11.    Confidentiality . The contents, but not the mere existence of this Agreement are and shall be kept confidential by the Parties.

 

12.    Amendment and Modifications . Subject to applicable law, this Agreement may be amended, modified and supplemented only by written agreement between the Parties hereto which states that it is intended to be a modification of this Agreement.

 

13.    Waiver of Compliance . Any failure of either Party to comply with any obligation, covenant, agreement or condition herein may be expressly waived in writing by the other party, but such waiver or failure to insist upon strict compliance with such obligation, covenant, agreement or condition shall not operate as a waiver of, or estoppel with respect to, any subsequent or other failure.

 

14.    Waiver . No failure on the part of any Party to exercise or delay in exercising any right hereunder shall be deemed a waiver thereof, nor shall any single or partial exercise preclude any further or other exercise of such or any other right.

 

15.    Governing Law, Jurisdiction and Venue . This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction). Each party irrevocably consents and submits to the personal jurisdiction and venue of the federal and state courts located in San Diego County, California and irrevocably waives any and all claims and defenses which such party might otherwise have in any action or proceeding in any of such courts based upon any alleged lack of personal jurisdiction, improper venue, forum non conveniens or any similar claim or defense. The prevailing party in any action brought pursuant to the terms hereof shall be entitled to its attorneys’ fees and costs.

 

  - 4 -  

 

  

16.    Specific Performance . The Parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. Accordingly, in addition to any other right or remedy to which it may be entitled at law or in equity, (a) Buyer will be entitled to seek an injunction or injunctions or specific performance, without the posting of any bond, to prevent breaches of this Agreement by Seller and to enforce specifically the terms and provisions of this Agreement, in addition to any other remedy to which such Party is entitled at law or in equity and (b) Seller will be entitled to seek an injunction or injunctions or specific performance, without the posting of any bond, to enforce specifically the terms and provisions of this Agreement, to prevent breaches of this Agreement, in addition to any other remedy to which such Party is entitled at law or in equity.

 

17.    Dispute Resolution; Arbitration . If any contest or dispute arises between the parties with respect to this Agreement, other than injunctive and equitable relief with regard to Section 15 hereof, such contest or dispute shall be submitted to binding arbitration in Wilmington, Delaware in accordance with the rules and procedures of the Commercial Arbitration Rules and the expedited arbitration procedures of the American Arbitration Association (“AAA”) then in effect. The decision of the arbitrator shall be final and binding on the parties and may be entered in any court of applicable jurisdiction. The parties shall bear their own legal fees in any arbitration and shall split the fees of the AAA and the arbitrator.

 

18.    Counterparts . This Agreement may be executed simultaneously in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

19.    Headings . The headings of the Sections of this Agreement are inserted for convenience only and shall not constitute a part hereof or affect in any way the meaning or interpretation of this Agreement.

 

20.    Third Parties . Except as specifically set forth or referred to herein, nothing herein expressed or implied is intended or shall be construed to confer upon or give to any person or corporation other than the Parties hereto and their successors or assigns, any rights or remedies under or by reason of this Agreement.

 

21.    Severability . If any provision of this Agreement is held by a court of competent jurisdiction to be unlawful or unenforceable, such provisions shall be considered severed from the provisions of this Agreement but all remaining provisions of this Agreement shall remain in full force and effect.

 

  - 5 -  

 

  

22.    Notices and Demands . All notices, requests, demands or other communications required by, or otherwise with respect to this Agreement shall be in writing and shall be deemed to have been duly given to any party when delivered personally (by courier service or otherwise), against receipt, when delivered by telecopy and confirmed by return telecopy, or when actually received when mailed by registered first-class mail, postage prepaid and return receipt requested in each case to the applicable addresses set forth below:

 

Seller :

 

David W. Evans

4141 Jutland Drive, Suite 215

San Diego, CA 92117

Telephone: 937-548-7970

Facsimile: 937-548-2773

Email: devans@vectorvision.com

 

Buyer :

 

Guardion Health Sciences, Inc.

15150 Avenue of Science, Suite 200

San Diego, CA 92128

Attention: Michael Favish

Telephone: 858-605-9055 Ext 201

Facsimile: 858-630-5543

Email: mfavish@guardionhealth.com

 

with a copy (which shall not constitute notice) to:

 

SHEPPARD MULLIN RICHTER & HAMPTON LLP

333 South Hope Street, 43rd Floor

Los Angeles, CA 90071

Attention: David I. Sunkin, Esq.

Telephone: (213) 617-4252

Facsimile: (213) 443-2750

Email: dsunkin@sheppardmullin.com

 

23.   Entire Agreement . This Agreement sets forth the final, complete and exclusive agreement and understanding of the Parties hereto in respect of the subject matter contained herein, and supersedes all prior agreements, promises, covenants, arrangements, communications, representations or warranties, whether oral or written, by any officer, employee or representative of any party hereto.

 

[Signature Page Follows]

 

  - 6 -  

 

  

IN WITNESS WHEREOF , the Parties have caused this Agreement to be executed and delivered to be effective as of the date first written above.

  

Dated: September 29 , 2017 Seller
   
  /David Evans/
  David Evans
  Chief Executive Officer
   
Dated: September 29 , 2017 Buyer
   
  VectorVision Ocular Health, Inc.
   
  /Michael Favish/
  Michael Favish
  President

 

Signature Page to IP Purchase Agree m ent

 

 

 

  

SCHEDULE A

 

Country   App. No.   Filing Date   Title
USA   15277849   September 27, 2016   METHOD AND APPARATUS FOR VISION ACUITY TESTING
USA   15445586   February 28, 2017  

METHOD AND APPARATUS FOR

VISION ACUITY TESTING

 

  - 8 -  

 

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

 

To the Board of Directors

Guardion Health Sciences, Inc.

 

We hereby consent to the incorporation by reference in the Registration Statement on Form S-1 (No. 333-209488) of Guardion Health Sciences, Inc. of our report dated September 26, 2017, relating to the financial statements of VectorVision, Inc., which is attached as Exhibit 99.2 to the Current Report on Form 8-K of Guardion Health Sciences, which was filed with the SEC on October 5, 2017.

 

 

/s/ Weinberg & Company, P.A.

 

Weinberg & Company, P.A.

 

Los Angeles, California

October 5, 2017

 

 

 

Exhibit 99.1

 

 
FOR IMMEDIATE RELEASE
 
Guardion Health Sciences, Inc.
15150 Avenue of Science, Ste. 200
San Diego, CA 92128
Ph 858.605.9055; Fax 858.630.5543
www.guardionhealth.com

 

 

 

Guardion Health Sciences Concludes

Acquisition of VectorVision

 

San Diego, California – October 2, 2017 – Guardion Health Sciences, Inc. (“Guardion” or the “Company”), a leader in the field of ocular health technologies and products, has acquired VectorVision, Inc. (“VectorVision”) effective as of September 29, 2017. 

 

VectorVision is a world leader in standardized vision testing, and the leader in the field of contrast sensitivity, glare disability and ETDRS (Early Treatment Diabetic Retinopathy Study) visual acuity testing with its proprietary CSV-1000 device. The VectorVision testing equipment is widely used by both eye care clinicians and ophthalmic researchers, and has become the established benchmark for standardized, highly sensitive and repeatable vision testing. The acquisition of VectorVision expands Guardion’s technical portfolio and further establishes the Company’s position at the forefront of early detection, intervention and monitoring of a range of eye diseases and conditions.  

 

Guardion acquired substantially all the assets of VectorVision, including trademarks, copyrights and other intellectual property, and assumed certain liabilities of VectorVision, in exchange for the issuance of 3,050,000 shares of its common stock, which represent approximately 11% of Guardion’s issued and outstanding shares immediately following the transaction.

 

In conjunction with the transaction, the founding shareholder of VectorVision, Dr. David Evans, is joining Guardion’s Board of Directors. Dr. Evans is an internationally recognized expert in vision correction surgery, eye physiology and vision testing technology. He received his Bachelor of Science degree in Human Factors Engineering from the United States Air Force Academy, a Master of Science degree and Masters in Business Administration from Wright State University in Dayton, Ohio, and a Ph.D. in Ocular Physiology from Indiana University.

 

 

 

 

Dr. Evans commented, “I am very excited about joining forces with Guardion. A new age of eye healthcare is upon us, and we now have the availability of novel treatment interventions which can lead to vision recovery in disease states where recovery was previously not possible. The VectorVision technology is the recognized world standard for contrast sensitivity testing, and we expect our technology to play a critical role in helping doctors measure the visual function recovery associated with new interventions that may be developed by Guardion and others, as well as demonstrating to patients the benefits of these interventions.”

 

Michael Favish, Guardion’s CEO and founder, added, “We believe that the VectorVision acquisition marks just the beginning of the expansion of Guardion’s technology portfolio, and demonstrates our commitment to building the Company into the market leader in ocular health early detection and management. We are delighted to welcome Dr. Evans to our Board of Directors, and we look forward to working with him as we continue to advance the VectorVision technology and support our doctor partners and the patients that they serve.”

 

A more complete description of the previously described transaction, including a copy of the transaction documents, is filed in a Current Report on Form 8-K with the Securities and Exchange Commission and is available at www.sec.gov.

 

About VectorVision ®

 

VectorVision ® specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and ETDRS (Early Treatment Diabetic Retinopathy Study) acuity vision testing. Its patented standardization system provides the practitioner or researcher the ability to delineate very small changes in visual capability, either as compared to the population or from visit to visit. VectorVision ® ’s CSV-1000 device is considered the standard of care for clinical trials. Dr. David Evans, founder of VectorVision ® , is recognized as the leading expert in clinical contrast sensitivity and glare testing. He has provided his testing expertise and data analysis capability to a wide range of leading ophthalmic companies including AMO, Alcon, AcuFocus, Pharmacia, Otsuka, Novartis and others. Dr. Evans has published more than 30 scientific articles and 3 book chapters in the areas of refractive surgery, glaucoma, ocular blood flow and visual function, and is the inventor of 5 patents related to vision testing devices.

 

 

 

 

About Guardion Health Sciences, Inc.

 

Guardion Health Sciences, Inc. is a specialty health sciences company that develops, formulates and distributes condition-specific medical foods, with an initial medical food product that addresses a depleted macular protective pigment, a known risk factor for age-related macular degeneration (“AMD”), and a significant component of functional vision performance.  Guardion Health Sciences, Inc. has also developed a proprietary medical device, the MapcatSF ® , which accurately measures the macular pigment density, therefore providing the only two-pronged evidence based protocol for the management of the macular pigment.

 

Forward-Looking Statement Disclaimer

 

The matters described herein include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company’s ability to raise sufficient financing to implement its business plan and its ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s recent filings with the U. S. Securities and Exchange Commission (the “SEC”), including the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and Post-Effective Amendment No. 1 to the Company’s Registration Statement on Form S-1, as well as the financial statements included therein, and in recent Quarterly Reports on Form 10-Q filings. These filings are available at the SEC’s website ( www.sec.gov ) The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Company Contact:

Michael Favish
Chief Executive Officer

Telephone: (858) 605-9055 x 201
E-mail: mfavish@guardionhealth.com

 

###

 

 

 

Exhibit 99.2

 

VectorVision, Inc.

Audited Financial Statements as of and for the Years Ended December 31, 2016 and 2015

Contents

 

Report of Independent Registered Public Accounting Firm   2
     
Financial Statements    
     
Balance Sheets – As of December 31, 2016 and 2015   3
   
Statements of Operations – For the Years Ended December 31, 2016 and 2015   4
   
Statements of Stockholders’ Equity (Deficiency) – For the Years Ended December 31, 2016 and 2015   5
     
Statements of Cash Flows – For the Years Ended December 31, 2016 and 2015   6
     
Notes to Financial Statements   7

 

     

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors

VectorVision, Inc.

San Diego, California

 

We have audited the accompanying balance sheets of VectorVision, Inc. (the "Company") as of December 31, 2016 and 2015 and the related statements of operations, stockholders' equity (deficiency), and cash flows for the years then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

 

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform our audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that we considered appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

 

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of VectorVision, Inc. as of December 31, 2016 and 2015, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1, the Company has experienced recurring net losses since inception and has a stockholders’ deficiency as of December 31, 2016. These matters raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1 to the financial statements. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

/s/ Weinberg & Company, P.A.  
   
Weinberg & Company, P.A.  
Los Angeles, California  
September 26, 2017  

 

  2  

 

 

VectorVision, Inc.

 

Balance Sheets

 

    December 31,  
    2016     2015  
             
Assets                
                 
Current assets                
Cash   $ 7,160     $ 5,698  
Accounts receivable     18,301       9,656  
Inventories     87,155       122,632  
Prepaid expenses     2,537       2,884  
                 
Total current assets     115,153       140,870  
                 
Property and equipment, net     11,756       15,353  
                 
Total assets   $ 126,909     $ 156,223  
                 
Liabilities and Stockholders’ Equity (Deficiency)                
                 
Current liabilities                
Accounts payable and accrued liabilities   $ 74,365     $ 79,394  
Line of credit     32,760       20,173  
Promissory notes payable to related party     38,087       37,317  
                 
Total liabilities     145,212       136,884  
                 
Commitments and contingencies                
                 
Stockholders’ Equity (Deficiency)                
                 
Common stock, $0.00 par value; 750 shares authorized; 124 and 124 shares issued and outstanding at December 31, 2016 and December 31, 2015     -       -  
Additional paid-in capital     51,410       51,410  
Accumulated deficit     (69,713 )     (32,071 )
                 
Total stockholders’ equity (deficiency)     (18,303 )     19,339  
                 
Total liabilities and stockholders’ equity (deficiency)   $ 126,909     $ 156,223  

 

See accompanying notes to financial statements.

 

  3  

 

 

VectorVision, Inc.

 

Statements of Operations

 

    Years Ended December 31,  
    2016     2015  
             
Revenue   $ 231,458     $ 258,263  
                 
Cost of goods sold     84,520       90,368  
                 
Gross profit     146,938       167,895  
                 
Operating expenses                
Sales and marketing     12,353       7,159  
General and administrative     164,003       173,076  
                 
Total operating expenses     176,356       180,235  
                 
Loss from operations     (29,418 )     (12,340 )
                 
Other expenses:                
Interest expense     8,224       8,060  
                 
Net loss   $ (37,642 )   $ (20,400 )

 

See accompanying notes to financial statements.

 

  4  

 

 

VectorVision, Inc.

 

Statements of Stockholders’ Equity (Deficiency)

 

    Common Stock                    
    Shares     Amount     Additional
Paid-In
Capital
    Accumulated
Deficit
    Total
Stockholders’
Equity (Deficiency)
 
Balance at December 31, 2014     125     $ -     $ 51,410     $ (11,671 )   $ 39,739  
Common stock retired     (1 )     -       -       -       -  
Net loss – January 1, 2015 through December 31, 2015     -       -       -       (20,400 )     (20,400 )
Balance at December 31, 2015     124       -       51,410       (32,071 )     19,339  
Net loss – January 1, 2016 through December 31, 2016     -       -       -       (37,642 )     (37,642 )
Balance at December 31, 2016     124     $ -     $ 51,410     $ (69,713 )   $ (18,303 )

 

See accompanying notes to financial statements.

 

  5  

 

 

VectorVision, Inc.

 

Statements of Cash Flows

 

    Years Ended December 31,  
    2016     2015  
             
Operating Activities                
Net loss   $ (37,642 )   $ (20,400 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Depreciation and amortization     3,597       10,215  
Changes in operating assets and liabilities:                
(Increase) decrease in -                
Accounts receivable     (8,645 )     5,330  
Inventories     35,477       16,663  
Prepaid expenses     347       (2,779 )
Increase (decrease) in -                
Accounts payable and accrued expenses     (5,029 )     (1,857 )
                 
Net cash (used in) provided by operating activities     (11,895 )     7,172  
                 
Financing Activities                
Proceeds from issuance of promissory notes, related party     38,087       10,000  
Payments on promissory notes, related party     (37,317 )     (8,270 )
Line of credit     12,587       (14,931 )
                 
Net cash provided by (used in) financing activities     13,357       (13,201 )
                 
Cash:                
Net increase (decrease)     1,462       (6,029 )
Balance at beginning of period     5,698       11,727  
Balance at end of period   $ 7,160     $ 5,698  
                 
Supplemental disclosure of cash flow information:                
Cash paid for -                
Interest   $ 8,224     $ 8,060  
Income taxes   $ -     $ -  

 

See accompanying notes to financial statements.

 

  6  

 

 

VectorVision, Inc.

Notes to Financial Statements

Years Ended December 31, 2016 and 2015

 

1. Organization and Business Operations

 

Organization and Business

 

VectorVision, Inc. (the “Company”) was formed in November 1987 as an Ohio-based S Corporation and was founded by David W. Evans, PhD, MBA. The Company develops, manufactures and sells equipment and supplies for standardized vision testing for use by eye doctors, in clinical trials, for real-world vision evaluation and industrial vision testing.

 

VectorVision specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and Early Treatment Diabetic Retinopathy Study (“ETDRS”) acuity vision testing. The Company’s patented standardization system provides the practitioner or researcher the ability to delineate very small changes in visual capability, either as compared to the population or from visit to visit.

 

Going Concern and Liquidity

 

The financial statements have been prepared assuming the Company will continue as a going concern. The Company had a net loss of $37,642 during the year ended December 31, 2016, and had a stockholders’ deficiency of $18,303 as of December 31, 2016. The Company expects to continue to incur cash outflows from operations that will prevent or limit growth in the near-term. As a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued.

 

The Company’s auditors have also included explanatory language in their opinion that there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.

 

The Company will continue to incur significant manufacturing, promotional, and administrative expenses associated with its current product line. Additionally, the Company’s long-term viability and growth may depend upon the successful development and commercialization of new products. If the Company is unable to generate sufficient revenues and margins or access supplemental capital resources on a timely basis, the Company may be forced to reduce or discontinue its technology and product development programs and curtail or cease operations. There is no assurance that the Company will be able to generate sufficient revenues, or be able to access any capital resources.

 

2. Summary of Significant Accounting Policies

 

Basis of Presentation and Use of Estimates

 

The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).

 

The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Those estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, and accruals for potential liabilities.

 

  7  

 

 

Fair Value of Financial Instruments

 

The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as noted below. Disclosure as to transfers into and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required.

 

Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives.

 

Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges.

 

Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded, non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models.

 

The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end.

 

The Company believes the carrying amount of its financial instruments (consisting of cash, accounts receivable, and accounts payable and accrued liabilities) approximates fair value due to the short-term nature of such instruments. The fair value of the Company’s line of credit and promissory notes approximates their carrying value given the interest rates of such notes.

 

Concentration of Credit Risk and Other Risks and Uncertainties

 

Cash balances are maintained at a large, well-established financial institution. At times, cash balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. Insurance coverage limits are $250,000 per depositor at each financial institution. All cash balances were fully insured at December 31, 2016 and 2015.

 

Inventories

 

The Company’s inventories are stated at the lower of weighted-average cost or market. The cost of finished goods and raw materials is determined on a first-in, first-out basis. The Company evaluates its inventories for obsolescence and recoverability at each reporting period.

 

Property and Equipment

 

Property and equipment are initially recorded at their historical cost. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from five to seven years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.

 

Impairment of Long-Lived Assets

 

The Company reviews long-lived assets, consisting of property and equipment, for impairment at each fiscal year end or when events or changes in circumstances indicate the carrying value of these assets may exceed their current fair values. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the assets. Assets to be disposed of are separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The Company has not historically recorded any impairment to its long-lived assets. In the future, if events or market conditions affect the estimated fair value to the extent that a long-lived asset is impaired, the Company will adjust the carrying value of these long-lived assets in the period in which the impairment occurs. As of December 31, 2016 and 2015, the Company had not deemed any long-lived assets as impaired, and was not aware of the existence of any indicators of impairment at such dates.

 

  8  

 

 

Revenue Recognition

 

The Company’s revenue is comprised primarily of sales of medical device equipment and supplies to consumers both in the U.S. and internationally. Revenue is recognized when the risk of loss transfers to our customers and collection of the receivable is reasonably assured, which generally occurs when the product is shipped. A product is not shipped without an order from the customer and an appropriate credit evaluation.

 

We review accounts receivable for uncollectible accounts and provide an allowance for doubtful accounts as needed, which is based upon a review of outstanding receivables, historical collection information, and existing economic conditions. We write off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when received as an increase in the allowance for doubtful accounts. As of December 31, 2016, we had no outstanding accounts receivable that we believed were at risk of non-collection.

 

The Company provides a standard one-year warranty that covers replacement for damaged parts. Product returns for the years ended December 31, 2016 and 2015 were insignificant.

 

Income Taxes

 

The Company operates as an “S” Corporation. As such, it is taxed as a pass-through entity whereby substantially all income tax attributes are passed through to the individual members except for the minimum state income tax.

 

Recent Accounting Pronouncements

 

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. Based on the FASB’s Exposure Draft Update issued on April 29, 2015, and approved in July 2015, Revenue from Contracts With Customers (Topic 606): Deferral of the Effective Date, ASU 2014-09 is now effective for reporting periods beginning after December 15, 2017, with early adoption permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The adoption of ASU 2014-09 is not expected to have any impact on the Company’s financial statement presentation or disclosures.

 

In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (ASU 2016-02), Leases (Topic 842). ASU 2016-02 requires a lessee to record a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, on the balance sheet for all leases with terms longer than 12 months, as well as the disclosure of key information about leasing arrangements. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. The Company has not yet evaluated the impact of the adoption of ASU 2016-02 on the Company’s financial statement presentation or disclosures.

 

  9  

 

 

In March 2016, the FASB issued Accounting Standards Update No. 2016-09 (ASU 2016-09), Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 requires, among other things, that all income tax effects of awards be recognized in the statement of operations when the awards vest or are settled. ASU 2016-09 also allows for an employer to repurchase more of an employee's shares than it can today for tax withholding purposes without triggering liability accounting and allows for a policy election to account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted for any entity in any interim or annual period. The adoption of ASU 2016-09 is not expected to have any impact on the Company’s financial statement presentation or disclosures.

 

Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

 

3. Inventories, net

 

Inventories consisted of the following: 

    December 31,  
    2016     2015  
Raw materials   $ 72,952     $ 111,517  
Finished goods     14,203       11,115  
    $ 87,155     $ 122,632  

 

Included in the above are reserves for slow-moving inventory of $28,000 and $20,000, recorded by the Company in 2016 and 2015, respectively.

 

4. Property and Equipment, net

 

Property and equipment consisted of the following: 

    December 31,  
    2016     2015  
Leasehold improvements   $ 4,898     $ 4,898  
Vehicles     42,630       42,630  
Research and testing equipment     29,918       29,918  
Furniture and fixtures     26,566       26,566  
Computer equipment     19,242       19,242  
Office equipment     25,303       25,303  
      148,557       148,557  
Less accumulated depreciation and amortization     (136,801 )     (133,204 )
    $ 11,756     $ 15,353  

 

For the years ended December 31, 2016 and 2015, depreciation and amortization expense was $3,597 and $10,215, respectively, all of which was included in general and administrative expense.

 

5. Line of Credit

 

The Company maintains a line of credit (“LOC”) with Chase Bank to meet short term liquidity requirements. Maximum borrowings under the LOC are $35,000 and are due on demand. The LOC is secured by the Company’s business assets, including accounts receivable, inventory, and equipment. The LOC carries an 8% interest rate, requires monthly payments due on the 25 th of each month, and has an annual fee of $150 in addition to any interest accrued. Outstanding balances under the LOC were $32,760 and 20,173 as of December 31, 2016 and 2015, respectively.

 

  10  

 

 

6. Commitments and Contingencies

 

Operating Lease

 

The Company leases approximately 12,000 of office and warehouse space for $1,350 per month. The space is owned by DWT Evans LLC, a company owned David Evans, VectorVision’s CEO. A new 10-year lease agreement was executed in February 2017, to commence March 1, 2017. As of December 31, 2016, remaining average monthly lease payments (including the new 2017 lease) were $1,882 through February 2027.

 

The approximate future minimum lease payments under non-cancelable operating leases at December 31, 2016 are as follows:

 

Years ending December 31,

 

2017   $ 19,200  
2018     20,290  
2019     20,898  
2020     21,520  
After 2020     147,748  
    $ 229,656  

 

Rent expense was $16,200 and $16,200 for the years ended December 31, 2016 and 2015, respectively.

 

Contingencies

 

The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company’s management does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s business, financial condition, results of operations or cash flows.

 

7. Related Party Transactions

 

The Company periodically enters into unsecured loan agreements with related parties, mostly family members of the CEO, to fund working capital needs. These loans do not have specific repayment terms and are not subject to interest charges. The Company pays back these loans as cash flows permit. As of December 31, 2016 and 2015, the Company held outstanding loan balances of $38,087 and $37,317, respectively, with these related parties.

 

As discussed in Note 6, the Company leases its operating facilities from DWT Evans LLC, a company owned by VectorVision CEO David Evans.

 

In December 2015, A. W. Evans, Jr., Uncle of CEO David Evans, gifted his one share of VectorVision common stock back to the Company. No additional consideration was transferred pursuant to this transaction. The Company retired this common stock.

 

8. Income Taxes

 

The Company, with the consent of its shareholders, has elected under the Internal Revenue Code to be an “S” corporation. In lieu of corporation income taxes, the shareholders of an “S” corporation are taxed on their proportional share of the Company’s taxable income. Therefore, no provision, or liability for federal income taxes has been included in these financial statements.

 

  11  

 

 

9. Subsequent Events

 

On March 1, 2017, the Company entered into a non-binding letter of intent (“LOI”) with Guardion Health Sciences, Inc. a Delaware corporation (“Guardion”), whereby the parties set forth an outline of the terms and conditions pursuant to which the Guardion would acquire all of the outstanding shares of stock of VectorVision in exchange for a to be determined number of shares of common stock of Guardion. The transaction is subject to significant conditions precedent to closing, including, but not limited to, the satisfactory completion of due diligence, the determination of the amount of purchase consideration, the negotiation of definitive transaction documents, and other matters, no later than the August 31, 2017 expiration date of the LOI, as amended.

 

  12  

 

Exhibit 99.3

 

VectorVision, Inc.

Unaudited Condensed Financial Statements as of and for the Six Months Ended June 30, 2017 and 2016

Contents

 

Condensed Financial Statements  
   
Balance Sheets – As of June 30, 2017 (Unaudited) and December 31, 2016 2
   
Statements of Operations (Unaudited) – For the Six Months Ended June 30, 2017 and June 30, 2016 3
   
Statement of Stockholders’ Equity (Deficiency) (Unaudited) – For the Six Months Ended June 30, 2017 4
   
Statements of Cash Flows (Unaudited) – For the Six Months Ended June 30, 2017 and June 30, 2016 5
   
Notes to Condensed Financial Statements (Unaudited) 6

 

 

 

 

VectorVision, Inc.

 

Condensed Balance Sheets

 

    June 30,     December 31,  
    2017     2016  
    (Unaudited)        
Assets                
                 
Current assets                
Cash   $ 1,276     $ 7,160  
Accounts receivable     58,526       18,301  
Inventories     98,471       87,155  
Prepaid expenses     2,621       2,537  
                 
Total current assets     160,894       115,153  
                 
Property and equipment, net     10,016       11,756  
                 
Total assets   $ 170,910     $ 126,909  
                 
Liabilities and Stockholders’ Equity (Deficiency)                
                 
Current liabilities                
Accounts payable and accrued liabilities   $ 103,947     $ 74,365  
Line of credit     24,123       32,760  
Promissory notes payable related party     38,087       38,087  
                 
Total liabilities     166,157       145,212  
                 
Commitments and contingencies                
                 
Stockholders’ Equity (Deficiency)                
                 
Common stock, $0.00 par value; 750 shares authorized; 124 and 124 shares issued and outstanding at June 30, 2017 and December 31, 2016     -       -  
Additional paid-in capital     51,410       51,410  
Accumulated deficit     (46,657 )     (69,713 )
                 
Total stockholders’ equity (deficiency)     4,753       (18,303 )
                 
Total liabilities and stockholders’ equity (deficiency)   $ 170,910     $ 126,909  

 

See accompanying notes to condensed financial statements.

 

  2  

 

 

VectorVision, Inc.

 

Condensed Statements of Operations

 

    Six Months Ended June 30,  
    2017     2016  
    (Unaudited)     (Unaudited)  
Revenue   $ 250,881     $ 126,381  
                 
Cost of goods sold     82,463       28,645  
                 
Gross profit     168,418       97,736  
                 
Operating expenses                
Research and development     7,500       -  
Sales and marketing     15,981       4,814  
General and administrative     118,469       79,818  
                 
Total operating expenses     141,950       84,632  
                 
(Loss) income from operations     26,468       13,104  
                 
Other expenses:                
Interest expense     3,412       4,214  
                 
Net (loss) income   $ 23,056     $ 8,890  

 

See accompanying notes to condensed financial statements.

 

  3  

 

 

VectorVision, Inc.

 

Condensed Statement of Stockholders’ Equity (Deficiency)

(Unaudited)

 

    Common Stock                    
    Shares     Amount    

Additional

Paid-In

Capital

   

Accumulated

Deficit

   

Total

Stockholders’

Equity (Deficiency)

 
Balance at December 31, 2016     124     $ -     $ 51,410     $ (69,713 )   $ (18,303 )
Net income – January 1, 2017 through June 30, 2017     -       -       -       23,056       23,056  
Balance at June 30, 2017     124     $ -     $ 51,410     $ (46,657 )   $ 4,753  

 

See accompanying notes to condensed financial statements.

 

  4  

 

 

VectorVision, Inc.

 

Condensed Statements of Cash Flows

 

    Six Months Ended June 30,  
    2017     2016  
    (Unaudited)     (Unaudited)  
Operating Activities                
Net income   $ 23,056     $ 8,890  
Adjustments to reconcile net income to net cash (used in) provided by operating activities:                
Depreciation and amortization     1,740       1,807  
Changes in operating assets and liabilities:                
(Increase) decrease in -                
Accounts receivable     (40,225 )     (7,656 )
Inventories     (11,316 )     12,290  
Prepaid expenses     (84 )     823  
Increase (decrease) in -                
Accounts payable and accrued expenses     29,582       (24,158 )
                 
Net cash provided by (used in) operating activities     2,753       (8,004 )
                 
Financing Activities                
Line of credit     (8,637 )     9,560  
                 
Net cash (used in) provided by financing activities     (8,637 )     9,560  
                 
Cash:                
Net (decrease) increase     (5,884 )     1,556  
Balance at beginning of period     7,160       5,698  
Balance at end of period   $ 1,276     $ 7,254  
                 
Supplemental disclosure of cash flow information:                
Cash paid for -                
Interest   $ 1,448     $ 1,602  
Income taxes   $ -     $ -  

 

See accompanying notes to condensed financial statements.

 

  5  

 

 

VectorVision, Inc.

Notes to Condensed Financial Statements

(Unaudited)

Six Months Ended June 30, 2017 and 2016

 

1. Organization and Business Operations

 

Organization and Business

 

VectorVision, Inc. (the “Company”) was formed in November 1987 as an Ohio-based S Corporation and was founded by David W. Evans, PhD, MBA. The Company develops, manufactures and sells equipment and supplies for standardized vision testing for use by eye doctors, in clinical trials, for real-world vision evaluation and industrial vision testing.

 

VectorVision specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and Early Treatment Diabetic Retinopathy Study (“ETDRS”) acuity vision testing. The Company’s patented standardization system provides the practitioner or researcher the ability to delineate very small changes in visual capability, either as compared to the population or from visit to visit.

 

Going Concern and Liquidity

 

The financial statements have been prepared assuming the Company will continue as a going concern. The Company has had limited revenues to date and had an accumulated deficit of $46,657 as of June 30, 2017. The Company expects to continue to incur cash outflows from operations that will prevent or limit growth in the near-term. As a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued.

 

The Company’s independent registered public accounting firm has also included explanatory language in their report accompanying the Company’s audited financial statements for the year ended December 31, 2016 that there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.

 

The Company will continue to incur significant manufacturing, promotional, and administrative expenses associated with its current product line. Additionally, the Company’s long-term viability and growth may depend upon the successful development and commercialization of new products. If the Company is unable to generate sufficient revenues and margins or access supplemental capital resources on a timely basis, the Company may be forced to reduce or discontinue its technology and product development programs and curtail or cease operations. There is no assurance that the Company will be able to generate sufficient revenues, or be able to access any capital resources.

 

2. Summary of Significant Accounting Policies

 

Basis of Presentation and Use of Estimates

 

The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).

 

The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Those estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, and accruals for potential liabilities.

 

  6  

 

 

Interim Unaudited Financial Information

 

The accompanying financial statements for the six months ended June 30, 2017 and 2016 are unaudited. In the opinion of management, these financial statements have been prepared on the same basis as the audited financial statements included herein and include all adjustments, including normal recurring adjustments, necessary to present fairly the Company's financial position, results of operations and cash flows. The information disclosed in the notes to the financial statements for such interim periods is also unaudited.

 

Revenue Recognition

 

The Company’s revenue is comprised primarily of sales of medical device equipment and supplies to consumers both in the U.S. and internationally. Revenue is recognized when the risk of loss transfers to our customers and collection of the receivable is reasonably assured, which generally occurs when the product is shipped. A product is not shipped without an order from the customer and an appropriate credit evaluation.

 

We review accounts receivable for uncollectible accounts and provide an allowance for doubtful accounts as needed, which is based upon a review of outstanding receivables, historical collection information, and existing economic conditions. We write off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when received as an increase in the allowance for doubtful accounts. As of June 30, 2016 and December 31, 2016, we had no outstanding accounts receivable that we believed were at risk of non-collection.

 

The Company provides a standard one-year warranty that covers replacement for damaged parts. Product returns for the six-month periods ended June 30, 2017 and 2016 were insignificant.

 

Recent Accounting Pronouncements

 

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. Based on the FASB’s Exposure Draft Update issued on April 29, 2015, and approved in July 2015, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, ASU 2014-09 is now effective for reporting periods beginning after December 15, 2017, with early adoption permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The adoption of ASU 2014-09 is not expected to have any impact on the Company’s financial statement presentation or disclosures.

 

In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (ASU 2016-02), Leases (Topic 842). ASU 2016-02 requires a lessee to record a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, on the balance sheet for all leases with terms longer than 12 months, as well as the disclosure of key information about leasing arrangements. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. The Company has not yet evaluated the impact of the adoption of ASU 2016-02 on the Company’s financial statement presentation or disclosures.

 

  7  

 

 

In March 2016, the FASB issued Accounting Standards Update No. 2016-09 (ASU 2016-09), Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 requires, among other things, that all income tax effects of awards be recognized in the statement of operations when the awards vest or are settled. ASU 2016-09 also allows for an employer to repurchase more of an employee's shares than it can today for tax withholding purposes without triggering liability accounting and allows for a policy election to account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted for any entity in any interim or annual period. The adoption of ASU 2016-09 is not expected to have any impact on the Company’s financial statement presentation or disclosures.

 

Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

 

3. Inventories, net

 

Inventories consisted of the following:

 

    June 30,     December 31,  
    2017     2016  
Raw materials   $ 83,013     $ 72,952  
Finished goods     15,458       14,203  
    $ 98,471     $ 87,155  

 

Included in the above are reserves for slow-moving inventory totaling $48,000, as of June 30, 2017 and December 31, 2016.

 

4. Property and Equipment, net

 

Property and equipment consisted of the following: 

 

    June 30,     December 31,  
    2017     2016  
Leasehold improvements   $ 4,898     $ 4,898  
Vehicles     42,630       42,630  
Research and testing equipment     29,918       29,918  
Furniture and fixtures     26,566       26,566  
Computer equipment     19,242       19,242  
Office equipment     25,303       25,303  
      148,557       148,557  
Less accumulated depreciation and amortization     (138,541 )     (136,801 )
    $ 10,016     $ 11,756  

 

For the six months ended June 30, 2017 and 2016, depreciation and amortization expense was $1,740 and $1,807, respectively, all of which was included in general and administrative expense.

 

 

5. Line of Credit

 

The Company maintains a line of credit (“LOC”) with Chase Bank to meet short term liquidity requirements. Maximum borrowings under the LOC are $35,000 and are due on demand. The LOC is secured by the Company’s business assets, including accounts receivable, inventory, and equipment. The LOC carries an 8% interest rate, requires monthly payments due on the 25 th of each month, and has an annual fee of $150 in addition to any interest accrued. Outstanding balances under the LOC were $24,123 and $32,760 as of June 30, 2017 and December 31, 2016, respectively.

 

  8  

 

 

6. Commitments and Contingencies

 

The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company’s management does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s business, financial condition, results of operations or cash flows.

 

7. Related Party Transactions

 

The Company periodically enters into unsecured loan agreements with the CEO and various family members to fund working capital needs. These loans do not have specific repayment terms and are not subject to interest charges. The Company pays back these loans as cash flows permit. As of June 30, 2017 and December 31, 2016, the Company held an outstanding loan balance of $38,087 with these related parties.

 

The Company leases its operating facilities from DWT Evans LLC, a company owned by VectorVision CEO David Evans. During the six months ended June 30, 2017 and 2016, general and administrative costs included $9,300 and $8,100, respectively, under this lease arrangement.

 

8. Subsequent Events

  

On September 29, 2017, Guardion Health Sciences, Inc. (“Guardion”), through a wholly-owned subsidiary, completed the acquisition of substantially all of the assets and liabilities of the Company in exchange for 3,050,000 shares of Guardion’s common stock, pursuant to the terms of an Asset Purchase and Reorganization Agreement, which was entered into on an arms-legnth basis between the parties. Dr. David Evans, the founder of VectorVision, was appointed to Guardion’s Board of Directors on September 29, 2017.

 

  9